Pharmaceutical formulations of bionanoparticles for siRNA delivery by Metwally, Abdelkader
1 
 
 
 
 
Pharmaceutical formulations of 
bionanoparticles for siRNA delivery 
 
Abdelkader Ali Metwally BSc (Alexandria), MSc (Ain Shams) 
 
A thesis submitted for the degree of Doctor of Philosophy 
 
University of Bath 
 
Department of Pharmacy and Pharmacology 
Bath BA2 7AY, UK 
 
November 2011 
 
 
 
COPYRIGHT 
Attention is drawn to the fact that copyright of this thesis rests with the author. A copy of this 
thesis has been supplied on condition that anyone who consults it is understood to recognise 
that its copyright rests with the author and that they must not copy it or use material from it 
except as permitted by law or with the consent of the author. 
 
This thesis may be made available for consultation within the University Library 
and may be photocopied or lent to other libraries for the purposes of consultation. 
 
 
 
 
Signed:  ………………………………. 
 
 
 
2 
 
Table of Contents 
 
Contents listed                 page number 
Title   Pharmaceutical formulations of bionanoparticles  
for siRNA delivery      1 
Table of Contents         2 
Acknowledgements         3 
Abstract          4 
Aims          5 
Chapter One Introduction and review of siRNA formulation   6 
Chapter Two Efficient gene silencing by self-assembled complexes of  
 siRNA and symmetrical fatty acid amides of spermine  32 
Chapter Three Self-assembled lipoplexes of siRNA using fatty acid amide 
guanidines, based on spermine, effect efficient gene silencing 61 
Chapter Four Efficient silencing of EGFP reporter gene with siRNA  
 delivered by asymmetrical N4,N9-diacyl spermines  81 
Chapter Five Quantitative silencing of EGFP reporter gene by 
 self-assembled siRNA lipoplexes of mixtures of LinOS  
or DOS with either cholesterol or DOPE    112 
Chapter Six On consideration of mechanisms     132 
Conclusions          154 
References          158 
Output arising from this research       181 
 
 
 
3 
 
Acknowledgements 
 
I thank Dr Ian S. Blagbrough for his supervision and dedicated support throughout this 
work. 
I thank the Egyptian Government for a fully funded studentship for my project. 
I thank Dr C. Pourzand (University of Bath) and Dr O. Reelfs (University of Bath) for 
helpful discussions about stably expressing EGFP cell lines and cell biology assays.  
I also acknowledge CRUK Cell Service (Clare Hall Laboratories, South Mimms, Herts, 
U.K.) for providing the HeLa-EGFP-Centrin cell line and Dr Y. Liu for the details of the 
construct.  
I thank S. Crocket (University of Bristol) for assistance with particle size and -potential 
measurements, and J. Mantell (University of Bristol) for running the cryo-TEM study. The 
expert help of Dr A. Rogers (Microscopy and Analysis Suite), C. Rehbein (Mass 
Spectrometry), and Dr T. Woodman (NMR Spectroscopy), all at the University of Bath, is 
also gratefully acknowledged. 
I thank my lab colleagues and the technical staff in the Department of Pharmacy and 
Pharmacology: Kevin Smith, Jo Carter, and Don Perry. 
I am grateful to the endless enthusiastic support that I have received from my parents and 
my wife Amira. 
 
 
 
4 
 
Abstract 
 
The aims of this thesis are to design and synthesize non-viral cationic lipid vectors based 
on spermine, for the intracellular delivery of siRNA (short interfering RNA) and the 
subsequent siRNA mediated gene silencing. Two parameters were varied:  the type of fatty 
acid and the cationic head-group. Among the symmetrical spermine conjugates, N4,N9-
dierucoyl spermine (DES) resulted in higher siRNA delivery compared to N4,N9-dioleoyl 
spermine (DOS), while enhanced green fluorescent protein (EGFP) silencing in HeLa cells 
showed that the unsaturated fatty acid conjugates are more efficient than the saturated fatty 
acid ones, and cell viability was 75%-85% for conjugates with chain length ≥ 18. Two 
cationic lipids with guanidine head-groups, N1,N12-diamidino-N4,N9-dioleoylspermine and 
N1,N12-diamidino-N4-linoleoyl-N9-oleoylspermine, were more efficient in EGFP gene 
silencing compared to cationic lipids with shorter C12 (lauroyl) and very long C22 (erucoyl) 
chains, with cell viability (64%-83% for chain length ≥ 18). Changing the cationic head-
group to guanidine did not offer a significant advantage in gene silencing over the conjugates 
with terminal primary amine groups. The asymmetrical N4-linoleoyl-N9-oleoyl-1,12-diamino-
4,9-diazadodecane (LinOS) resulted in the best gene silencing, while LigOS (with one 
lignoceroyl 24:0 chain) resulted in the best siRNA delivery. Conjugates with two unsaturated 
fatty chains generally resulted in better EGFP gene silencing, while conjugates with one 
saturated chain and one unsaturated chain resulted in better siRNA delivery. Increasing the 
chain length also resulted in increased siRNA delivery (cell viabilities of asymmetrical > 
74%, LinOS 88%). siRNA lipoplexes prepared using mixtures of LinOS with either 
cholesterol or DOPE (1,2-dioleoyl-sn-glycero-3-phosphoethanolamine) resulted in increased 
siRNA delivery, and enhanced EGFP silencing, with LinOS/Chol mixture (1:2 molar ratio) 
resulting in the highest siRNA delivery and the best gene silencing (EGFP reduced to 20%). 
Temperature studies of intracellular entry showed that the majority of lipoplexes are 
internalized by endocytosis, however the majority of gene-silencing occurs due to lipoplexes 
internalized via another mechanism.  
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Aims 
 
The aims of this thesis are to design, synthesize, and evaluate non-viral cationic lipid 
vectors, based on spermine, for the intracellular delivery of siRNA and the subsequent siRNA 
mediated gene silencing. The synthesized vectors should optimally be efficient (approaching 
100% silencing) and non-toxic. Two parameters related to the design of the non-viral vector 
will be varied: the type of fatty acid (chain length and saturation) and the cationic head group 
type. A structure-activity relationship (SAR) study is therefore to be carried out to find the 
best combination of these parameters. This SAR study will encompass the design, synthesis, 
and characterization of a series of symmetrical spermine conjugates, a series of 
guanidinylated spermine conjugates, and a series of asymmetrical spermine conjugates. 
Evaluating the ability of the synthesized spermine conjugates to bind siRNA and form 
lipoplexes, and evaluating the lipoplex diameter and zeta potential will then follow. The 
efficiency of in vitro siRNA delivery and gene silencing by these siRNA lipoplexes prepared 
with spermine conjugates, as well as quantifying their safety will enable the best vector 
design parameters to be evaluated. A formulation based approach introducing neutral helper 
lipids (cholesterol and DOPE) in the lipoplex formulation will also be investigated. Finally, 
aspects of the mechanisms involved in siRNA delivery and gene silencing will be considered. 
These aims will be met through six objectives, divided into Chapters: 
1. A focussed and critical review of gene silencing mediated by siRNA, siRNA in clinical 
trials, and factors affecting siRNA delivery. 
2. Synthesis and characterization of five symmetrical diacyl spermine conjugates, 
investigating their SAR with respect to siRNA delivery, gene silencing, and effects on cell 
viability in vitro in HeLa cells stably expressing enhanced green fluorescent protein, EGFP. 
3. Synthesis, characterization, and SAR of four guanidinylated diacyl spermine conjugates. 
4. Synthesis, characterization, and SAR of seven asymmetrical diacyl spermine conjugates. 
5. Coformulation of selected spermine conjugates with the neutral helper lipids cholesterol 
and DOPE to investigate their siRNA delivery, gene silencing, and effect on cell viability 
in vitro. 
6. Further coformulation of selected spermine conjugates with reagents which enhance 
siRNA escape from lipoplexes or from endosomes and investigations of the mechanism of 
intracellular delivery of selected lipoplex preparations by decreasing the temperature and 
thus inhibiting endocytosis. 
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Chapter One  Introduction and review of siRNA formulation 
 
RNA interference 
History and mechanism of RNA interference 
Small interfering RNA (siRNA, also known as short interfering RNA) is a double-
stranded RNA (dsRNA), typically of 21-25 nucleotides per strand. Sequence specific post-
transcriptional gene silencing by siRNA has many potential therapeutic applications1 as well 
as being an important tool in the study of functional genomics. siRNA operates as a part of 
the cellular mechanism called RNA interference (RNAi), which was first noticed in petunia 
flowers (Petunia hybrida) which showed reduced pigmentation on the introduction of 
exogenous genes that were meant to increase pigmentation.2, 3 These experiments aimed at 
increasing the pigmentation of the petunia flowers by means of introducing additional gene 
constructs expressing either chalcone synthase2, 3 or dihydroflavonol-4-reductase.2 However, 
the resultant plants produced completely white flowers and/or flowers with white or pale 
sectors on a pigmented background. The exact mechanism was not identified at the time and 
was simply termed co-suppression. The transcription level of the suppressed chalcone 
synthase genes in Petunia flowers was found to be similar to that of the non-suppressed 
genes, and thus the co-suppression must have been in the post-transcriptional level.4 Later in 
1997, the suppression of chalcone synthase endogene in Petunia flowers was suggested to be 
related to formation of RNA duplexes by intermolecular pairing of complementary sequences 
between the coding sequence and the 3′ UTR sequence of the transgene mRNA.5 In 1998, 
Fire, Mello and co-workers reported the reduction or inhibition (hence genetic ‘interference’) 
of the expression of the unc-22 gene in Caenorhabditis elegans by means of dsRNA that is 
homologous to 742 nucleotides in the targeted gene,6 a discovery that was awarded the Nobel 
Prize in medicine or physiology in 2006. The target gene expresses an abundant although 
nonessential myofilament protein. Decreasing unc-22 activity resulted in an increasingly 
severe twitching phenotype, while complete inhibition resulted in impaired motility and 
muscle structural defects. The target gene inhibition was best achieved with dsRNA, while 
using the individual sense or anti-sense RNA strands resulted only in modest silencing. The 
authors also noticed that only few copies of the dsRNA are required per cell to initiate a 
potent and specific response, rejecting the hypothesis that the mechanism of interaction with 
target gene mRNA is stoichiometric in nature, and thus the role of the dsRNA in the 
interference machinery must be catalytic or amplifying. 
Elbashir et al. found in 2001 that sequence-specific gene silencing of endogenous and 
heterologous genes with 21 nucleotide siRNA occurs in mammalian cell cultures.7 The 
reporter genes coding for sea pansy (Renilla reniformis) and firefly (Photinus pyralis) 
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luciferases were silenced successfully in different cell lines including human embryonic 
kidney cells (293) and the cervix cancer cells (HeLa), as well as the endogenous gene coding 
for the nuclear envelope proteins lamin A and lamin C in HeLa cells. The authors used 
dsRNA of length 21 or 22 nucleotides with symmetrical 3' 2-nucleotide overhangs on each 
strand, since dsRNA having length >30 nucleotides initiate an immune response (induce 
interferon synthesis) that leads to non-specific mRNA degradation, which was evident from 
non-specific silencing of luciferase with 50 and 500 nucleotides dsRNA in HeLa S3 cells, 
COS-7 cells (kidney cells of the African green monkey), and NIH/3T3 cells (mouse 
fibroblasts).7  
Since then, RNAi mechanism has been, and still is, investigated and reviewed 
thoroughly.8-13 RNAi mechanism involves the incorporation of dsRNA segments (e.g. 
siRNA) that have a complementary sequence to the targeted mRNA in a protein complex. 
This core complex which carries-out mRNA degradation is the RNA induced silencing 
complex (RISC).14-16 The key protein in the degradation process belongs to the argonaute 
family of proteins, which contain a domain with RNase H (endonuclease) type of activity that 
catalyse cleavage of the phosphodiester bonds of the targeted mRNA . The assembly of RISC 
and subsequently its function to mediate sequence specific mRNA degradation occur in the 
cytoplasm of the cell.12 The source of the dsRNA segments incorporated in RISC can be 
endogenously processed microRNA (miRNA), short hairpin RNA (shRNA), or synthetic 
siRNA. miRNA is produced from endogenous DNA through the action of RNA polymerase 
II resulting in the formation of non-coding RNA called primary miRNA (pri-miRNA), which 
is processed in the nucleus by a protein complex containing an enzyme known as Drosha and 
a dsRNA binding protein cofactor called Pasha (DGCR8). Drosha cleaves pri-miRNA to 
produce (pre-miRNA), a dsRNA of 70–90 nucleotides and having a hairpin loop, which binds 
to Exportin 5 protein and is transferred from the nucleus into the cytoplasm. Pre-miRNA is 
processed by Dicer (RNase III enzyme) in the cytoplasm to give miRNA, typically of 22 
nucleotides in length and having two nucleotide overhangs at the 3' position.12, 17 shRNA is 
produced by transcription from an exogenous DNA that is delivered to the nucleus, and codes 
for a hair pin shaped RNA with segments of length 19-29 nucleotides and loop of 9 
nucleotides18, 19 which can then be processed by Dicer and incorporated in the RNAi 
machinery. 
Once in the cytoplasm, the processed dsRNA (miRNA, processed shRNA, or siRNA) is 
then incorporated into a protein complex (in some literature sources referred to as RISC-
loading complex, RLC). In Drosophila the RLC is composed of the dsRNA, heterodimer 
protein DCR2 (Dicer variant)/R2D2. Some literature resources suggested the presence of the 
catalytic argonaute proteins as well in this complex. The active RISC is formed when one of 
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the RNA strands in the complex is cleaved (the passenger strand) and the strand with the less 
thermodynamic stable 5' end (guide/anti-sense strand) remains in the complex. The mRNA 
with complementary sequence to the guide strand binds to the active RISC and is cleaved by 
the endoribonuclease activity of the argonaute component of the complex (Figure 1). 
 
Nucleus
Dicer Dicer
RISC
Argonaute
Cytoplasm
Pri-miRNAPre-miRNA
Pre-miRNA dsRNA
siRNAmiRNA
mRNA
mRNA
cleavage
Sense 
strand
cleavage
DNA
transcription
RISC
 
 
Figure 1. RNAi mechanism in an eukaryotic cell. The source of antisense strand incorporated 
in RISC can be miRNA, processed exogenous long dsRNA, or synthetic siRNA delivered to 
the cell.  
 
RNA duplex structure 
RNA is a polymer of ribonucleotides. Each RNA nucleotide is composed of one 
nucleobase, the monosaccharide pentose ribose, and one phosphate group. The nucleobases in 
RNA are adenine (purine base), guanine (purine base), uracil (pyrimidine base), and cytosine 
(pyrimidine base) (Figure 2). A nucleoside is formed when each base is connected via a 
glycosidic bond to the anomeric carbon 1' of ribose, thus when glycosylated, adenine, 
guanine, uracil, and cytosine nucleobases give adenosine, guanosine, uridine, and cytidine 
nucleosides. Each two nucleosides are connected via a phosphate diester bond between the 3' 
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of one nucleoside and 5' of the next nucleoside to form the RNA polynucleotide strand. The 
main differences in the primary structure of RNA and DNA are that RNA pentose is ribose 
while DNA pentose is 2'-deoxyribose, and the RNA incorporates the nucleobase uracil 
instead of thymine. 
 
 
 
Figure 2. Nucleobases and pentoses of RNA and DNA. 
 
In order to form an RNA duplex (Figure 3), the strands with complementary nucleotide 
sequence bind together by hydrogen bonds. Adenine is bound to uracil with two hydrogen 
bonds while guanine is bound to cytosine with three hydrogen bonds, thus forming what is 
known as Watson-Crick base pairs. RNA duplexes under normal physiological conditions are 
in the form of A-helix. This type of duplex is a right-handed helix.20-22  
The presence of the 2'-hydroxyl group of the ribose and the lack of the methyl group on 
the nucleotide uridine (in contrast to the methylated thymidine) results in structural 
differences between RNA and DNA, with the 2'-hydroxyl group of RNA being the major 
cause of the differences. The sugar phosphate backbone of RNA duplexes is stabilized by the 
2' hydroxyl in the C3'-endo position, while DNA is in the C2'-endo position (Figure 4).  
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Figure 3. siRNA duplex typically 21-25 nucleotides per strand. 
 
 
 
Figure 4. 3'-endo ribose configuration of RNA (left) vs. 2'-endo (right) of 2'-deoxyribose in 
DNA. Shown is cytidine (RNA) and deoxycytidine (DNA) with the 3' hydroxyl 
phosphorylated. The hydrogen atoms at C2' and C3' were not displayed for clarity.  
 
Thus RNA duplex takes the A helix form while the DNA helix takes the B form. The A-
helix form is suggested to have a greater hydration shell, giving RNA duplexes more 
thermodynamic stability and more rigidity compared to DNA duplexes.20-22 RNA A-helix 
completes one complete rotation in 11–12 base pair (bp) compared to 10 bp for DNA, with a 
rise of 2.7 Å per bp of RNA.23 The A- helix geometry has been suggested to be the major 
factor explaining why dsRNA and not dsDNA is involved in the RNAi machinery,24 where 
the A-helix geometry between the guide strand and the complementary target mRNA is 
essential for the catalytic activity of the argonaute 2 protein in the RISC.  
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As a result of the presence of a hydroxyl group in the 2' position of the ribose in the RNA 
backbone, the RNA phosphodiester backbone is more susceptible to hydrolysis by nucleases 
compared to the DNA which lacks the 2' hydroxyl in its 2'-deoxyribose.25 Incubation of 
siRNA in fetal bovine or human serum at 37 °C resulted in the degradation and partial or 
complete loss of activity.26 When incubated in human plasma at 37 °C, more than 50% of the 
unmodified siRNA was degraded within one minute, and practically all siRNA was 
completely degraded within 4 hours.27 Although Ribonuclease A (RNase A, an 
endoribonuclease) cleaves single stranded RNA, siRNA degradation in serum was reported to 
be mainly due to RNase-like activity,28 which is suggested to occur during transient breaking 
of the hydrogen bonds joining the two siRNA strands. In addition to RNase A family of 
enzymes, blood serum contains also phosphatases and exoribonucleases which can also affect 
degradation of siRNA at nuclease sensitive sites on both strands.29 
 
Therapeutic potential of RNAi based therapies 
RNAi based therapies emerged in the period following its discovery in 1998, and are 
promising therapeutic candidates to treat various types of diseases, ranging from age related 
macular oedema to respiratory tract infections to various types of cancer.30-32 In addition to 
siRNA based therapies, shRNA33, 34 and miRNA35 are potential therapeutic tools. siRNA 
based therapeutics are already in phase I and phase II of clinical trials. Representative 
examples of clinical trials involving siRNA are shown in Table 1. The basic concept is the 
reduction or inhibition of the expression of a protein that is involved in the 
pathophysiological pathway of the target disease (silencing/knocking-down the target gene). 
This concept is evident from using Cand5 siRNA targeting the mRNA translating the 
vascular endothelial growth factor (VEGF), thus reducing/inhibiting angiogenesis and 
preventing progression of wet age related macular oedema (Table 1).36 Atu027 siRNA targets 
the protein kinase N3, the latter plays a role in cancer metastasis.37 
The therapeutic application of siRNA requires overcoming several barriers (Figure 5) for 
its intracellular delivery and the subsequent functional gene silencing activity.38-40 Those 
barriers are mainly due to siRNA specific characteristics, most important are having a highly 
negative charge due to their phosphate backbone (on average 40-50 negative charges per 
siRNA), being susceptible to degradation by nucleases, and having relatively large molecular 
weight (13-15 kDa) compared to conventional small drug molecules. First, local delivery 
(such as intravitreal) is different from intravenous delivery, where the latter will subject the 
siRNA to the serum ribonucleases, which results in degrading non-modified siRNA within 
time periods that varies from minutes to hours.27 siRNA injected intravenously in rats was 
reported to be cleared rapidly from circulation and accumulates in kidneys within minutes of 
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injection,41 making it useful only if the target organ is the kidney. In order to gain access into 
the cytoplasm where siRNA can exert its biological activity, the polyribonucleotide must pass 
first through the interstitial space then through cell membrane. This will be a difficult task, 
since both the extracellular matrix in many tissue types and the cell membrane incorporate 
negatively charged glycosaminoglycans (e.g. heparan sulfate).42 In addition, cell membrane 
has negatively charged phospholipids (e.g. phosphatidyl serine phospholipids) and the 
membrane is negatively charged.42, 43 The net result is unfavourable repulsive interaction with 
the naked siRNA. 
As a result, different strategies were developed to overcome the barriers to reproducible 
and functional siRNA delivery. These strategies fall into two general categories. One 
category is modifying the siRNA. The other category is deploying a vector to protect the 
siRNA and increase its efficiency of delivery.  
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Figure 5. Summary of barriers to successful gene-silencing mediated by siRNA after 
intravenous injection, whether delivered naked or incorporated in nanoparticles. 
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Strategies to achieve efficient siRNA delivery and gene silencing 
siRNA modifications 
siRNA modifications include those carried out at the ribose residue, at the phosphate 
backbone, at the RNA nucleotides, the siRNA termini, and/or by conjugation of other 
molecules to the siRNA molecule. Modifications to the ribose at the 2' position are 
common,44 and include 2'-O-alkylation (e.g. 2'-O-Methyl and 2'-O-Methylethoxy) 
modifications. 2'-Fluoro RNA is another common modification. Locked nucleic acids (LNAs) 
have a methylene bridge connecting the 2'-O to the 4'-C of the ribose unit, locking the sugar 
in the 3'-endo conformation. These modifications lead to an increased ribonuclease 
resistance44, 45 Modifications at the phosphate backbone include phosphorthioate, 
boranophosphate, and methylphosphonate linkages44, 45 and is reported to increase siRNA 
stability against various ribonucleases and phophodiesterases.46 siRNA nucleotides can be 
substituted with DNA nucleotides aiming at increasing stability and/or decreasing unwanted 
siRNA off-target effects.47 Modifications of the 3' overhangs (usually two nucleotides in 
length), include incorporating deoxyribonucleotides aiming to reduce costs and increasing 
stability towards 3' exoribonucleases. The 5'-termini chemical phosphorylation of the 
antisense strands results in higher gene silencing efficiency, while blunt ended duplexes were 
reported to be more resistant to exonucleases. The advantages of each of the aforementioned 
techniques, other modification strategies, as well as the considerations related to the degree of 
modification and its effect on gene silencing efficiency and associated cytotoxic effects were 
reviewed thoroughly.44, 48-50  
The conjugation of drug molecules, aptamers, lipids, polymers, and peptides/ proteins to 
siRNA could enhance in vivo delivery characteristics.51 The main aims of such conjugations 
are to enhance siRNA stability, increase in vivo half-life, control biodistribution, increase 
efficiency of intracellular delivery, while maintaining the gene silencing activity.  
One strategy is to increase the hydrophobicity of the siRNA. Cholesterol was conjugated 
to the 5' termini of siRNA, the cholesterol−siRNA conjugate (chol-siRNA) resulted in better 
intracellular delivery compared to unmodified siRNA and retained gene silencing activity in 
vitro in -galactosidase expressing liver cells.52 When cholesterol was conjugated to the 3' 
terminus of the sense (passenger) strand of siRNA, the conjugate had improved in vivo 
pharmacokinetics as the intravenous administration of chol-siRNA in mice resulted in its 
distribution and detection in the fat tissues, heart, kidneys, liver, and lungs, even 24 h after 
intravenous injection.53 No significant amounts of unmodified siRNA were detected in the 
tissues 24 h after the intravenous injection. Conjugation of siRNA to bile acids and long-
chain fatty acids, in addition to cholesterol, mediates siRNA uptake into cells and gene 
silencing in vivo.54 The shorter chain fatty-acid conjugates, namely lauroyl (C12), myristoyl 
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(C14) and palmitoyl (C16) did not silence the target apolipoprotein B mRNA levels in mouse 
livers after intravenous injection. siRNA fatty-acid conjugates having the long saturated 
chains stearoyl (C18) and docosanoyl (C22), significantly reduced apolipoprotein B mRNA 
levels. 
Cell penetrating peptides (CPP) are used to facilitate cellular membrane crossing of many 
molecules of various properties such as antisense oligonucleotides, peptides, and proteins and 
are used already in vivo.55 siRNA was conjugated to penetratin and transportin, to silence 
luciferase and the green fluorescent protein (GFP) in different types of mammalian cells.56 
However, in vivo lung delivery in mouse of siRNA conjugated to penetratin and TAT(48-60), 
targeting p38 MAP kinase mRNA showed that the reduction in gene expression was peptide 
induced and the penetratin conjugated siRNA resulted in innate immunity response.57  
siRNA functioning against the vascular endothelial growth factor (VEGF) mRNA was 
conjugated to poly(ethylene glycol) (PEG, 25 kDa) via a disulfide linkage at the 3' terminus 
of the sense strand.58 The siRNA-PEG conjugate formed polyelectrolyte complex micelles 
(PEC) by electrostatic interaction with the cationic polymer polyethyleneimine (PEI). The 
formed VEGF siRNA-PEG/PEI PEC micelles showed enhanced stability against nuclease 
degradation compared to the unmodified siRNA. These micelles efficiently silenced VEGF 
gene expression in prostate carcinoma cells (PC-3) and showed superior VEGF gene 
silencing compared to VEGF siRNA/PEI complexes in the presence of serum. PEG 
conjugation on its own enhanced the stability of the siRNA in serum containing medium. The 
prolonged stability of the PEC micelles was suggested to be due to the presence of PEG 
chains in the outer micellar shell layer, thus sterically hindering nuclease access into the 
siRNA in the micelle core.58  
Targeting molecules such as antibodies59 and aptamers (peptides or single stranded DNA 
or RNA that have selective affinities toward target proteins)60 have also been conjugated to 
siRNA, with the aim of increasing the efficiency of siRNA delivery to the targeted tissues. 
Conjugating molecules to siRNA requires specific considerations. First, the site of 
conjugation (3' and/or 5' terminus, on sense and/or antisense strand) should be chosen such 
that it does not affect the activity of the siRNA and its ability to be incorporated in the RISC, 
or its ability to bind the target mRNA in the correct helix conformation. Second, the 
conjugated siRNA might have new properties that were not present in the unmodified parent 
siRNA. An example is the in vivo immune response resulting from the penetratin-siRNA 
conjugate.57 Third, the conjugation process is multi-step, and the chemical reaction 
intermediates and products require efficient purification in order to meet the specifications of 
in vivo applications. These steps need to be repeated for each siRNA under investigation, 
which can be costly and time consuming. Thus, although there are clear advantages to 
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synthesize siRNA conjugates, there are also disadvantages, and conjugation is therefore one 
of two valuable approaches in the toolbox for preparing siRNA based therapies. The other 
valuable tool is complexing or incorporating the siRNA in a vector.  
 
Table 1. Representative clinical trials using siRNA (http://clinicaltrials.gov/ct2/home, 
accessed on 20/8/2011). 
siRNA Disease 
Vector/ 
Route 
Phase Sponsor 
Cand5/ 
Bevasiranib 
Diabetic macular 
oedema 
None/ 
Intravitreal 
Phase II 
Opko Health 
(Miami, USA) 
Cand5/ 
Bevasiranib 
Age-related macular 
degeneration 
None/ 
Intravitreal 
Phase II 
(Phase III halted) 
Opko Health 
(Miami, USA) 
ALN-RSV01 
Respiratory syncytial 
virus infection 
None/ 
Intranasal 
Phase II 
Alnylam 
Pharmaceuticals 
(Cambridge, USA) 
CALAA-01 
Solid tumour/ 
melanoma 
Cyclodextrin 
nanoparticles/ 
Intravenous 
Phase I 
Calando 
(Pasadena, CA, 
USA) 
Atu027 
Colorectal cancer 
metastasizing to the 
liver 
AtuPlex- 
Liposome/ 
Intravenous 
Phase I 
Silence 
Therapeutics 
(London, UK) 
Two siRNA 
against 
TGFBI and 
COX-2 
STP705 
Wound healing 
Nanoparticles/ 
Intravenous 
Phase I 
Sirnaomics 
(Gaithersburg, MD, 
USA) 
I5NP 
Protection from acute 
kidney injury after 
cardiac bypass surgery 
None/ 
Intravenous 
 
Phase I 
Quark 
Pharmaceuticals 
(Fremont, USA) 
 
Viral vectors for shRNA delivery  
Vectors for RNAi based therapies are either viral or non viral vectors. Viral vectors (Table 
2) are used to deliver genes encoding hairpin RNA structures such as shRNA and miRNA, 
which are then processed by the cellular RNAi machinery to the functional silencing 
dsRNA.61, 62 Viral vectors offer two main advantages, the first is the very high efficiency 
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compared to non-viral vectors,63 which can reach few orders of magnitude more than that 
achieved with non-viral vectors, and the second is the potential of long term expression of the 
delivered RNAi therapeutic, which is very useful in the treatment of chronic diseases such as 
HIV infection and viral hepatitis.64, 65 Retroviruses are enveloped, single stranded RNA 
viruses and have a genome capacity of 7-10 kilobases (kb). They preferentially target 
dividing cells which limits their use to mitotic tissues (thus for example excluding brain and 
neurons). Retroviruses integrate their DNA in the host genome using an integrase enzyme, 
which provides the advantage of stable long term expression of the delivered transgene in the 
host cell and its descendents. However, integrating new DNA sequences into host genome 
carries the risk of insertional mutagenesis.63, 66 shRNA expression cassette delivered by a 
retroviral vector was used in rats to silence a RAS oncogene in order to suppress tumour 
growth.67 Herpes virus was used successfully to deliver shRNA targeting exogenous -
galactosidase or endogenous trpv1 gene mRNA in the peripheral neurons in mice by injecting 
once directly into the sciatic nerve of the animals.68  
Unlike other retroviruses, lentiviruses can infect dividing as well as differentiated and 
non-dividing cells. The lentiviral genome can accommodate 7.5 kb,62 and their genome is 
integrated in the host cell genome, lentiviral vectors are generally preferred for long-term 
expression of transgenes, and efficient delivery in vivo to the brain, eye, and liver to induce 
long-term transgene expression as reported.69 A lentiviral vector was used to deliver shRNA 
targeting Smad3 gene mRNA, and enhanced myogenesis of old and injured muscles.70 
Adenoviruses are non-enveloped viruses, with linear double stranded DNA. They 
preferably infect the upper respiratory tract and the ocular tissue. Their genome can 
accommodate up to 8 kb which can be extended to ≥25 kb in modified viruses that have their 
viral genes deleted.63 These viruses can infect post mitotic cells and thus are good candidates 
for neurological diseases. Unless delivering genes that can exist as episomes in host cells, 
adenoviruses result only in transient expression of their cargo. However, although the host 
cells with the episome can express the delivered genes for the cell life time, these cells will 
eventually be removed by the host immune system.63 shRNA targeting VEGF that was 
delivered by an adenoviral vector resulted in potent inhibition of angiogenesis and tumour 
growth in mice.71 
Adeno-associated virus is a single stranded DNA non-pathogenic virus that can 
accommodate a 4.7 kb genome. They can infect dividing or non-dividing cells. The 
replication of adeno-associated virus requires co-infection with adenovirus. The viral genome 
integrates into the host cell genome at a specific location on chromosome 19.63 Direct 
intracerebellar injection in a mouse model of spinocerebellar ataxia of an adeno-associated 
viral vector delivering a cargo expressing shRNA targeting polyglutamine induced 
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neurodegeneration, significantly restored cerebellar morphology and improved motor 
coordination in the mice.72 
 
Table 2. Summary of properties of viral vectors that are commonly used in gene therapy 
(adapted from http://www.genetherapynet.com/viral-vectors.html, accessed on 21/8/2011). 
 
 
Retrovirus/ 
Lentivirus 
Adenovirus 
Adeno-
associated  virus 
Herpes 
virus 
V
ir
al
 v
ec
to
r 
pr
op
er
tie
s Genome ssRNA dsDNA ssDNA dsDNA 
Capsid Icosahedral Icosahedral Icosahedral Icosahedral 
Envelope Enveloped  None None Enveloped 
Viral Polymerase Positive Negative Negative Negative 
Diameter (nm) 80-130 70-90 18-26 150-200 
Genome size (kb) 7-10 38 5 120-200 
G
en
e 
th
er
ap
y 
re
la
te
d 
Infection tropism Dividing* 
Dividing/ 
Non-dividing 
Dividing/ 
Non-dividing 
Dividing/ 
Non-dividing 
Virus genome 
integration 
Integrating Non-integrating Integrating Non-integrating 
Transgene 
expression 
Lasting Transient Lasting Transient 
Packaging 
capacity (kb) 
7-8 8 4.5 >30 
 
* Lentiviral vectors can infect non-dividing cells as their pre-integration complex can traverse 
the nuclear membrane pores (NMP), in contrast to retrovirus pre-integration complex which 
does not traverse NMP, requiring the host cell division to integrate the retroviral genome.73 
 
Although highly efficient in delivering their cargo, viral vectors have their disadvantages. 
Adenoviral vectors have the disadvantage of triggering a strong immune (adaptive and 
innate) response by repeated administration, in addition to target organ immunotoxicity, 
specially hepatotoxicity,74-76 which resulted in 1999 in the death of one 18-year-old male who 
received high dose of adenovirus that was delivered directly in the hepatic artery in a clinical 
gene therapy safety study.77 Clonal T-cell acute lymphoblastic leukemia caused by insertional 
mutagenesis in a gene therapy completed clinical trial involving patients suffering X-linked 
severe combined immunodeficiency (SCID-X1) was reported in one out of the 10 patients 
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using a retroviral vector.78 Integration of the vector genome material in the antisense 
orientation 35 kb upstream of the protooncogene (LMO2) caused over expression of the gene 
in the leukemic cells. In a similar study, 4 out of 9 patients developed leukemia within 3-6 
years post-treatment mainly due to vector-mediated upregulation of host cellular 
oncogenes.79, 80 In addition, immune responses (whether adaptive or innate) of varying 
degrees depending on the type of vector, dose, and target organs were reported for lentiviral, 
adenoviral, adeno-associated viral vectors.76 
Current research on viral vectors for gene therapy is focussed on approaches such as 
vector engineering e.g. modifying the viral capsid or pseuodotyping the envelope, different 
delivery strategies, and administration to immune-privileged sites that can tolerate the 
delivered viral vectors without responding with an inflammatory response.76, 81 Other research 
focuses on the essential scaling-up process of vector production and increasing the packaging 
efficiency of the vectors,81 the processes without which, the wide spread and successful 
therapeutic use of the viral vectors will be very difficult to achieve.  
 
Non viral vectors 
Non-viral vectors for gene and siRNA delivery are an alternative to the viral vectors, as 
they do not suffer many of the disadvantages of the viral vectors, especially immunogenicity 
and tumourigenicity. The non-viral vectors can be classified generally as peptides, polymeric 
based vectors, carbohydrate based, and lipid based.82 Cell penetrating peptides (CPPs), also 
known as peptide transduction domains (PTDs), have shown the ability to cross the cellular 
membrane despite their relatively high molecular weight and size (Table 3). PTDs generally 
are short amphipathic and/or cationic peptides that can transport many hydrophilic molecules 
across the cell membrane. A wide range of molecules including liposomes,83, 84 peptides, 
proteins,85 peptide nucleic acids 86 and polynucleotides87 are delivered intracellularly using 
PTDs and they have also been applied in vivo.55, 88, 89  
The TAT protein, which is derived from HIV-1, was found in 1988 that it could be taken 
up by cells growing in tissue culture,90 and it was reported that a small basic region of TAT 
(48–60) was essential for uptake by the cells.91 PTDs include antennapedia homeodomain 
protein (Antp, penetratin), mitogen-activated protein (MAP), poly-arginine, transportan, 
VP22 55, 88. Two major pathways are involved in the uptake of PTDs and PTD-cargos: direct 
translocation at 4 °C and 37 °C and endocytosis-translocation at 37 °C. These mechanisms 
depend on many factors: cargo size, cell line, PTD concentration, and the type of PTD.55, 92, 93 
siRNA can be conjugated covalently to the CPP or can be complexed with the cationic 
groups of basic amino acids that are present in the backbone of the CPP. As a representative 
example of non-covalent complexation, CADY,94 which is basic due to its five arginine 
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residues can complex with the negatively charged siRNA. Another example of non-covalent 
complexation is the poly-arginine CPP.95  
 
Table 3. Selected CPPs used for siRNA delivery.55 
CPP Sequence of CPP 
Type of 
association 
with siRNA 
Target mRNA 
CADY 
GLWRALWRLLRSLWRLL
WRA 
Non-covalent GAPDH, p5394 
EB1 
LIRLWSHLIHIWFQNRRL
KWKKK 
Non-covalent Luc96 
MPG 
GALFLGFLGAAGSTMGA
WSQPKKKRKV 
Non-covalent Luc, GAPDH97 Oct-3/498 
Poly-arginine RRRRRRRRR Non-covalent VEGF95 
Penetratin RQIKIWFQNRRMKWKK 
Covalent 
Covalent 
Covalent 
Luciferase (Luc), EGFP56 
SOD1, caspase-399 
Luc, p38 MAP kinase57, 100 
Transportan 
LIKKALAALAKLNIKLLY
GASNLTWG 
Covalent Luc, EGFP100 
TAT GRKKRRQRRRPPQ Covalent EGFP, CDK9101 
 
PEI (Figure 6) is known as a very efficient plasmid DNA (pDNA) delivery vector. 
However, PEI as a siRNA delivery vector is reported to be much less efficient.102, 103 This 
decreased efficiency is due to the dissociation of the siRNA/PEI complex upon interaction 
with the negatively charged cell membrane, which is suggested to be because of the short 
length of siRNA and the associated weak electrostatic interaction with PEI.104, 105 Another 
drawback of PEI is its relatively high toxicity.106 Thus, in addition to linear PEI, PEI 
polymers with a wide range of molecular weights were developed to increase PEI efficiency 
and/or decrease toxicity, although not all PEI are suitable for siRNA delivery.107 The main 
advantage of PEI is the ability of its variety of amino-groups to be protonated at lower pH 
(inside endosomes) leading to what is known as the “proton sponge effect”,108 and efficient 
escape from endosomes. 
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Figure 6. Representative examples of polyamines used in siRNA delivery either as is (PEI) 
or as a part of cationic polymers and/or lipids (e.g. spermine).  
 
One approach to enhance siRNA delivery with PEI is increasing the hydrophobicity of 
PEI by covalently conjugating alkyl chains,109 where increasing the hydrophobic alkyl chain 
length generally improved the stability of the PEI/siRNA complex. In a similar strategy, 
cholesterol was conjugated to PEI110 with decreased toxicity of the conjugates. Low 
molecular weight PEI (MW < 5 kDa) is less toxic than the higher molecular weight PEI (≈25 
kDa), but less efficient in polynucleotide delivery, thus, cross linking of the low molecular 
weight PEI with disulfide bonds which are cleaved in the reducing environment of the 
cytoplasm increased the efficiency of siRNA delivery through the enhanced release of siRNA 
in the cytoplasm.111 
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Chitosan is a biocompatible and biodegradable polysaccharide that is a copolymer of N-
acetyl-D-glucosamine and D-glucosamine. Chitosan has weakly basic properties due to the 
presence of the D-glucosamine residue with a pKa value 6.2-7.0. The molecular weight of 
chitosan affects the complex stability, size, zeta-potential and in vitro gene knock-down of 
siRNA/chitosan nanoparticles.112 Chitosan with high molecular weight (64.8-170 kDa), 
formed stable complexes with siRNA and resulted in high gene knock-down efficiency in 
H1299 (human lung carcinoma) cells, while chitosan with low molecular weight (10 kDa) 
could not complex the siRNA into stable nanoparticles and showed almost no knockdown.113 
The method of association affects gene silencing efficiency, where chitosan-TPP/siRNA 
nanoparticles (siRNA entrapped inside the nanoparticles, and TPP is sodium tripolyphosphate 
and used as a polyanion to cross-link with the cationic chitosan groups by electrostatic 
interactions) showed high siRNA binding and better gene silencing in vitro compared to 
siRNA/chitosan particles prepared by simple complexation and adsorption of siRNA onto 
chitosan.114  
Although chitosan has good potential as a non-viral gene delivery vector, its wide use is 
largely limited due to its poor solubility (because of their pKa, chitosan amino groups are 
only partially protonated at the physiological pH 7.4), poor stability of its siRNA complexes 
at the physiological pH, and low transfection efficiency. Various strategies are adopted to 
overcome these drawbacks, such as covalently conjugating PEG polymers to chitosan and 
binding targeting ligands to enhance cell specificity.112 
Cyclodextrins (CD) are cyclic oligosaccharides composed of 6, 7, or 8 D(+)-glucose units, 
known as α-CD, β-CD, or γ-CD respectively, that are linked by α-1,4-linkages. Polymers 
conjugated to β-CD lack immunogenicity and hence are attractive vectors for polynucleotide 
delivery. β-CD have a hydrophilic outer surface and a hydrophobic inner cavity which enable 
them to form inclusion complexes. Efficient cellular transfection of siRNA labelled with a 
fluorescent tag into human embryonic lung fibroblasts (MRC-5 cells) was observed by 
siRNA complexes with the β-CD guanidine derivatized bis-(guanidinium)-tetrakis-(β-
cyclodextrin) tetrapod (having four β-CD units).115 The ability of β-CD to form inclusion 
complexes was used to develop a siRNA delivery vector. β-CD was covalently bound to a 
polycationic segment (to electrostatically bind siRNA), while adamantane-PEG-transferrin 
(adamantane can fit in the β-CD cavity) formed an inclusion complex which can enhance the 
stability of siRNA nanoparticles in vivo.116 This system was used to deliver siRNA silencing 
the EWS-FLI1 gene thus inhibiting tumour growth in a murine model of metastatic Ewing's 
sarcoma. 
Dendrimers have a central core to which are connected several branched arms in a manner 
that can be symmetrical or asymmetrical. During the synthesis of dendrimers, arms 
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(branches) are added to the core structure. Each addition is called a generation and increases 
the previous generation number by one. Due to their unique structure, dendrimers can have a 
planar, elliptical, or spherical shape depending on generation number. Among the most 
widely used dendrimers are polyamidoamine (PAMAM) and polypropylenimine (PPI) 
dendrimers.117 Dendrimers which have positively charged cationic groups on their outer 
surface are commonly used for polynucleotide delivery. The transfection efficiency of 
dendrimers increases with increasing the charge density or generation number.118 However, 
dendrimers with high generation number are generally more cytotoxic compared to 
dendrimers with low generation number.119 Usually the inner space near the core is larger 
compared to outer space near the surface due to the lower density of molecules (less number 
of arms) near the core, which allow small molecules to be incorporated in the inner space. 
Owing to the relatively large molecular weight of polynucleotides, they are usually bound to 
the surface of cationic dendrimers and not in the inner space of the dendrimer. Generally, the 
toxicity of dendrimers is lower than that of PEI or poly-L-lysine (PLL).120 One advantage of 
dendrimers is that they have pH buffering capacity (proton-sponge effect), an important 
feature for endosomal escape and enhancing the release of polynucleotides.118, 121  
PPI dendrimers with high generation numbers (4 and 5) were more efficient in forming 
discrete nanoparticles with siRNA and in gene silencing in A549 (human lung cancer) cells 
than lower generation dendrimers (2 and 3). The PPI dendrimers with generation number 5 
were more toxic, probably due to the increased positive charge density per dendrimers, than 
generation 4 dendrimers.122 Complex formation between PAMAM dendrimers having an 
ethylenediamine core with siRNA as a function of three variables was reported.123 The ionic 
strength of the medium (without or with 150 mM NaCl), the generation number (4, 5, 6 and 
7) and the N/P ratio (ratio of positively charged amine groups per negative phosphate) were 
varied. The size of the complexes depended on the ionic strength of the media, with the 
strong electrostatic interactions in medium without NaCl making siRNA/dendrimer 
complexes smaller than those obtained in 150 mM NaCl. Both the intracellular delivery and 
silencing of EGFP expression in cell culture was dependent on complex size, with smaller 
complexes being massively delivered, and resulting in the highest silencing of EGFP 
expression. siRNA complexed with generation 7 dendrimers resulted in the highest silencing 
of EGFP expression both in human brain tumour cell line T98G-EGFP (35%) and mouse 
macrophage cell line J-774-EGFP (45%) cells, in spite of having lower protection of siRNA 
against degradation with RNase A, showing the importance of formulation procedures on the 
efficiency of transfection.123 
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Cationic lipids as non-viral vectors for siRNA and DNA delivery 
Gene delivery by cationic lipids 
Gene delivery (DNA transfection) with cationic lipids (Figure 7) dates back to 1987 when 
it was reported by Felgner et al.,124 and the term ‘lipofection’ was coined. Small unilamellar 
liposomes containing the cationic lipid N-[1-(2,3-dioleyloxy)propyl]-N,N,N-trimethyl 
ammonium chloride (DOTMA) was reported to spontaneously complex DNA completely 
entrapping the DNA, and enhanced fusion with the cell membrane in vitro in cell cultures, 
resulting in efficient delivery and expression of the delivered DNA. The lipofection was 5-
100-fold more effective than the commonly used transfection techniques at the time by either 
calcium phosphate or DEAE-dextran (diethylaminoethyl-dextran), depending on the cell line 
used.124 Cationic lipids have polar and non polar domains and thus are amphiphilic in nature, 
with three general structural domains: (a) a cationic hydrophilic head-group (positively 
charged). The head group can carry a permanent positive charge as in quaternary ammonium 
groups, or can be protonated at the physiological pH 7.4, such as primary and secondary 
amine groups. There can be one cationic group per lipid molecule (monovalent cationic 
lipids) or more than one cationic group per lipid molecule (multivalent cationic lipids); (b) a 
hydrophobic domain coavalently attached by a linker to the cationic head-group. This domain 
can be in the form of either alkyl chains (commonly 2 chains) of various chain lengths (with 
various oxidation states) or can be a steroid such as cholesterol; (c) the linker between the 
head group and the hydrophobic domain.125, 126 This linker controls the biodegradation of the 
cationic lipid and its stability under different conditions according to the type of chemical 
bonds (e.g. ester, ether, or amide). Each domain can be controlled to change a specific 
character of the cationic lipid, e.g. using a bioresponsive linker (disulfide)127 which is reduced 
in the intracellular environment by glutathione/glutathione reductase and enhance 
biodegradation characters of the lipid and decrease its cytotoxicity. 
 
The cationic head-group  
The cationic head-group’s main function is to electrostatically bind the negatively charged 
phosphates of the polynucleotides. The complexes of cationic lipids with polynucleotides 
such as DNA and siRNA are called lipoplexes. This requires the presence of a positive charge 
on the head group at the physiological pH 7.4, i.e. the pKa of the head group is ideally at least 
one unit higher than the physiological pH. The most commonly used head groups contain 
nitrogen (e.g. amines or guanidines). However other head groups, e.g. arsonium and 
phosphonium have been reported.128 Arsonium is less toxic than arsenic (III), and in vitro 
cytotoxicity evaluation showed that arsonium and phosphonium are less toxic than the 
ammonium group.128, 129  
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Figure 7. Representative examples of cationic lipids used in DNA and siRNA delivery. 
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One property that can be changed by controlling the type of the head group is the head 
group cross-sectional area. The greater the difference between the cross-sectional area of the 
polar head-group and that of the hydrophobic domain, with the former is designed to be 
smaller than the latter, the greater is the ability of the cationic lipid to fuse with the cell 
membrane and endosomal membrane and the greater is the release of polynucleotides from 
their complex with the cationic lipid due to the decreased structural stability of the lipid 
assembly.126, 130 The hydration of the head group affects its cross-sectional area, thus, the 
conjugation of groups which decrease the hydration state (such as hydroxyalkyl groups that 
form intermolecular H-bonds) decreases the head group cross-sectional area. 
Thus, gene delivery by DOTMA and DOTAP (1,2-dioleoyloxy-3-[trimethylammonio]-
propane) was enhanced by incorporation of a hydroxyethyl group to yield the lipids DORIE 
(1,2-dioleyloxypropyl-3-dimethyl-hydroxyethyl ammonium bromide) and DORI (N-[1-(2,3-
dioleoyloxy)propyl-N-[1-(2-hydroxy)ethyl]-N,N-dimethyl ammonium iodide) respectively.131, 
132 The head group cross-sectional area can be also controlled by subtle changes to the head 
group structure. The DC-Chol (3(N-(N',N'-dimethylaminoethane)carbamoyl)cholesterol) 
with dimethylamino head-group resulted in more efficient transfection compared to DC-Chol 
with diethylamino or diisopropylamino head-groups, probably due to increased steric 
repulsion of the head groups.  
The in vitro gene transfer with six non-cholesterol-based cationic lipids (each having two 
alkyl chains) with a single guanidinium head-group in CHO, COS-1, MCF-7, A549, and 
HepG2 cells was reported.133 These lipids were able to form lipoplexes with size range 
200−600 nm and -potential +3.4 to -34 mV. The efficiencies of the lipids which had an extra 
quaternized cationic centre were 2-4-fold more than that of the commercially available 
reagent Lipofectamine in transfecting COS-1, CHO, A-549, and MCF-7 cells. MTT viability 
assay in CHO cells showed high (>75%) cell viabilities at the lipid/DNA charge ratios used. 
DNase I protection assays showed that the lipids having the extra quaternized centre 
protected DNA better. These results shed light on the importance of choosing the type of 
head group and number of cationic centres in designing cationic lipids.133 
A series of cationic cholesterol derivatives were synthesized by covalently attaching the 
heterocycles imidazole, piperazine, pyridine, and morpholine groups (the head groups) to the 
parent cholesterol via a biodegradable carbamoyl linker.134 These lipids were compared with 
the parent DC-Chol with the linear amine head-group, and they generally showed better or 
comparable transfection efficiency of pCMV-luciferase into human HepG2 cells (human liver 
cancer cell line) in the presence or absence of FCS. The most efficient two of these lipids 
were with morpholine and piperazine head-groups, and they gave higher levels of gene 
expression in HepG2 and KZ2 (human melanoma cell line) which are generally very hard to 
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transfect with the commonly used reagents such as DC-chol, Lipofectamine, and PEI. In vivo 
studies with lipids having morpholine and piperazine head-groups resulted in successful 
delivery of the reporter gene to the target cells through intrasplenic injection.134 Cationic 
lipids which have more than one cationic head-group (multivalent cationic lipids) have more 
surface charge density than their monovalent (with one head group) analogues, and they are 
generally expected to better bind and complex polynucleotides. Many multivalent cationic 
lipids contain a natural occurring polyamine such as spermidine and spermine, which are well 
known to interact with the minor groove of B-DNA.135 The triamine spermidine and the 
tetramine spermine, and their diamine precursor putrescine, are organic polycations that are 
widely but unevenly distributed in both mammalian and non-mammalian cells and tissues. 
They have an essential role in controlling DNA, RNA and protein synthesis during normal 
and neoplastic growth, in cell differentiation, and in tissue regeneration.136 These polyamines 
exhibit many metabolic and neurophysiological effects in the nervous system, and are 
important for the developing and mature nervous system and affect modulation of ionic 
channels and calcium-dependent transmitter release.136-142 
Spermine (Figure 6) is incorporated in DOGS143 (dioctadecylamidoglycylspermine); 
spermidine bound in cholesteryl-spermidine.144 The free amine groups of spermine in 
cholesteryl-spermine conjugates have different pKa values and provide a buffering effect in 
the endosomes facilitating the escape of lipoplex from the endosomes.145 The length of the 
linear polyamine attached to the hydrophobic domain and the charge distribution on it affects 
the transfection efficiency of the cationic lipid.146 Addition of amine groups separated by 
methylene groups to the linear polyamine attached to a cholesterol residue did not 
automatically increase transfection efficiency regardless of the increased charge density. 
Molecular modelling simulations suggested that increasing chain length led to an increased 
number of folded conformations due to greater flexibility of the conjugates, which is 
unfavourable for interaction with DNA.125, 146 
The central tetramethylene motif of spermine was reported to be essential in conferring 
high transfection efficiency in a series of cholesterol-polyamine conjugates.145 It was 
suggested that the tetramethylene segment of spermine can bridge between the DNA 
complementary strands, while the polyamine with a central trimethylene segment would only 
bind with the adjacent phosphates on the same DNA strand. These results point to the 
importance of the structure of the polyamine head-group and the relation between its amine 
groups, and also points to the fact that increasing efficiency of transfection is not only a 
matter of increasing number of positive charges per head group.  
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The hydrophobic domain 
The length, saturation state and type of the hydrophobic chains conjugated to cationic 
lipids affect their transfection efficiency.147-149 Although these factors were studied 
extensively for the effect on transfection, and although the majority of studies accepted that 
the type of alkyl chains influence the outcome of transfection, it is difficult to set a definitive 
set of rules to describe the best type of alkyl chains to be conjugated to the polar head-groups. 
The contribution of the alkyl chains (and the hydrophobic domain) to the cationic lipid 
properties as a whole is what determines the transfection efficiency of the lipid.  
Results obtained with DMRIE150 (1,2-dimyristyloxypropyl-3-dimethyl-hydroxyethyl-
ammonium bromide), glycine betaine conjugates131 with two alkyl chains, alkyl acyl carnitine 
esters having chains of length C12 to C18,151 lactic acid conjugates of N,N-dialkyl amine 
group,152 lipids related to DOTAP with two alkyl chains (C12-C18) linked to the head group 
through ether bonds,153 and cationic lipids with different hydroxyethyl or dihydroxypropyl 
ammonium backbones and esterified hydrocarbon chains and hydroxy substituents154 showed 
that a comparison of the cationic lipids based only on the lengths of the two saturated 
aliphatic chains led to the observation of the superior transfection efficiency of C14 chains 
over the longer C16 and C18 chains.125, 126 It was proposed that a shorter chain length 
facilitates mixing with cellular membranes131 which is important for endosomal escape.155  
In another set of experiments, the longer chain C18 oleoyl (with one cis-double bond) was 
found to be more efficient than cationic lipids with shorter chain lengths. Varying the chain 
length in N4,N9-diacyl spermines plasmid DNA delivery from C10 to C18 resulted in the 
conjugate with the C18 oleoyl chains to be the most efficient and less toxic than the shorter 
chain conjugates.156 A series of multivalent gemini surfactants with the hydrophobic chains 
systematically varied resulted in the conjugates with C18 oleoyl chains to be better in 
transfection than the C16 and C14 alkyl chains.157 Chain saturation also was shown to affect 
the efficiency of transfection. The results of studies on a set of cationic triester phosphatidyl 
choline derivatives (each having two alkyl chains) show a strong dependence of their 
transfection efficiency on the lipid hydrocarbon chain characteristics, where transfection 
activity increases with increasing chain unsaturation from fully saturated to having two 
double bonds. Transfection efficiency decreased with increasing chain length (increasing the 
total number of carbons per lipid molecule ~30-50). Maximum transfection was with 
monounsaturated myristoleoyl 14:1 chains.149 The data obtained from transfection 
experiments with 20 cationic phosphatidylcholine (PC) derivatives show that hydrocarbon 
chain variations results in transfection efficiencies that varies by more than 2 orders of 
magnitude. The most important variables were chain saturation state and total number of 
carbon atoms in the lipid chains. Transfection increased with decreasing chain length and 
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increasing chain unsaturation. Best transfection efficiency was found for cationic lipids with 
monounsaturated (myristoleoyl) 14:1 chains.147 Higher levels of transfection were also 
reported with lipids having oleoyl chains in comparison with stearoyl chains.150, 151 
Unsaturated chains promote lipid fusion between the lipoplexes and the various cellular 
membranes, which is essential for delivery and endosomal escape.126, 147, 158  
Cholesterol derivatives with various cationic head-groups were synthesized to investigate 
their efficiency as siRNA delivery vectors. The transfection efficiencies of siRNA lipoplexes 
prepared with the cationic cholesterol derivatives DC-Chol, cholesteryl-3-carboxyamido-
ethylene-N-hydroxyethylamine (OH-Chol), and N-hydroxyethylaminopropane carbamoyl 
cholesterol (HAPC) was investigated in human prostate tumour cells that stably express the 
luciferase gene (PC-3-Luc). When lipoplexes were prepared in water, HAPC was more 
effective in knocking-down luciferase activity than OH-Chol and DC-Chol.159 The presence 
of NaCl while preparing the lipoplexes increased the gene silencing efficiency of luciferase, 
while it did not affect efficiency of HAPC. The commercially available transfection reagent, 
Lipofectamine 2000 (a cationic lipid liposomal preparation) resulted in strong gene silencing 
by siRNA, but exhibited increased toxicity (~40% cell viability), in contrast to OH-Chol, DC-
Chol, and HAPC lipoplexes (~80–100% cell viability). These results indicated that siRNA 
lipoplexes prepared with OH-Chol, and HAPC can efficiently suppress gene expression 
without increased cytotoxicity.159 
 
The linker 
The linker is represented by the type (hence properties) of the functional group and the 
length (number of carbons) of the linker. The linker has two main functions: (a) to covalently 
conjugate the polar head-group to the hydrophobic domain; (b) to control the biodegradability 
of the cationic lipid and/or introduce a new property to the cationic lipid, e.g. responding to 
the intracellular reducing environment.126, 160 The most commonly used linkers are amide, 
carbamate, ester, ether, orthoesters, and disulfide linkers. 
Both amides and ester bonds are biodegradable and hence are hypothesized to be less 
toxic than other non-biodegradable bonds (e.g. ethers).161 Lipids with a pyridinium head-
group (with palmitoyl 16:0 hydrophobic domains and with ester and amide linkers) were used 
to prepare liposomes with either DOPE or cholesterol at the cationic lipid/helper-lipid molar 
ratio of 1:1. Following transfection of Chinese hamster ovary (CHO) cells with lipoplexes 
delivering plasmids expressing EGFP, the cationic lipids having amide linkers significantly 
increased transfection efficiency in all liposomal formulations compared to their counterparts 
having the ester linker.162 The high transfection efficiency of lipids with amide linker was 
suggested to be due to their lower phase transition temperature which makes the liposome’s 
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bilayer structure more stable in aqueous media during the transfection process as well as 
liposome storage. The phase transition temperature of a lipid is the temperature at which there 
is a change in the lipid’s physical state from the ordered gel phase (where the hydrocarbon 
chains are closely packed and fully extended) to the disordered liquid crystalline phase 
(where the hydrocarbon chains are fluid and randomly oriented).162 
Depending on the structure of the cationic lipid, the linker influence on transfection 
efficiency can be more than on cytotoxicity. Cholesterol-based cationic lipids that have 
different nitrogenous heterocyclic head-groups (N-methylimidazole, N-methylmorpholine, 
and pyridine) and acid-labile linkers (carbamate, ester, and N,O-acetal ether) were used to 
transfect human embryonic kidney 293 (HEK 293) cells with EGFP plasmid.163 Choosing 
those linkers was based on the concept that incorporation of acid-labile bonds in the cationic 
lipid structure enhances the release of polynucleotides from the endosomes, therefore 
increasing the transfection efficiency.164 N,O-Acetals are known to undergo hydrolysis in 
acidic environment.163, 164 The results showed that the structure of these lipids only slightly 
affected their cytotoxicity but largely changes the efficiency of intracellular accumulation of 
the polynucleotides. The lipids having the cationic head-groups pyridine and/or 
methylimidazole head-groups with either an ester or a carbamate linker resulted in better 
transfection efficiency as compared with the cationic lipids with either the N-
methylmorpholine head-groups and/or an ether linker. The lipid that has a pyridine head-
group and a carbamate linker to deliver EGFP plasmid resulted in comparable transfection 
efficiency with that of the commercially available Lipofectamine 2000. 
Two cleavable cationic lipids having a linear or a cyclic ortho ester linker between the 
cationic head-group and the unsaturated hydrophobic domain (two oleoyl chains) were 
previously reported.165 It is hypothesized that the acidic pH in the endosomes catalyzes the 
hydrolysis of the linker group to result in fragmentation products that destabilize the 
endosomal membranes. At pH 7.4, the lipids (with DOPE) formed stable lipoplexes with 
plasmid DNA. Decreasing the pH enhanced the hydrolysis of the ortho ester linkers which 
removed the cationic head-groups and caused lipoplex aggregation. At pH 5.5, the cationic 
lipid N-[2-methyl-2-(1',2'-dioleylglyceroxy)dioxolan-4-yl]methyl-N,N,N-trimethylammonium 
iodide that have a cyclic ortho ester linker showed increased pH-sensitivity and caused the 
permeation of its lipoplexes to model biomembranes within the time span of endosomal 
processing before the lysosomal degradation. This lipid markedly increased gene transfection 
(~3-50-fold) of the luciferase reporter protein in monkey kidney fibroblast (CV-1) and human 
breast cancer (HTB-129) cells in culture compared to the pH-insensitive control lipid 
DOTAP lipoplexes.165  
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Transfection with DNA lipoplexes of three thiocholesterol-derived gemini cationic lipids 
possessing disulfide linkages incorporated between the cationic head-group and the 
thiocholesterol backbone in order to render the lipids biodegradable was reported.166 
Comparing transfection in prostate cancer line (PC3AR) and a human keratinocyte cell line 
(HaCat) with two commercially available reagents showed comparable or better expression of 
GFP in the transfected cells. Cytotoxic studies showed the nontoxic property of these 
lipid−DNA complexes at different N/P ratios used for transfection studies. The rationale 
behind this design was to ensure the destabilization of the lipid-polynucleotide lipoplexes in 
the cytoplasm after reduction of the disulfide linker by the intracellular glutathione (GSH), 
which is the most abundant low molecular weight thiol present in cells and is involved in 
controlling cellular redox environment. GSH is found at high intracellular concentrations and 
very low extracellular concentrations e.g. blood plasma concentrations (2 µM) are 1000-fold 
less than concentration in erythrocytes (2 mM). This large difference between intra- and 
extracellular environments provides a potential mechanism for release of polynucleotides 
from lipoplexes of lipids that have a disulfide linker.166 
In Chapter 2, five symmetrical acyl spermine derivatives (fatty acid amides of spermine) 
are synthesized, characterized, and evaluated as non-viral vectors for siRNA. The 
intracellular delivery of siRNA and the subsequent sequence specific gene silencing will be 
quantified by flow cytometry techniques (FACS analysis). The ability of the spermine 
conjugates to bind siRNA and form nanoparticles is investigated. The effect of the complexes 
of siRNA lipoplexes on the cell viability 48 h post transfection is measured. The SAR study 
in Chapter 2 aims to indentify the most efficient fatty acid(s) in terms of high gene-silencing 
efficiency and high cell viability. 
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Chapter Two  Efficient gene silencing by self-assembled complexes of siRNA and 
symmetrical fatty acid amides of spermine 
 
1. Introduction 
 
Cationic lipids are widely used as non-viral vectors for the intracellular delivery of DNA 
and later oligonucleotides such as siRNA.160, 167, 168 The cationic head-group of a cationic lipid 
should contain one or more functional groups that can acquire a positive charge at a 
physiological pH of 7.4 such as amines (primary, secondary, tertiary, and quaternary),169, 170 
guanidines, imidazoles, or pyridinium salts.169 The positive charge on the cationic head-group 
interacts electrostatically with the negative charge of the phosphate backbone of the siRNA 
while the hydrophobic part of the cationic lipids promotes the formation of vesicles or 
siRNA/cationic lipid aggregates called lipoplexes. The hydrophobic moiety of cationic lipids 
can affect the siRNA delivery and the biological activity (gene knock-down) according to its 
physical and chemical properties such as chain length and saturation state.147 Therefore in this 
Chapter, a series of symmetrical diacyl lipopolyamines are designed in order to prepare 
lipoplex formulations (without any pre-preparation of liposomes) of an Alexa Fluor 647-
tagged siRNA to investigate if they are suitable for efficient gene silencing in target cells, by 
forming nanoparticles which will efficiently enter cells either by endocytosis only (a major 
pathway) or possibly by endocytosis in combination with fusion between siRNA lipoplexes 
and the plasma membrane (a minor pathway).171  
In this Chapter, five symmetrical diacylated spermine conjugates are designed and 
synthesized, with variation in the length (from short C12 lauroyl to very long C22 erucoyl) 
and/or oxidation state from stearoyl (18:0) to oleoyl (18:1) to linoleoyl (18:2). The two acyl 
fatty chains are regiospecifically covalently bound to spermine at the N4- and N9-positions. 
Detailed evidence for the characterisation of the nanoparticles, the delivery of Alexa Fluor 
647-tagged siRNA, the subsequent silencing of EGFP in HeLa cells stably expressing the 
fluorescent protein, and cell viability evaluation after transfection are provided. These results 
are compared with those obtained with the commercially available transfection reagents 
Lipofectamine 2000 (liposomal) and TransIT-TKO (non-liposomal). Gene silencing studies 
in comparable systems on human embryonic kidney 293T cells stably expressing GFP,172 
HeLa705 cells expressing luciferase,173 human embryonic retinoblast cells (911 cells) stably 
expressing luciferase,174 HeLa cells expressing GFP,171, 175, 176 and glioma cells (C6) 
expressing GFP177 have been reported.  
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2. Materials and methods 
 
2.1. Materials and general methods 
Glassware used when anhydrous conditions were required was heated for 18 h at 80 °C, 
assembled while hot, filled with anhydrous nitrogen then allowed to cool to 20 °C before 
being used. Thin layer chromatography (TLC) was performed using aluminium-backed plates 
coated with Kieselgel 60 F254 (Merck). Ninhydrin (0.2 g) in ethanol (100 mL) was used for 
detecting polyamines on TLC plates. KMnO4 solution was used as universal indicator for 
lipopolyamines and other compounds/impurities on TLC plates (prepared by dissolving 1.5 g 
of KMnO4, 10 g K2CO3, and 1.2 mL 10% NaOH in 200 mL water). Column chromatography 
was performed over flash silica gel 60 (35-75 μm; Prolabo-Merck). Dicyclohexyl 
carbodiimide (DCC), 4-dimethylaminopyridine (DMAP), fatty acids, fatty acid chlorides, 
G418, hydrazine monohydrate, N-carbethoxyphthalimide, spermine, and triethylamine 
(TEA), were purchased from Sigma-Aldrich (Gillingham, UK). All solvents were purchased 
from Fisher Scientific UK (Loughborough, UK). Anhydrous dichloromethane (DCM) was 
distilled over calcium hydride. Anhydrous tetrahydrofuran (THF) was distilled from sodium 
benzophenone ketyl. Cell culture media were purchased from Gibco (Invitrogen Ltd, Paisley, 
UK). NMR spectra were recorded in chloroform-D using a Varian Mercury 400 (operating at 
400 MHz for 1H and 100.8 MHz for 13C) spectrometer. The high resolution (HR) time-of-
flight mass spectra were obtained on a Bruker Daltonics micrOTOF mass spectrometer using 
electrospray ionisation (ESI). Transfection reagents Lipofectamine 2000 (liposomal) and 
TransIT-TKO (proprietary non-liposomal cationic polymer/lipid formulation) were purchased 
from Invitrogen and Mirus Bio (Cambridge, UK). AllStars negative controls siRNA (siNC) 
tagged with Alexa Fluor® 647 (AF647) at the 3'-position (siNC-AF) were purchased from 
Qiagen (Crawley, UK) as was siRNA against EGFP labelled with Alexa Fluor® 647 (siEGFP-
AF) at the 3'-position of the sense strand, sequences:   
Sense strand:  5'-GCAAGCUGACCCUGAAGUUCAUTT-3',  
Anti-sense strand:  5'-AUGAACUUCAGGGUCAGCUUGCCG-3',  
Target DNA sequence:  5'-CGGCAAGCTGACCCTGAAGTTCAT-3'.  
 
2.2. Synthesis of fatty acid amides of spermine 
N-Carbethoxyphthalimide (0.44 g, 2 mmol) was added to a solution of 1,12-diamino-4,9-
diazadodecane (spermine) (0.20 g, 1 mmol) in DCM (10 mL). The solution was stirred 20 °C 
for 3 h then evaporated to dryness in vacuo and the residue was either purified over silica gel 
(DCM/MeOH 10:1 then 2:1 v/v) or alternatively used directly in the following step. To a 
solution of 1,12-diphthalimido-4,9-diazadodecane in DCM (10 mL) and TEA (0.28 mL, 2 
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mmol) fatty acid chloride (2 mmol), or alternatively fatty acid (2 mmol), DMAP (0.24 g, 2 
mmol), and DCC (0.4 g, 2 mmol) were added and stirred for 18 h under nitrogen atmosphere. 
The solvent was then evaporated to dryness in vacuo and the residue was treated with 
hydrazine monohydrate (2 mL) in a mixture of DCM (15 mL) and THF (15 mL) and heated 
under reflux for 4 h then the solvent was evaporated in vacuo to dryness and the residue 
purified over silica gel (DCM/MeOH 10:1 v/v then DCM/MeOH/NH4OH 20:10:1 v/v/v) to 
afford the title compounds as the free bases which were then fully characterised by both high-
field 1H and 13C NMR spectroscopy and HR-ESI-MS.  
 
N4,N9-Dierucoyl-1,12-diamino-4,9-diazadodecane (DEruS). 
To a solution of 1,12-diphthalimido-4,9-diazadodecane (0.46 g, 1 mmol) in DCM (30 mL) 
erucic acid (0.68 g, 2 mmol), DMAP (0.24 g, 2 mmol), and DCC (0.4 g, 2 mmol) were added. 
The solution was stirred at 20 °C for 18 h under an atmosphere of nitrogen, then filtered and 
the filtrate was evaporated to dryness in vacuo. The residue was reacted with hydrazine 
monohydrate (2 mL) in a mixture of DCM (15 mL) and THF (15 mL) and heated under 
reflux for 4 h, cooled to 20 °C, and then the solvent was evaporated in vacuo. The residue 
was purified over silica gel (DCM/MeOH 10:1 v/v then DCM/MeOH/NH4OH 20:10:1 v/v/v) 
to afford the title compound (0.34 g, 40% over two steps). 1H NMR, 0.8 (t, J = 7 Hz, 6H, 
H22'), 1.1-1.3 (m, 60H, H4'-H11', H16'-H21', 2 x NH2), 1.4-1.6 (m, 12H, H2, H6, H7, H11, 
H3'), 1.9 (m, 8H, H12'-H15'), 2.2-2.4 (m, 4H, H2'), 2.5-2.7 (m, 4H, H1, H12), 3.2-3.6 (m, 8H, 
H3, H5, H8, H10), 5.2 (m, 4H, H13', H14'). 13C NMR, 14.0 (C22'), 22.6 (C21'), 25.1-32.8 
(C2, C6, C7, C11, C12, C3'-C12', C15'-C20'), 33.1 (C2'), 39.2-39.4 (C1, C12), 42.6-47.4 (C3, 
C5, C8, C10), 129.8 (C13', C14'), 172.8-173.0 (C1'). HRMS, found (M+H)+ 843.8364, 
C54H107N4O2 requires (M+H)+ 843.8389; found (M+Na)+ 865.8194, C54H106N4O2Na requires 
(M+Na)+ 865.8208.  
 
N4,N9-Dilauroyl-1,12-diamino-4,9-diazadodecane (DLauS). 
To a solution of 1,12-diphthalimido-4,9-diazadodecane (2.31 g, 5 mmol) in DCM (30 mL) 
and TEA (1.4 mL, 10 mmol) lauroyl chloride (2.4 mL, 10 mmol) was added. The solution was 
stirred for 18 h at 20 °C, and then the solvent was evaporated to dryness in vacuo. The residue 
was reacted with hydrazine monohydrate (2 mL) in a mixture of DCM (15 mL) and THF (15 
mL) and heated under reflux for 4 h, cooled to 20 °C, and then the solvent was evaporated in 
vacuo. The residue was purified over silica gel (DCM/MeOH 10:1 v/v then 
DCM/MeOH/NH4OH 10:5:1 v/v/v) to afford the title compound (1.46 g, 40% over two steps). 1H 
NMR, 0.9 (t, J = 7 Hz, 6H, H12'), 1.2-1.3 (m, 32H, H4'-H11'), 1.4-1.7 (m, 12H, H2, H6, H7, 
H11, H3'), 1.9 (m, 2 x NH2), 2.1-2.3 (m, 4H, H2'), 2.5-2.7 (m, 4H, H1, H12), 3.2-3.5 (m, 8H, H3, 
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H5, H8, H10). 13C NMR, 14.0 (C12'), 22.6 (C11'), 25.1-32.7 (C2, C6, C7, C11, C4'-C10'), 33.1-
36.8 (C2'), 38.1-39.4 (C1, C12), 42.5-47.7 (C3, C5, C8, C10), 172.9-173.3 (C1'). HRMS, found 
(M+H)+ 567.5553, C34H71N4O2 requires (M+H)+ 567.5572 C34H71N4O2 567.5572. 
 
N4,N9-Dilinoleoyl-1,12-diamino-4,9-diazadodecane (DLinS).  
To a solution of 1,12-diphthalimido-4,9-diazadodecane (0.46 g, 1 mmol) in DCM (30 mL) 
linoleic acid (0.56 g, 2 mmol), DMAP (0.24 g, 2 mmol), and DCC (0.4 g, 2 mmol) were 
added. The solution was stirred at 20 °C for 18 h under an atmosphere of nitrogen, then 
filtered and the filtrate was evaporated to dryness in vacuo. The residue was reacted with 
hydrazine monohydrate (2 mL) in a mixture of DCM (15 mL) and THF (15 mL) and heated 
under reflux for 4 h, cooled to 20 °C, and then the solvent was evaporated in vacuo and the 
residue purified over silica gel (DCM/MeOH 10:1 v/v then DCM/MeOH/NH4OH 20:10:1 
v/v/v) to afford the title compound (0.29 g, 40% over two steps). 1H NMR, 0.8 (t, J = 7 Hz, 
6H, H18'), 1.2-1.3 (m, 28H, H4'-H7', H15'-H17'), 1.4-1.8 (m, 16H, H2, H6, H7, H11, H3', 2 x 
NH2), 1.9-2.0 (m, 8H, H8', H14'), 2.0-2.3 (m, 4H, H2'), 2.5-2.7 (m, 8H, H1, H12, H11'), 3.2-
3.4 (m, 8H, H3, H5, H8, H10), 5.2-5.3 (m, 8H, H9', H10', H12', H13'). 13C NMR, 14.0 (C18'), 
22.4 (C17'), 25.0-33.0 (C2, C6, C7, C11, C2'-C8', C11', C14'-C16'), 39.0-39.3 (C1, C12), 
42.4-47.6 (C3, C5, C8, C10), 127.8-130.0 (C9', C10', C12', C13'), 172.7-173.0 (C1'). HRMS, 
found (M+H)+ 727.6851, C46H87N4O2 requires (M+H)+ 727.6824. 
 
N4,N9-Dioleoyl-1,12-diamino-4,9-diazadodecane (DOS). 
To a solution of 1,12-diphthalimido-4,9-diazadodecane (2.31 g, 5 mmol) in DCM (30 mL) 
and TEA (1.4 mL, 10 mmol) oleoyl chloride (3.3 mL, 10 mmol) was added. The solution was 
heated under reflux for 18 h, cooled to 20 °C, and then the solvent was evaporated to dryness in 
vacuo. The residue was reacted with hydrazine monohydrate (2 mL) in a mixture of DCM (15 
mL) and THF (15 mL) and heated under reflux for 4 h, cooled to 20 °C, and then the solvent was 
evaporated in vacuo. The residue was purified over silica gel (DCM/MeOH 10:1 v/v then 
DCM/MeOH/NH4OH 10:5:1 v/v/v) to afford the title compound (1.46 g, 40% over two steps). 1H 
NMR, 0.8 (t, J = 7 Hz, 6H, H18'), 1.2-1.3 (m, 40H, H4'-H7', H12'-H17'), 1.4-1.8 (m, 12H, H2, 
H6, H7, H11, H3'), 1.9-2.1 (m, 8H, H8', H11'), 2.1-2.3 (m, 4H, H2'), 2.6-2.8 (m, 8H, H1, H12, 2 
x NH2), 3.2-3.5 (m, 8H, H3, H5, H8, H10), 5.3-5.4 (m, 4H, H9', H10'). 13C NMR, 14.1 (C18'), 
22.6-29.7 (C2, C6, C7, C11, C4'-C8', C11'-C17'), 31.9 (C3'), 33.1 (C2'), 38.9-39.2 (C1, C12), 
42.5-47.4 (C3, C5, C8, C10), 129.8 (C9', C10'), 172.9 (C1'). HRMS, found (M+H)+ 731.7162, 
C46H91N4O2 requires (M+H)+ 731.7137. 
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N4,N9-Distearoyl-1,12-diamino-4,9-diazadodecane (DSS). 
To a solution of 1,12-diphthalimido-4,9-diazadodecane (2.31 g, 5 mmol) in DCM (30 mL) 
and TEA (1.4 mL, 10 mmol) stearoyl chloride (3.3 mL, 10 mmol) was added. The solution was 
stirred for 18 h at 20 °C, and then the solvent was evaporated to dryness in vacuo. The residue 
was reacted with hydrazine monohydrate (2 mL) in a mixture of DCM (15 mL) and THF (15 
mL) and heated under reflux for 4 h, cooled to 20 °C, and then the solvent was evaporated in 
vacuo. The residue was purified over silica gel (DCM/MeOH 10:1 v/v then 
DCM/MeOH/NH4OH 10:5:1 v/v/v) to afford the title compound (1.46 g, 40% over two steps). 1H 
NMR, 0.9 (t, J = 7 Hz, 6H, H18'), 1.2-1.4 (m, 56H, H4'-H17'), 1.4-1.7 (m, 12H, H2, H6, H7, 
H11, H3'), 1.9-2.0 (m, 4H, 2 x NH2), 2.1-2.3 (m, 4H, H2'), 2.6-2.8 (m, 4H, H1, H12), 3.2-3.4 (m, 
8H, H3, H5, H8, H10). 13C NMR, 14.0 (C18'), 22.6 (C17'), 25.0-32.7 (C2, C6, C7, C11, C3'-
C16'), 33.1 (C2'), 38.9-39.4 (C1, C12), 42.4-47.43(C3, C5, C8, C10), 12), 172.9-173.1 (C1'). 
HRMS, found (M+H)+ 735.7428, C46H95N4O2 requires (M+H)+ 735.7450.  
 
2.3. HeLa cell line stably expressing EGFP (HeLa-EGFP) 
The HeLa cell line stably expressing the red-shifted enhanced variant of wild-type GFP 
(EGFP) used here as a reporter protein was obtained from the Cell Service at Cancer Research 
UK (CRUK, London Research Institute, Clare Hall Laboratories, South Mimms, London, UK) 
and was constructed by Dr Yilun Liu. Briefly, the centrin protein (CEN) was subcloned into the 
expression vector pEGFP-C1 (Clontech, Cowley, UK), downstream of EGFP, under the control 
of the human CMV promoter. The plasmid was linearized and transfected into HeLa cells. 
Stably transfected cells were selected with G418 and maintained as a polyclonal cell line, 
cultivated in DMEM medium supplemented with 10% FCS, penicillin base (50 units/mL), 
streptomycin (50 g/mL), and G418 (1 mg/mL). The cells were passaged every 3 or 4 days and 
cultures were routinely checked under inverted light microscope for any signs of microbial 
contamination. The FCS used in culture media preparations and other experiments is heat 
inactivated at 56 °C for 45 min. The percentage of EGFP positive cells was >80% as measured 
by flow cytometry (FACS) (data not shown) and regularly was verified prior to siRNA 
transfection experiments.  
 
2.4. Transfection studies of HeLa cells stably expressing EGFP 
Cells were trypsinized (0.25% trypsin in PBS, 3-4 min incubation at 37 °C, 5% CO2) at 
confluency 80-90% and counted under an inverted light microscope by means of a 
haemocytometer using trypan blue dye (0.4% dye in 0.81% sodium chloride and 0.06% 
dibasic potassium phosphate) to exclude dead cells. The cells were then seeded at a density of 
37 
 
65,000 cells/well in 24-well plates and were incubated for 24 h at 37 °C, 5% CO2, prior to 
transfection. On the day of transfection, the lipoplexes were prepared by mixing two 
solutions A and B. Solution A was prepared by adding the specified volume of an ethanol 
solution containing the required amount of the cationic lipid to Opti-MEM serum-free 
medium (total volume is 50 L), followed by mixing with a vortex mixer for 2-3 s. Solution 
B was prepared by adding the required volume of siRNA stock solution to Opti-MEM serum-
free medium to make a final volume of 15 L of 1 siRNA, then mixing briefly by 
pipetting gently up and down by means of a micropipette . Solution B was then added to 
solution A (in Eppendorf microtubes, 1.5 mL) followed by mixing for 4 s by means of a 
vortex mixer. The lipoplexes were then allowed to form for 20 min at 20 °C. The 24-well 
plates containing the HeLa cells were then removed from the incubator, and the lipoplex 
solutions (65 L) were added to each well containing 935 L DMEM (10% FCS) to make the 
final volume 1 mL. The plates were then incubated for 48 h at 37 °C, 5% CO2. siRNA against 
EGFP used in these experiments has 24 base-pairs, thus each molecule of siRNA contains 46 
negative charges corresponding to 46 negatively charged phosphate groups in the siRNA 
backbone. The synthesized spermine fatty acid amides each contain two terminal primary 
amine groups which will be positively charged at physiological pH 7.4, therefore, each 
cationic lipid molecule carries two positive charges. N/P ratio was calculated using the 
following equation:  
 
siRNAdsinphosphatesofnumbertotalsiRNAofmolesofnumber
lipidcationicofmolesofnumberPN



0.2/  
Transfection with the commercial non-viral vectors Lipofectamine 2000 and TransIT-
TKO was carried out according to the protocol supplied by the manufacturers. 
 
2.5. Flow Cytometry (FACS) 
For analysis of delivery and then reduction of expression of EGFP by flow cytometry 
(fluorescence-activated cell sorting, FACS), cells were washed twice with PBS and then were 
trypsinized (0.25% trypsin in PBS, 5-7 min incubation at 37 °C, 5% CO2) and resuspended in 
DMEM medium containing 10% FCS and without phenol red. Cells were centrifuged (1,000 
rpm Falcon 6/300 MSE, London, UK, for 5 min) then washed twice by resuspending in PBS 
containing 0.1% BSA, and then re-centrifuged (1,000 rpm for 5 min). The collected cells 
were then resuspended in PBS and transferred to a flow cytometer tube (Becton Dickinson, 
UK), and kept on ice at 1 °C and protected from light until starting FACS analysis. Cells 
were then analyzed (10,000 or 20,000 events) using a FACSCanto flow cytometer (Becton 
Dickinson, UK), equipped with an argon ion laser at 488 nm for excitation, a Long Pass (LP) 
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filter at 502 nm and a detector at 530 nm (range +/-15 nm) for green fluorescence emission, 
and a helium/neon laser at 633 nm for excitation of Alexa Fluor 647 and a detector at 660 nm 
(range +/- 10 nm). EGFP expression was calculated as:   
100% 
cellscontrolofcefluorescenEGFP
cellsdtransfecteofcefluorescenEGFPEGFP  
 
siRNA delivery was evaluated (48 h post-transfection) by means of normalizing the 
geometric mean fluorescence (calculated using BD FACSDivaTM software) of the Alexa 
Fluor 647 of each sample relative to the geometric mean fluorescence of Alexa Fluor 647-
siRNA delivered by either of two standards (DOS or TransIT-TKO). 
 
2.6. Confocal microscopy cell imaging 
Cells were trypsinized (0.25% trypsin in PBS, 3-4 min incubation at 37 °C, 5% CO2) at 
confluency 80-90% and counted under an inverted light microscope by means of a 
haemocytometer using trypan blue dye (0.4% dye in 0.81% sodium chloride and 0.06% 
dibasic potassium phosphate) to exclude dead cells. Cells were then seeded at a density of 
65,000 cells/well in 24-well plates that have a round-glass cover slip (12 mm in diameter, 
sterilized) already placed in each well and were incubated for 24 h prior to transfection. The 
lipoplexes preparation and the transfection protocol were carried out as described above 
(section 2.4). After 48 h, the cell culture media, in each well, was aspirated and the cells were 
washed with PBS (3 x 0.5 mL). The cell membrane was then stained with wheat germ 
agglutinin (WGA) conjugated to Alexa Fluor® 555 (WGA is a cationic probe that can bind to 
glycoconjugates in cell membrane such as N-acetylglucosamine and N-acetylneuraminic acid 
(sialic acid) residues). The concentration of WGA-Alexa Fluor 555 working solution was 
adjusted to a concentration of 5 µg/mL in Hank’s balanced salt solution without phenol red. 
The cells were then incubated for 10 min in the dye working solution at 37 °C, 5% CO2 in the 
dark. The cells were then washed with PBS (3 x 0.5 mL) and then fixed with 4% 
paraformaldehyde in PBS solution for 20 min at 20 °C in the dark. The cover slips were then 
removed from each well, washed gently with PBS (2 x 0.5 mL), left to dry briefly in air, and 
then mounted on glass slides using Mowiol (polyvinyl alcohol) solution as the mounting 
media and left in the dark at 20 °C (18 h) to allow hardening of the mounting media. The 
cells were examined using a Carl Zeiss laser scanning microscope LSM 510 meta, with 
EGFP excitation 488 nm, emission 509 nm (505-550 nm band pass filter), Alexa Fluor 555 
excitation 543 nm, emission 565 nm (560-615 nm band pass filter), and Alexa Fluor 647 
excitation 633 nm, emission 668 nm (657-753 nm meta detector). 
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2.7. Cell viability assay 
Cells were trypsinized (0.25% trypsin in PBS, 3-4 min incubation at 37 °C, 5% CO2) at 
confluency 80-90% and counted under an inverted light microscope by means of a 
haemocytometer using trypan blue dye (0.4% dye in 0.81% sodium chloride and 0.06% 
dibasic potassium phosphate) to exclude the dead cells. Cells were then seeded at a density of 
6,500 cells per well of 96-well plates that have flat bottom wells, and incubated for 24 h at 37 
°C, 5% CO2. The lipoplexes were prepared using the same protocol in section 2.4. The 
transfection was carried out using the same protocol as transfecting the 24-well plates 
(Section 2.4) with the exception of reducing the amount of lipoplexes such that each well of 
the 96-well plates contains 1.5 pmol siRNA in a final volume of 100 L/well of DMEM that 
contains 10% FCS. After 44 h, alamarBlue® 178 (10 L) was added to each well. After 
incubation (3.5 h), the absorbance of each well was measured at 570 nm and 600 nm using a 
microplate-reader (VERSAmax), using the cell culture media in 3 wells without alamarBlue 
as blank. The amount of reduced alamarBlue at 570 nm was calculated as: 
)( 600570 RAAreducedamount    
600
570
AOx
AOxR  
R is correction factor for cell culture medium (without cells). AOx570 and AOx600 are the 
absorbance of oxidized alamarBlue at 570 and 600 nm respectively, and are measured by 
adding 10 L of alamarBlue to 3 wells of each 96-well plate that contain 100 L cell culture 
media without cells directly prior to measuring the absorbance. Percentage viability was 
calculated as:  
100% 
cellscontrolofalamarBlueofreducedamount
cellssampleofalamarBlueofreducedamountviability  
 
2.8. Particle size and zeta potential measurements 
Lipoplexes were prepared by mixing two solutions A and B. Solution A was prepared by 
adding the specified volume of an ethanolic solution containing the required amount of the 
cationic lipid to HEPES (final volume 250 µL, 10 mM buffer, pH 7.4) and mixing for 2-3 s 
by means of a vortex mixer. Solution B was prepared by adding the specified volume of stock 
siRNA solution to a HEPES buffer solution (10 mM, pH 7.4) to make a final volume of 75 
L (1 M siRNA solution), and mixing gently by pipetting up and down using a 
micropipette. Solution B was then added to solution A (in an Eppendorf microtube, 1.5 mL), 
followed by mixing for 3-4 s by means of a vortex mixer. The lipoplexes were then allowed 
to form for 20 min at 20 °C. Before carrying out the measurements, samples were diluted to a 
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final volume of 3 mL with HEPES buffer and mixed gently. Dynamic light scattering (DLS) 
and -potential measurements were carried out using a Malvern Zetasizer Nano S90 with 
refractive index 1.59, viscosity 0.89 cP, dielectric constant 79, at 25 °C with equilibrium time 
3 min. DLS measures the hydrodynamic diameter which is expressed as the mean Z-Average 
diameter in nm. This diameter was calculated from the translational diffusion coefficient by 
using the Stokes-Einstein equation: 
D3
)(

kTHd   
where:- 
d(H) = hydrodynamic diameter 
D = translational diffusion coefficient 
k = Boltzmann’s constant 
T = absolute temperature 
η = viscosity  
he-potential (in mV) was measured by determining the electrophoretic mobility of the 
lipoplexes in buffer medium and was calculated according to Henry equation: 


3
)(2 afU E   
where UE = electrophoretic mobility, ε = dielectric constant, = zeta potential, η = viscosity 
and f(κa) = Henry’s function, κa measures the ratio of the particle radius to electrical double 
layer thickness. Electrophoretic determinations of -potential were commonly made in 
aqueous media having moderate concentration of electrolyte, and f(κa) in this case = 1.5, 
which is referred to as the Smoluchowski approximation. 
Both lipoplex diameter and -potential were recorded as averages of three and six 
measurements respectively ± SD. 
 
2.9. siRNA Binding (RiboGreen Intercalation Assay) 
RiboGreen working solution was prepared by diluting RiboGreen stock solution 1 to 400 
in TE buffer (10 mM Tris-HCl, 1 mM EDTA, pH 7.5 diluted 1 to 20 in RNase free water). 
The lipoplexes were prepared by mixing two solutions A and B. Solution A was prepared by 
adding the specified volume of an ethanol solution containing the required amount of the 
cationic lipid to TE buffer (total volume is 50 L), followed by mixing with a vortex mixer 
for 2-3 s. Solution B was prepared by adding the required volume of siRNA stock solution to 
TE buffer to make a final volume of 15 L of 1 siRNA, then mixing briefly by pipetting 
gently up and down by means of a micropipette . Solution B was then added to solution A (in 
Eppendorf microtubes, 1.5 mL) followed by mixing for 4 s by means of a vortex mixer. The 
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lipoplexes were then allowed to form for 20 min at 20 °C. The lipoplexes were prepared at 
the lipid/siRNA ratios that showed the best reduction in EGFP expression. RiboGreen 
working solution (40 μL) was added to each well of a 96-well plate (flat, black bottom) 
containing free siRNA (1 pmol) or siRNA lipoplexes (1 pmol siRNA/well). Each well 
contained a final volume of 120 µL. The fluorescence was measured (n = 4) using FLUOstar 
Optima Microplate Reader (BMG-LABTECH), ex = 480 nm and em = 520 nm. The amount 
of siRNA available to interact with the dye was calculated by subtracting the values of 
RiboGreen background fluorescence (RiboGreen without siRNA) from each measurement, 
and expressed as a percentage of the control that contained naked siRNA only, calculated as:   
100% 
siRNAnakedofcefluorescenRiboGreen
complexesofcefluorescenRiboGreensiRNAfree  
 
2.10. Statistical analysis 
All data are presented as mean + SD (n = 3 as triplicate of triplicate experiments unless 
otherwise stated where n = 2 as triplicate samples of duplicate experiments). The mean values 
and SD were determined using MS Office Excel 2003. Statistical significance of differences 
between data was evaluated by Student’s unpaired two tailed t-test. A value of p < 0.05 was 
considered significant and p values were determined using GraphPad online software 
(http://www.graphpad.com/quickcalcs/index.cfm). 
 
3. Results and discussion 
 
3.1. Synthesis of fatty acid amides of spermine 
Spermine (N,N′-bis(3-aminopropyl)-1,4-diaminobutane or 4,9-diazadodecane-1,12-
diamine) was used as the starting material to synthesize the five desired fatty acid amide 
conjugates:  N4,N9-dierucoyl spermine 1, N4,N9-dilauroyl spermine 2, N4,N9-dilinoleoyl 
spermine 3, N4,N9-dioleoylspermine 4, and N4,N9-distearoyl spermine 5 (Figure 1 and Table 
1). Spermine has two terminal primary amine groups (N1 and N12) and two secondary amine 
groups (N4 and N9). In order to conjugate the fatty acids to the N4 and N9 amine groups, the 
two terminal primary amine groups of spermine were chemo-selectively protected with the 
phthalimido protecting group using Nefkens’ reagent (N-carbethoxyphthalimide, 2 eq. in 
DCM). 
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Nefkens’ reagent (N-carbethoxyphthalimide)   Spermine 
      (4,9-diazadodecane-1,12-diamine) 
  
DEruS, 1 
 
  
DLauS, 2 
  
DLinS, 3 
  
DOS, 4 
  
DSS, 5 
 
Figure 1. N4,N9-Difatty acid amides of spermine. 
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Nefkens’ reagent (Figure 1) was introduced by G. H. L. Nefkens179 as a mild 
phthaloylating reagent for amino acids. Sosnovsky et al.180 were the first to report the use of 
Nefkens’ reagent for the selective protection of primary amine groups in the presence of 
secondary amine groups in polyamines. Several research groups reported the use of Nefkens’ 
reagent to protect primary amine groups of polyamines since Sosnovsky et al. published their 
work.181, 182  
 
Table 1. N4,N9-Difatty acid amides of spermine. The fatty acids are described by two 
numbers separated by a colon, first the chain length and then the number of double bonds. 
Particle size, ζ-potential, and siRNA binding of fatty acid amides of spermine measured at 
the cationic lipid/siRNA ratios that showed best knock-down. 
 
The 1H-NMR and 1H-1H-NMR-COSY (Figure 2) is of 1,12-diphthalimido-4,9-
diazadodecane (Figure 4, top right). The integration of the peaks at δ = 1.5-1.8 shows that 
there are 2 protons attached to the amine groups, in addition to the 4 protons of carbons 
number 2 and 11. There are 4 protons (H1, H12) next to the phthalimido groups, deshielded, 
at δ = 3.6, as well as the 8 protons (deshielded, H3, H5, H8, and H10) next to the free 
secondary amine groups at δ = 2.4-2.5. The presence of the two phthalimide protecting 
groups can be verified by the aromatic protons integrating for 8 protons at δ = 7.5-7.7. Taken 
altogether with the HRMS shown in Figure 3, it is evident that the phthalimido groups were 
at positions 1 and 12 of the spermine; i.e. the terminal primary amines are the protected ones, 
while the secondary amine groups at 4 and 9 positions are free, which are essential features 
for the successful synthesis of the target N4,N9-spermine conjugates. 
Name of compound 
Fatty 
acid 
Particle size 
(nm) ± SD 
-potential 
(mV) ± SD 
% fluorescence 
of RiboGreen 
N4,N9-Dierucoylspermine 
DEruS 1 
Erucic 
(22:1) 
192 ± 1 63 ± 4 2 ± 1 
N4,N9-Dilauroylspermine 
DLauS 2 
Lauric 
(12:0) 
283 ± 41 25 ± 4 5 ± 1 
N4,N9-
Dilinoleoylspermine 
DLinS 3 
Linoleic 
(18:2) 
353 ± 8 54 ± 1 6 ± 2 
N4,N9-Dioleoylspermine 
DOS 4 
Oleic 
(18:1) 
247 ± 4 54 ± 1 2 ± 1 
N4,N9-Distearoylspermine 
DSS 5 
Stearic 
(18:0) 
145 ± 24 41 ± 7 4 ± 1 
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Figure 2. 1H-NMR (upper) and 1H-1H-COSY (lower) of 1,12-diphthalimido-4,9-
diazadodecane. 
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Figure 3. HRMS of 1,12-diphthalimido-4,9-diazadodecane. 
 
The fatty acids were conjugated to the N4- and N9-position of the diphthalimido protected 
spermine by one of two methods as shown in the scheme in Figure 4, either fatty acyl 
chloride (lauroyl, oleoyl, or stearoyl) (2 eq.) and triethylamine (2 eq.) or alternatively fatty 
acid (erucic or linoleic) (2 eq.), DCC (2 eq.), DMAP (2 eq.) were added to the diphthalimido 
protected spermine solution in anhydrous DCM. After the completion of conjugation 
reaction, as evident by the complete disappearance of 1,12-diphthalimido-4,9-diazadodecane 
spot using TLC, the solution was filtered and then the filtrate was evaporated in vacuo and 
the residue was dissolved in 1:1 mixture of DCM/THF. Refluxing then with hydrazine (2 
mL) resulted in deprotection of the primary amine groups and the precipitation of 
phthalhydrazide (2,3-dihydro-1,4-phthalazinedione) which was removed by filtration. The 
required fatty acid conjugates of spermine were purified by flash silica column 
chromatography to homogeneity by TLC.  
 
 
 
 
Figure 4. Synthesis of N4,N9-diacyl spermine conjugates. 
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Figure 5. 1H-NMR of DES. 
 
Figure 5 shows the 1H-NMR of DES, C54H106N4O2, which is the spermine fatty acid 
conjugate with the highest molecular weight (having the largest number of carbon atoms in 
the fatty acyl chains). The most important features necessary for the identification of the 
target product, include: (a) the presence of the double bond protons (4 protons at δ = 5.3); (b) 
the presence of 8 protons at δ = 3.2-3.3, which are deshielded because they are next to the 
nitrogen atoms of the amide groups, indicating the successful conjugation of the fatty acids to 
the N4 and N9; (c) 6 protons at δ = 0.9 representing the two terminal methyl groups of the two 
conjugated fatty acids; (d) 4 protons at δ = 2.5-2.7 representing two CH2 groups deshielded 
because they are next to an amine group, which means that the amine groups are successfully 
deprotected; (e) The total proton integration which fits the formulae of DES, including the 
four protons of the amine groups at δ = 1.3. Taken altogether, in addition to the found HRMS 
results reported, it can be concluded that the target compound has been synthesised 
successfully. 
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Figure 6. 1H-1H-NMR COSY of DES. 
 
Figure 6 shows the 1H-NMR COSY of DES. The assignments of 1H-NMR of DES can be 
verified, as seen from the cross peaks representing protons of 1 and 12 in relation to protons 
2, 6, 7, and 11. The cross peaks of protons of 3, 5, 8, and 10 to protons 2, 6, 7, and 11 can 
also be seen as shown in Figure 6. Cross peaks relating protons of the terminal methyl groups 
to the fatty acyl chains CH2 groups can also be seen. The absence of any cross peaks of the 
NH2, verifying the presence of the terminal NH2 protons, can be noticed. 
 
3.2. Lipoplex particle size, ζ-potential, and siRNA binding 
The particle size and ζ-potential (Table 1) measurements were carried out on the 
lipoplexes at the cationic lipid/siNC (AllStars siRNA negative control) ratio which gave the 
best knock-down for the specified fatty acid amide of spermine. Particle size characterization 
by dynamic light scattering showed that the particle size of the formed lipoplexes varied from 
145 to 353 nm which is within the size range for lipoplexes required for siRNA and/or DNA 
delivery, probably via endocytosis. The largest lipoplex diameter (353 nm) was obtained with 
3 while the smallest (145 nm) was obtained with 5. There was no obvious direct relationship 
between the lipoplex particle size and the characteristics (chain length and/or number of 
double bonds) of the fatty acid used. The ζ-potentials of the lipoplexes were all positive (+25-
63 mV), playing a role in the stabilization of the lipoplexes by imparting repulsion between 
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the formed lipoplexes and preventing their aggregation. The positive charge of the lipoplexes 
also facilitates interaction with the negatively charged cell membrane. The RiboGreen 
binding assay depends on the increased fluorescence (approx. 1000-fold) of bound 
RiboGreen dye compared to the free (unbound) dye which is practically non-fluorescent.183 
The RiboGreen siRNA binding assay results (Table 1) show that the spermine conjugates 
were able to bind the siNC efficiently as shown by the reduction of RiboGreen fluorescence 
to 2-6% relative to the RiboGreen fluorescence of the free siNC control. Thus, the 
lipospermines successfully bound siNC, formed lipoplexes having positive -potential and 
had diameter in the nanometre range, which are favourable characteristics for transfection 
with lipoplexes.  
 
3.3. Transfection with siRNA and evaluating delivery and knock-down 
 
The human cervical epithelial adenocarcinoma HeLa cell line184 is a well-described model 
of cancer cells and is commonly used as a target for proof of principle of transfection 
efficiency185, 186 and hence is a relevant tool for studies on siRNA- or shRNA-mediated 
silencing. In this Chapter, as a first step towards assessing the efficiency of the compounds at 
delivering siRNA into cells,  HeLa cells stably expressing a reporter gene coding for the 
fluorescent protein EGFP, under the control of a constitutive promoter, were chosen, a 
strategy used in a number of other studies.175, 176 The advantages of using a stably transfected 
cell line are that this simple experimental system allows expression of the protein, translated 
from the reporter gene at a steady-state level, and a fast assessment on the effect of EGFP-
directed siRNA delivery by flow cytometry (FACS) and fluorescence microscopy. Stable 
transfection of the target gene of interest (with expression vector pEGFP-C1 pDNA in this 
study) only requires the cells to be kept under selective pressure with an antibiotic (G418 in 
the current system) to prevent loss of pDNA at each cell division. Furthermore, as in this 
experimental system, cell populations studied are asynchronous, any potential effects of the 
cell cycle on the reporter gene are averaged and the related protein levels will vary with the 
efficiency in silencing of the delivered siRNA. 
GFP (and EGFP) is an 11-stranded -barrel threaded by an -helix along the axis of the 
cylinder (Figure 7). The chromophore is attached to the -helix and is located perfectly in the 
centre of the cylinder.187 The GFP chromophore is intrinsic to the protein primary structure, 
and no other substrates or co-factors are required for the fluorescence. The chromophore 
responsible for light absorption is located within a hexapeptide at positions 64–69 of GFP 
(and EGFP). This region contains a Ser65-dehydroTyr66-Gly67 tripeptide which acts as the 
minimal fluorophore in GFP.188  
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Figure 7. Upper left: EGFP protein structure showing the barrel shaped structure, with -
sheets in green, -helix in violet, and random coils in light blue. Upper right:  EGFP from 
different viewer perspective showing the fluorophore located in the centre in the ball-and-
stick models (EGFP protein data bank entry 2Y0G).189 Middle:  (a) Thr65, Tyr66, and Gly67 
residues constitute the fluorophore (b) the structure of the EGFP mature fluorophore 
(imidazolidinone) shown in green.187 Lower:  (c) the GFP fluorophore incorporates Phe64 (not 
Leu64) and Ser65 (not Thr65) (d) GFP mature fluorophore. 
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The Clontech pEGFP used to transfect the HeLa cells in this thesis express an EGFP 
variant which has Ser65 to Thr mutation and Phe64 to Leu mutation, and exhibits ~35-fold 
brighter fluorescence compared to wild type GFP, and enhanced folding. This EGFP has a 
single peak of excitation at 490 nm making it more suitable than wild type GFP for detection 
using the commonly used fluorescein filters and argon ion lasers of flow cytometers. EGFP 
also contains more than 190 silent base mutations which allow mammalian cells to translate 
the EGFP mRNA more efficiently, thus increasing EGFP expression. EGFP contains the 
Kozak consensus sequence which increases the efficiency of translation in eukaryotic cells, a 
neomycin resistance DNA sequence to allow for selection, and the cytomegalovirus promoter 
(CMV), for constitutive expression in mammalian cells.187, 188 
The three amino acids (Thr65, Tyr66, and Gly67) present in the central -helix of the barrel 
shaped EGFP are shown in Figure 7, Lower (a). These amino acids undergo cyclization to 
form the imidazolidinone ring, followed by dehydration then oxidation to form the mature 
chromophore, which is shown in green, Figure 7 Lower (b).  
Lipoplexes prepared with the synthetic fatty acid spermine conjugates 1-5 and siRNA 
tagged with the fluorescent dye Alexa Fluor 647 (siEGFP-AF) were delivered to modified 
HeLa cells that stably express EGFP in order to evaluate both the delivery of siRNA and the 
knock-down of EGFP expression. Both the delivery of siRNA and EGFP knock-down were 
evaluated by calculating the geometric mean fluorescence of Alexa Fluor 647 and EGFP by 
means of flow cytometry (FACS analysis) after gating the population of healthy cells (Figure 
8a). The gates AF647 and GFP are set for the calculation of the geometric mean fluorescence. 
The increase in Alexa Fluor 647 fluorescence within the gated population (i.e. delivery of 
fluorescent siEGFP-AF) and the decrease in EGFP fluorescence (i.e. knock-down) are shown 
in Figures 8d-8i. The amount of Alexa Fluor 647 fluorescence 48 h post-transfection was 
used to evaluate the relative efficiency of siEGFP-AF delivery by the lipospermine 
conjugates. Lipoplexes of 1 showed the highest Alexa Fluor 647 fluorescence (159 units) at 6 
µg of 1 (Figure 9 Upper). Lipoplexes of 4 were second (17 units) at 6 µg of 4 (Figure 9 
Lower). Typically, there is a relationship between the amount of each fatty acid spermine 
conjugate and the intensity of the Alexa Fluor 647 fluorescence measured, except for 2 at 
0.75-3 µg and for 3 at 1.5 and 3 µg. Thus, increasing the amount of cationic lipid, from 0.75 
to 6 µg, gave an increase in Alexa Fluor 647 fluorescence (Figure 9 Upper and Lower). 
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(8a)   (8b)    (8c) 
 
 
 (8d)    (8e)    (8f) 
 
 
  
 
  (8g)   (8h)    (8i) 
 
Figure 8. (a), (d), and (g) The gating of a population of healthy cells (b) Alexa Fluor 647 
channel autofluorescence of control cells (c) EGFP expression of control cells (e) Alexa Fluor 
647 fluorescence after transfection with 4 at 6 µg/well (f) EGFP expression after transfection 
with 4 at 6 µg/well (e) Alexa Fluor 647 fluorescence after transfection with 1 at 6 µg/well (f) 
EGFP expression after transfection with 1 at 6 µg/well.  
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Figure 9. Upper:  siEGFP-AF delivery using 1. Values are presented as mean of normalized 
geometric mean fluorescence (AF fluorescence) ± SD (n = 2, triplicate samples of duplicate 
experiments). Lower:  siEGFP-AF delivery measured as the normalized values of Alexa 
Fluor 647 (AF) geometric mean fluorescence using 2-5. 
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Fatty acids with longer chain lengths and one C=C (erucoyl 22:1 and oleoyl 18:1) resulted 
generally in higher fluorescence at the same amount of lipid used. The least fluorescence was 
obtained with 2 (lauroyl 12:0) (Figure 9 Lower) which is saturated and has a relatively 
shorter chain length. 
The N/P ratio is defined as the ratio of cationic lipid ammonium ions to RNA phosphate 
anions. In this case, the numerator is calculated as the number of moles of cationic lipid 
multiplied by the positive charge carried, 2.0. The value 2.0 reflects the pKa of each primary 
amine (~10.5) and the pH at which the experiments are performed (7.4) using the Henderson-
Hasselbalch equation.190 The denominator is the total number of phosphate anions which here 
is calculated from the total number of moles of siEGFP-AF multiplied by the total number of 
phosphates in the double stranded siEGFP-AF, where a synthetic 24-mer carries 23 
phosphates in each strand following phosphoramidite synthesis. Though the terminal sugars 
of uncomplexed siRNA will be phosphorylated in cells, the lipoplexes are prepared before 
this reaction. Thus, at a fixed amount of siEGFP-AF (15 pmol), DOS at 6 g/well will have 
N/P = 23.8.  
Reduction in EGFP expression (Figures 10 and 11) was best achieved by lipoplexes of 4 
(19% at 6 µg cationic lipid, N/P = 23.8, and 22% at 3 µg) followed by 3 (28% at 1.5 µg). 
These values are comparable with the commercial agents Lipofectamine 2000 and TransIT-
TKO (both 24%). Lipoplexes of 4 (19% EGFP at 6 µg cationic lipid were statistically 
significantly different from Lipofectamine 2000 and TransIT TKO, with p < 0.05). 
Lipoplexes of 1 resulted in modest reduction of EGFP (43% at 6 µg). Lipoplexes of the 
saturated fatty acid conjugates 2 and 5 resulted in the lowest knock-down (highest EGFP 
expression) with values of 80% and 69% respectively. The overall better efficiency of 
unsaturated fatty acid spermine amides in reducing EGFP expression is attributed to the 
effects of double bonds restricting chain flexibility, allowing better interaction with the cell 
membrane lipids. The effect of saturation state of spermine fatty acid conjugates on their 
ability to transfect primary skin cell lines (FEK4, FCP4, FCP5, FCP7, and FCP8) and the 
cancer cell line HtTA transfected with pEGFP using the C18 derivatives of spermine 
linoleoyl (18:2), oleoyl (18:1), and stearoyl (18:0) was reported.191 The unsaturated oleoyl 4 
and linoleoyl 3 spermine conjugates were found to be much more efficient (3-5-fold) than the 
stearoyl 5 spermine conjugate. Higher fusogenic ability of unsaturated fatty acids (in the cis-
configuration) probably favours (L to HII) transition. A similar conclusion was reported192 
where unsaturated fluorinated lipospermines were more efficient than their saturated 
analogues due to the ability of unsaturated derivatives to promote membrane fusion and 
endosomal escape. 
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Figure 10. Reduction in EGFP expression in HeLa cells after transfection with 
lipoplexes of fatty acid amides of spermine at different cationic lipid/siEGFP-AF 
ratios. siEGFP-AF concentration is kept constant at 15 pmol/well. Values are presented 
as mean ± SD (n = 2). 
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Figure 11. Comparison of reduction in EGFP expression in HeLa cells (knock-down) at their 
optimal cationic lipid/siEGFP-AF ratios and compared with the commercially available 
transfection agents Lipofectamine 2000 (L, 2 L/well) and TransIT-TKO (T, 4 L/well). 
Values are presented as mean ± SD (n = 2) using erucoyl (1, 6 g/well), linoleoyl (3, 1.5 
g/well), oleoyl (4, 6 g/well), and stearoyl (5, 6 g/well). 
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There was no obvious direct relationship between the particle size and the efficiency of 
delivery or knock-down. The particle size of lipoplexes formed with vectors 2 and 4 were 283 
and 247 nm respectively, but 2 resulted in less delivery (3 units compared to 17 units of 4) 
and lower reduction in EGFP expression. Lipoplexes of 3 had larger particle size than 4 (353 
and 247 nm respectively) and 3 showed less EGFP reduction compared to 4. On the other 
hand, though lipoplexes of 5 had the lowest diameter (145 nm), they showed less reduction in 
EGFP (to 69%) compared to 3 and 4 (to 28% and to 19% respectively). These results show 
that, while keeping particle size within the normal lipoplex transfection range, particle size is 
not the only significant factor. Vectors 3, 4, and 5 have the same chain length while they 
differ in oxidation (saturation) state (18:2, 18:1, and 18:0 respectively). 
The amount of siEGFP-AF delivered was evaluated by the fluorescence of Alexa Fluor 
647 remaining after 48 h post-transfection. There was no direct relationship between the 
amount of siEGFP-AF delivered and the knock-down efficiency. Lipoplexes of 1 resulted in 
the highest delivery (159 units at 6 µg) and EGFP reduction (43%) while lipoplexes of 4 
resulted in less siEGFP-AF delivery (17 units at 6 µg) and EGFP reduction (19%) at the same 
amount of cationic lipid. The same can be said with respect to 3 (EGFP reduction to 28% at 
1.5 µg and delivery 3 units only) compared to 1. However, with respect to vectors 1, 4, and 5, 
the increase of Alexa Fluor 647 fluorescence is accompanied by better reduction in EGFP. 
These observations can be related to the different barriers to successful knock-down. 
Lipoplexes must first be internalized inside the cells (probably by endocytosis) followed by 
release from the endosomes before turning into lysosomes, then the release of siEGFP-AF in 
the cytoplasm to integrate with the RNAi machinery and promote the sequence specific gene 
silencing. Thus, it is not a necessity that higher number of lipoplexes (i.e. more siEGFP-AF 
get into the cells) corresponds to an increase in gene knock-down, because successful knock-
down will require the success of all the aforementioned steps. 
Figure 12 shows the effect of transfecting HeLa cells with AllStars negative control siNC-
AF at the optimum cationic lipid/ siNC-AF ratios that resulted in the best EGFP knock-down 
with respect to each of the spermine conjugate vectors. Although there was an increase in the 
levels of fluorescence of Alexa Fluor 647, there was no corresponding significant decrease in 
the EGFP expression levels, except for compound 2 which is relatively toxic (as discussed 
below in section 3.5). This indicates that the reduction of EGFP fluorescence levels when 
transfecting with siEGFP-AF directed against EGFP is due to the sequence-specific gene 
silencing mediated by the siRNA and not due to any cytotoxic or non-specified effects of the 
vector. The scrambled siNC-AF is reported by the manufacturer to lack homology to any 
mammalian genes and it also did not result in significant changes in EGFP expression due to 
off-target effects. siRNA against EGFP with sequence 5'-
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GCAAGCUGACCCUGAAGUUCAUTT-3' sense strand and 5'-
AUGAACUUCAGGGUCAGCUUGCCG-3' anti-sense strand has one report of off-target 
effects that might affect gene-expression in HeLa and HEK cell lines.186 The target DNA 
homology for silencing EGFP is 5'-CGGCAAGCTGACCCTGAAGTTCAT-3'.  
 
 
Figure 12. EGFP percentage expression 48 h post-transfection with scrambled 
negative control siNC-AF. Numbers in brackets are siNC-AF delivery expressed as 
Alexa Fluor 647 normalized geometric mean fluorescence ± SD. 
 
3.4. Confocal microscopy cell imaging 
 
Vector 4 was used to prepare lipoplexes with Alexa Fluor 647 labelled AllStars negative 
control siNC-AF and siRNA against EGFP (siEGFP-AF) at N/P = 23.8, the optimum ratio for 
the best EGFP knock-down (6 µg/15 pmol siEGFP-AF). Figure 13a shows the control HeLa 
cells (non-transfected) showing the bright green fluorescence of EGFP and the cell membrane 
stained with WGA-Alexa Fluor 555 (in blue). Figure 13b shows the HeLa cells 48 h post-
transfection where the fluorescence of EGFP is significantly reduced and bright red spots 
indicate the fluorescence of Alexa Fluor 647 tagged siEGFP-AF, showing the uptake of the 
tagged siRNA. Figure 13d shows a magnified image of one cell (from Figure 13b) where 
many red spots show the uptake of the Alexa Fluor 647 and the absence of any green colour, 
the obvious reduction in EGFP expression. Figure 13c shows HeLa cells 48 h post-
transfection with AllStars negative control siNC-AF, the red spots indicate cellular uptake of 
the tagged siRNA with no noticeable difference in EGFP fluorescence relative to the control 
HeLa cells (Figure 13a). Figure 13c provide evidence that the reduction in EGFP (seen in 
Figures 13b and 13d) is due to the sequence specific gene silencing by siEGFP-AF and not 
due to non-specific effects of N4,N9-dioleoylspermine 4. 
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  13a      13b 
 
 
 13c      13d 
Figure 13. Confocal microscopy cell imaging. EGFP fluorescence (green), cell membrane 
stained with WGA-Alexa Fluor 555 (blue), and Alexa Fluor 647 (red) represents tagged 
siRNA delivered with N4,N9-dioleoylspermine 4. 13a:  non-transfected HeLa cells 
(control); 13b and 13d:  HeLa cells 48 h post-transfection with siEGFP-AF; 13c:  HeLa 
cells transfected with AllStars negative control siNC-AF. 
 
3.5. Cell viability assay 
The alamarBlue assay was used to measure cell viability. The active component of the 
commercial alamarBlue was reported to be resazurin (Figure 14).193 It was reported that 
mitochondrial, cytosolic and microsomal enzymes reduce alamarBlue. The enzymes 
catalyzing alamarBlue reduction were suggested to be the various reductases present in both 
cytosol and microsomes, including alcohol and aldehyde oxidoreductases, cytochromes , 
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flavin reductase, NADH dehydrogenase and NAD(P)H:quinone oxidoreductase.194 As shown 
in Figure 15, there is spectral overlap of the oxidized and reduced form of alamarBlue. A 
simple and accurate method for calculating the amount of reduced alamarBlue was derived195 
and recommended by the alamarBlue supplier (equation shown in section 2.7 above). 
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Figure 14. The active component of alamarBlue is resazurin (oxidized, non-fluorescent, and 
blue in color) which is reduced by viable cells to resorufin (reduced form, fluorescent, red 
coloured). Resorufin can be further reduced in a reversible manner to colourless 
dihydroresorufin.193  
 
Figure 15. AlamarBlue absorbance of the oxidized (600 nm) and reduced (570 nm) forms. 
Taken from the manual supplied by the manufacturer (http://tools. 
invitrogen.com/content/sfs/manuals/PI-DAL1025-
1100_TI%20alamarBlue%20Rev%201.1.pdf, accessed on 5/9/2011). 
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Figure 16. Upper:  Cell viability alamarBlue assay of fatty acid amides of spermine at 
different cationic lipid/siNC ratios. siNC concentration is kept constant at 1.5 pmol/well (n = 
2). Lower:  Comparison of cell viability of HeLa cells after transfection with fatty acid 
amides of spermine at their optimal cationic lipid/siNC ratios and compared with the 
commercially available transfection agents Lipofectamine 2000 (L) and TransIT-TKO (T) 
Values are presented as mean ± SD (n = 2) using erucoyl (1, 0.6 g/well), linoleoyl (3, 0.15 
g/well), oleoyl (4, 0.6 g/well), and stearoyl (5, 0.6 g/well). 
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The cell viability assay was carried out in 96-well plates. In order to keep the viability 
assay conditions as close as possible to the conditions used in the knock down experiments 
which were carried out in 24-well plates, the amounts of siRNA and cationic lipid, and the 
number of cells/well were multiplied by the same factor (one tenth), thus maintaining the N/P 
ratio and the amount of siRNA per total number of cells constant while downscaling from the 
24-well format to the 96-well format. Thus, the 24-well format used 15 pmol siRNA/well, 6 
µg cationic lipid/well, and 65,000 cells/well, and the 96-well format used 1.5 pmol 
siRNA/well, 0.6 µg cationic lipid/well, and 6,500 cells/well. 
Cell viability evaluation after transfection was carried out with the alamarBlue assay. It 
can be seen from Figure 16 Upper that increasing the amount of lipid vector (from 0.075 µg 
to 0.6 µg) was accompanied by a decrease in cell viability. Short chain 2 (lauroyl, 12:0) was 
much more toxic than the other four spermine conjugates, at 0.6 µg of 2 there was only 3% 
cell viability. The cell viability with 2 was reported to be lower than that of N4,N9-dioleoyl 4 
or distearoyl 5 spermine used to transfect HtTA cell line with a scrambled (negative control) 
fluorescein-labelled siRNA.182 Indeed, while using the MTT cell viability assay, the fatty acid 
conjugates of spermine with shorter chain length (C12-C16) were reported to result in lower 
cell viability than the C18 fatty acid spermine conjugates.182 Figure 16 Lower shows that, 
with the exception of 2, all fatty acid spermine amides were at least as well tolerated as the 
commercially available reagents Lipofectamine 2000 and TransIT-TKO in HeLa cells. 
 
4. Conclusions 
 
Saturated shorter chain (C12:0) 2 showed concentration dependent toxicity when 
compared with the longer chain (C18-C22) spermine fatty acid amides. Transfection with 
lipoplexes of siEGFP-AF and N4,N9-difatty acid amides of spermine resulted in successful 
delivery and gene silencing of EGFP in HeLa cells. Varying the chain length or oxidation 
state of the fatty acids affected both the siEGFP-AF delivery and gene silencing efficiency 
with non-saturated fatty acids (C18:1), (C18:2), and (C22:1) being more efficient compared 
to saturated fatty acids (C12:0) and (C18:0). There was no evidence of a direct relationship 
between the amount of siEGFP-AF delivered and the efficiency of gene silencing. N4,N9-
Dilinoleoyl spermine 3 and N4,N9-dioleoyl spermine 4 were at least as efficient and as well 
tolerated as the commercially available market leaders Lipofectamine 2000 and TransIT-
TKO in HeLa cells. In Chapter 3, the effect of changing the two terminal cationic head-
groups from primary amine to guanidine groups will be investigated.  
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Chapter Three  Self-assembled lipoplexes of siRNA using fatty acid amide guanidines, 
based on spermine, effect efficient gene silencing 
 
1. Introduction 
 
In order to achieve gene silencing mediated by siRNA, the siRNA should be delivered 
intact to the cytoplasm of the cell. Due to the negative charge of the siRNA phosphate 
backbone, and its susceptibility to degradation by various nucleases, a vector is needed to 
achieve efficient intracellular delivery of siRNA. Cationic lipids are currently under 
investigation for the non-viral delivery of lipoplexes of DNA and siRNA.196-198 The polar 
(cationic) head-group can be an amine (primary, secondary, tertiary, and even quaternary e.g. 
imidazolium199), or guanidine functional group. Guanidines, the most basic functional group 
in biological chemistry, are positively charged at physiological pH 7.4 as they have pKa = 
12.5.190 Guanidines have the extra advantage, being bidentate, of being able to form two 
hydrogen bonds with negatively charged groups e.g. carboxylates, phosphates, sulfates 
present on the carbohydrates associated with the cell membrane, and this advantage has been 
used in other vectors (e.g. R8, Arg8200, 201) to transport cargoes across cell membranes. These 
characteristics led to the design of many non-viral vectors for DNA and siRNA, varying from 
cationic lipids incorporating guanidine head-groups202-204 e.g. AtuFECT,204 to cationic 
polymers205, 206 and dendrimers,115, 207 to carbohydrate derivatives,115, 208 and hydrogels of 
guanidinylated hyaluronic acid.209 The use of guanidinium-containing lipid based carriers for 
gene delivery dates back to 1996 where Lehn et al. synthesized two guanidinium cholesterol 
lipids; bis-guanidiniumspermidine-cholesterol (BGSC) and bis-guanidinium-trencholesterol 
(BGTC), each containing two guanidine groups, which were synthesized and evaluated for 
their DNA transfection efficiencies in eukaryotic cells210 (Figure 1) where they were found to 
be efficient DNA transfecting agents. Furthermore, BGTC was found to mediate transfection 
in an aqueous solution without the need to prepare it first in a liposomal form. 
In this Chapter, spermine is acylated with different fatty acids on its secondary amine 
groups, and then is guanidinylated at the terminal primary amine groups. The guanidinylated 
non-viral cationic lipid vectors are characterized and evaluated for their ability to deliver 
siRNA that targets EGFP in HeLa cells that stably express EGFP. 
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Figure 1. Some guanidines used in delivery of genes and other cargoes. 
 
2. Materials and methods 
 
2.1. Materials and general methods 
1,3-Di-Boc-2-(trifluoromethylsulfonyl)guanidine was purchased from Sigma-Aldrich 
(Gillingham, UK). All solvents and other chemicals were purchased as described in Chapter 2 
(Section 2.1), and all general procedures for preparing anhydrous solvents, and purification 
and characterization of the target compounds were carried out as described in Chapter 2 
(Section 2.1). 
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2.2. Synthesis of N1,N12-diamidino-N4,N9-diacylated spermines 
N-Carbethoxyphthalimide (0.44 g, 2 mmol) was added to a solution of 1,12-diamino-4,9-
diazadodecane (spermine) (0.20 g, 1 mmol) in DCM (10 mL). The solution was stirred 20 °C 
for 3 h then evaporated to dryness in vacuo and the residue was used directly in the following 
step. To a solution of 1,12-diphthalimido-4,9-diazadodecane in DCM (10 mL) and TEA (0.28 
mL, 2 mmol) fatty acid chloride (2 mmol), or alternatively fatty acid (2 mmol), DMAP (0.24 
g, 2 mmol), and DCC (0.4 g, 2 mmol) were added and stirred for 18 h under nitrogen 
atmosphere. To prepare, 1,12-diphthalimido-N4-linoleoyl-N9-oleoylspermine, first, 1,12-
diphthalimido-4-oleoylspermine was prepared by reacting 1,12-diphthalimido-4,9-
diazadodecane (1 mmol) with 1 (mmol) oleic acid using DCC as described in Chapter 2. 
After purifying the product over silica gel (DCM/MeOH 20:1 v/v then 10:1 v/v), it was 
further conjugated to linoleic acid (1 mmol) using DCC as the coupling agent. The solvent 
was then evaporated (for all of the prepared compounds) to dryness in vacuo and the residue 
was treated with hydrazine monohydrate (2 mL) in a mixture of DCM (15 mL) and THF (15 
mL) and heated under reflux for 4 h then the solvent was evaporated in vacuo to dryness and 
the residue purified over silica gel (DCM/MeOH 10:1 v/v then DCM/MeOH/NH4OH 20:10:1 
v/v/v) to afford the N4,N9 fatty acid amides of spermine. HRMS of N4,N9-dierucoylspermine, 
N4,N9-dilauroylspermine, and N4,N9-dioleoylspermine were found as previously described in 
Chapter 2 (Section 2.2). N4-Linoleoyl-N9-oleoyl-1,12-diamino-4,9-diazadodecane HRMS 
m/z, found (M+H)+ 729.6980, C46H89N4O2 requires (M+H) + 729.6986. 
The N1,N12-diamidino-N4,N9-diacylated spermines were prepared by reacting each of the 
prepared N4,N9-diacylated spermine (1 mmol) with 1,3-di-Boc-2-
(trifluoromethylsulfonyl)guanidine (2 mmol) and TEA (2 mmol) in DCM (10 mL) at 20 °C 
for 24 h. The reaction mixture was then evaporated to dryness in vacuo and the residue was 
purified over silica gel (DCM/MeOH 100:1 v/v then 100:2 v/v) and the required fractions 
were concentrated. The residue was then added to DCM (6 mL), TFA (2 mL) was added, and 
the mixture stirred at 20 °C for 4 h. The reaction mixture was then evaporated to dryness in 
vacuo to afford the title compounds as the trifluoroacetate salts.  
 
N1,N12-Di(N,N′-Bis(tert-butoxycarbonyl)amidino)-N4,N9-dierucoylspermine 
(DESdiBocG)  
1H NMR, 0.8 (m, 6H, H22'), 1.2-1.3 (m, 56H, H4'-H11', H16'-H21'), 1.3-1.4 (m, 40H, 
methyl groups of Boc, H6, H7), 1.4-1.8 (m, 10H, H2, H11, H3', 2 x NH attached to Boc), 1.9 
(m, 8H, H12', H15'), 2.3 (m, 4H, H2'), 3.1-3.3 (m, 12H, H1, H3, H5, H8, H10, H12), 5.2 (4H, 
H13', H14'), 8.2-8.4 (m, 2H, NH attached to C1 and C12). 
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N1,N12-Di(N,N′-Bis(tert-butoxycarbonyl)amidino)-N4,N9-dilauroylspermine 
(DLauSdiBocG)  
1H NMR, 0.8 (m, 6H, H12'), 1.2-1.3 (m, 32H, H4'-H11'), 1.4-1.5 (m, 40H, methyl groups 
of Boc, H6, H7), 1.4-1.8 (m, 10H, H2, H11, H3', 2 x NH attached to Boc), 2.3 (m, 4H, H2'), 
3.2-3.5 (m, 12H, H1, H3, H5, H8, H10, H12), 5.2 (4H, H13', H14'), 8.3-8.6 (m, 2H, NH 
attached to C1 and C12). 
 
N1,N12-Di(N,N′-Bis(tert-butoxycarbonyl)amidino)-N4,N9-dioleoylspermine (DOSdiBocG) 
1H NMR, 0.8 (m, 6H, H18'), 1.2-1.3 (m, 40H, H4'-H7', H12'-H17'), 1.3-1.4 (m, 40H, 
methyl groups of Boc, H6, H7), 1.4-1.9 (m, 10H, H2, H11, H3', 2 x NH attached to Boc), 2.0 
(m, 8H, H8', H11'), 2.4 (m, 4H, H2'), 3.0-3.3 (m, 12H, H1, H3, H5, H8, H10, H12), 5.3 (4H, 
H9', H10'), 8.1-8.4 (m, 2H, NH attached to C1 and C12).  
 
N1,N12-Di(N,N′-Bis(tert-butoxycarbonyl)amidino)-N4-linoleoyl-N9-oleoylspermine 
(DLinOSdiBocG) 
1H NMR, 0.9 (m, 6H, H18', H18"), 1.3-1.4 (m, 34H, H4'-H7', H15'-H17', H4"-H7", H12"-
H17"), 1.3-1.4 (m, 42H Methyl groups of Boc, H6, H7, 2 x NH attached to Boc), 1.4-1.8 (m, 
8H, H2, H11, H3', H3"), 2.0 (m, 8H, H8', H14', H8", H11"), 2.3 (m, 4H, H2', H2"), 2.8 (m, 
2H, H11'), 3.2-3.5 (m, 12H, H1, H3, H5, H8, H10, H12), 5.3 (6H, H9', H10', H12', H13', H9", 
H10"), 8.3-8.5 (m, 2H, NH attached to C1 and C12). 
 
N1,N12-Diamidino-N4,N9-dierucoylspermine (DESdiG, 1) 
1H NMR, 0.9 (m, 6H, H22'), 1.2-1.4 (m, 56H, H4'-H11', H16'-H21'), 1.5-1.9 (m, 12H, H2, 
H6, H7, H11, H3'), 2.0 (m, 8H, H12', H15'), 2.4 (m, 4H, H2'), 3.0-3.4 (m, 12H, H1, H3, H5, 
H8, H10, H12), 5.3 (4H, H13', H14'), 6.7-7.2 and 12.6-13.1 (broad, 10H, protonated 
guanidine groups protons). 13C NMR, 14.0 (C22'), 22.6 (C21'), 25.6-32.8 (C2'-C12', C15'-
C21', C2, C6, C7, C11), 38.7 (C1,C12), 43.6-48.1 (C3, C5, C8, C10), 114.0-116.9 (CF3), 
129.7-129.9 (C13', C14'), 157.1-161.2 (C of guanidine, C=O of TFA), 175.9 (C1', C1"). 
HRMS m/z, ESI found (M+H)+ 927.8795, C56H111N8O2 requires (M+H)+ 927.8825. 
 
N1,N12-Diamidino-N4,N9-dilauroylspermine (DLauSdiG, 2)  
1H NMR, 0.9 (m, 6H, H12'), 1.2-1.4 (m, 32H, H4'-H11'), 1.5-1.9 (m, 12H, H2, H6, H7, 
H11, H3'), 2.4 (m, 4H, H2'), 3.0-3.5 (m, 12H, H1, H3, H5, H8, H10, H12), 6.4-6.9, 7.2, 11.8-
12.6 (broad, 10H, protonated guanidines). 13C NMR, 14.0 (C12'), 22.5 (C11'), 25.6-32.8 (C2'-
C11', C2, C6, C7, C11), 38.7 (C1,C12), 43.0-48.0 (C3, C5, C8, C10), 113.9-116.8 (CF3), 
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157.1-161.0 (C of guanidine, C=O of TFA), 176.0 (C1', C1"). HRMS m/z, ESI found (M+H)+ 
651.5996, C36H75N8O2 requires (M+H)+ 651.6008. 
 
N1,N12-Diamidino-N4,N9-dioleoylspermine (DOSdiG, 3) 
1H NMR, 0.9 (m, 6H, H18'), 1.2-1.4 (m, 40H, H4'-H7', H12'-H17'), 1.5-1.9 (m, 12H, H2, 
H6, H7, H11, H3'), 2.0 (m, 8H, H8', H11'), 2.4 (m, 4H, H2'), 3.0-3.4 (m, 12H, H1, H3, H5, 
H8, H10, H12), 5.3 (8H, H9', H10'), 6.4-6.7, 7.0, 13.4-13.6 (broad, 10H, protonated 
guanidine groups protons). 13C NMR, 13.9 (C18'), 22.6 (C17'), 25.6-32.7 (C2'-C8', C11'-C17', 
C2, C6, C7, C11), 38.4 (C1, C12), 43.3-48.1 (C3, C5, C8, C10), 110.0-119.0 (CF3), 129.4-
130.1 (C9', C10'), 156.8-161.3 (C of guanidine, C=O of TFA), 176.8 (C1', C1"). HRMS m/z, 
ESI found (M+H)+ 815.7549, C48H95N8O2 requires (M+H)+ 815.7573. 
 
N1,N12-Diamidino-N4-linoleoyl-N9-oleoylspermine (DLinOSdiG, 4)  
1H NMR, 0.9 (m, 6H, H18',H18"), 1.2-1.4 (m, 34H, H4'-H7', H15'-H17', H4"-H7", H12"-
H17"), 1.5-1.6 (m, 8H, H6, H7, H3', H3"), 1.7-1.9 (m, 4H, H2, H11), 2.0 (m, 8H, H8', H14', 
H8", H11"), 2.4 (m, 4H, H2', H2"), 2.8 (m, 2H, H11'), 3.1-3.4 (m, 12H, H1, H3, H5, H8, 
H10, H12), 5.3-5.4 (6H, H9', H10', H12', H13', H9", H10"), 6.6-7.2 and 7.5-7.7 (broad, 10H, 
protonated guanidines). 13C NMR, 14.0 (C18',C18"), 22.5 (C17',C17"), 25.6-32.9 (C2'-C8', 
C14'-C17', C2"-C8", C11"-C17", C2, C6, C7, C11), 39.0 (C1,C12), 43.5-48.1 (C3, C5, C8, 
C10), 114.0-116.9 (CF3), 127.7-130.1 (C9', C10', C12', C13', C9", C10"), 157.4-161.2 (C of 
guanidine, C=O of TFA), 174.7 (C1',C1"). HRMS m/z, ESI found (M+H)+ 813.7384, 
C48H93N8O2 requires (M+H)+ 813.7416.  
 
2.3. Experimental Protocols 
Transfection experiments were carried out on HeLa cells stably expressing EGFP using 
the protocol described in Chapter 2 (Section 2.4). FACS analysis was carried out as described 
in Chapter 2 (Section 2.5). Confocal microscopy cell imaging was carried out as described in 
Chapter 2 (Section 2.6). Cell viability assay was carried out as described in Chapter 2 
(Section 2.7). Particle size and -potential measurements were carried out as described in 
Chapter 2 (Section 2.8). siRNA binding assay (RiboGreen intercalation assay) was carried 
out as described in Chapter 2 (Section 2.9). Statistical analysis was carried out as described in 
Chapter 2 (Section 2.10). 
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3. Results and discussion 
 
3.1. Synthesis of N1,N12-diamidine derivatives of spermine 
A series of novel lipoguanidines were designed in order to investigate the SAR of 
replacing primary amines with guanidine functional groups (Figures 2 and 3). These are 
formally called di-imidamides of alkanes and the nomenclature also permits N-
aminoiminomethyl. Where these compounds were referred to as guanidines, they are more 
correctly N-amidines of spermine. 
 
Figure 2. Schematic representation of the synthesis of N1,N12-diamidino-N4,N9-diacylated 
spermines. a:  N-carbethoxyphthalimide, DCM; b:  fatty acid, DCC, TEA; c:  hydrazine 
monohydrate, DCM/THF 1:1; d:  1,3-di-Boc-2-(trifluoromethylsulfonyl)guanidine, TEA, DCM; 
e:  TFA, DCM. 
 
  
DESdiG, 1 
  
DLauSdiG, 2 
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DOSdiG, 3 
 
  
LinOSdiG, 4 
 
Figure 3. N1,N12-Diamidine derivatives of different lipospermines 
 
Table 1. N1,N12-Diamidine derivatives of different lipospermines. The fatty acids are 
described by two numbers separated by a colon, first the chain length and then the 
number of double bonds. Particle size, ζ-potential, and RiboGreen binding of 
guanidinylated lipospermines were measured at the cationic lipid/siRNA ratios that 
showed best reduction in EGFP expression. 
Name of compound 
Fatty 
acid 
Diameter 
(nm) ± SD 
-potential 
(mV) ± SD 
% 
fluorescence 
of 
RiboGreen 
N1,N12-Diamidino-N4,N9-
dierucoylspermine  
DESdiG, 1 
Erucic 
22:1 
132 ± 4 50 ± 1 5 ± 2 
N1,N12-Diamidino-N4,N9-
dilauroylspermine  
DLauSdiG, 2 
Lauric 
12:0 
575 ± 61 28 ± 3 12 ± 3 
N1,N12-Diamidino-N4,N9-
dioleoylspermine  
DOSdiG, 3 
Oleic 
18:1 
303 ± 6 45 ± 3 0 ± 1 
N1,N12-Diamidino-N4-
linoleoyl-N9-
oleoylspermine  
LinOSdiG, 4 
Linoleic 
18:2 
Oleic 
18:1 
158 ± 24 45 ± 3 8 ± 2 
68 
 
Figure 4 shows the 1H NMR assignments of LinOSdiBocG. The most important features 
necessary to identify the target compound include:  (a) the presence of the double bonds 
protons (6 protons at δ = 5.3, H9', H10', H12', H13', H9", H10") which correspond to the two 
double bonds of the linoleoyl chain and the one double bond of the oleoyl chain; (b) the 
presence of 12 protons at δ = 3.2-3.5 (m, 12H, H1, H3, H5, H8, H10, H12), which are 
deshielded because they are next to the nitrogen atoms of the amide groups (protons 3, 5, 8, 
and 10), and next to the two terminal nitrogens of the guanidine groups (protons 1 and 12), 
indicating the successful conjugation of the fatty acids to the spermine N4 and N9 as well to 
the successful guanidinylation of the terminal primary amines; (c) 6 protons at δ = 0.9 (6H, 
H18', H18") representing the two terminal methyl groups of the two conjugated fatty acids; 
(d) 36 protons at δ = 1.3-1.4 (protons of the methyl groups of Boc); (e) The two protons at 
8.3-8.5 (NH attached to C1 and C12); (f) The total proton integration which fits the formulae 
of LinOSdiBocG, C68H124N8O10. Thus, the 1H NMR proves that the target compound was 
synthesized successfully.  
 
 
 
Figure 4. 1H-NMR of LinOSdiBocG. 
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Figure 5. 1H-1H-NMR COSY of LinOSdiBocG. 
 
Figure 5 shows the 1H-1H-NMR COSY of LinOSdiBocG. Among the most characteristic 
cross-peaks are those showing protons 6 and 7 (at δ = 1.3-1.4) cross-peak with protons 5 and 8 
(at δ = 3.2-3.5) while no other cross-peaks are observed at δ = 1.3-1.4, which fits with the 
methyl groups of Boc and the NH next to Boc groups, which will lack cross-peaks. Also of 
interest are the four protons at position 1 and 12 (δ = 3.2-3.5) which are next to the guanidine 
group, as they have one cross-peak with the NH of the guanidine groups next to C1 and C12, 
and another cross-peak with the protons at position 2 and 11 (δ = 1.4-1.8). These results further 
verify the successful synthesis of the target compound. 
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Figure 6. LinOSdiG 1H-NMR. 
 
Figure 6 shows the 1H NMR assignments of LinOSdiG 4. The most characteristic features 
essential to identify the target compound include: (a) the presence of the double bonds 
protons (6 protons at δ = 5.3, H9', H10', H12', H13', H9", H10") which correspond to the two 
double bonds of the linoleoyl chain and the one double bond of the oleoyl chain, as well to 
the 6 protons at δ = 0.9 (6H, H18', H18") representing the two terminal methyl groups of the 
two conjugated fatty acids, indicating the successful conjugation of the fatty acids; (b) the 
presence of 10 protons at δ = 6.6-7.7 which are the protonated guanidine groups protons; (c) 
The disappearance of the large peak at δ = 1.5 which was the peak due to methyl groups of 
Boc, thus indicating the successful deprotection of the guanidine; (d) 12 protons at δ = 3.1-
3.4 (protons 12H, H1, H3, H5, H8, H10, and H12) which are CH2 protons deshielded because 
they are next to either amide group nitrogen or guanidine group nitrogen.  
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Figure 7. 1H-1H-NMR COSY of LinOSdiG. 
 
Figure 7 shows the 1H-1H-NMR COSY of LinOSdiG. The most characteristic cross-peaks 
are: (a) The cross-peaks of protons H2 and H11 (δ = 1.7-1.9) with protons H3 and H10 (δ = 
3.1-3.4), as well as protons H6 and H7 (δ = 1.5-1.6) with H5 and H8 (δ = 3.1-3.4). The 
guanidine protons (δ = 6.6-7.7) do not have any cross-peaks which is expected. The results of 
1H-NMR and 1H-1H-NMR COSY as well to the accurate HRMS obtained (m/z of (M+H)+ = 
813.7384, C48H93N8O2 requires (M+H)+ 813.7416) prove LinOSdiG successful synthesis.  
The four lipoguanidines will be used to investigate their efficiency and their effect on cell 
viability as non-viral vectors for siRNA delivery. An amidine group was attached to each of 
the two terminal primary amines of spermine to result in the di-guanidines (N1,N12-diamidino-
amines). Three fatty acids of different chain length and saturation were used to synthesise the 
lipoguanidines 1, 2, and 3 by acylation at N4 and N9 of spermine. The fourth lipoguanidine 
LinOSdiG 4 was synthesized by acylating sequentially using two different long-chain fatty 
acids (linoleic and oleic) to N4 and N9. 
The synthesis of the guanidinylated N4,N9-diacylated spermine conjugates started with the 
synthesis of the N4,N9-difatty acids spermine derivatives (Figure 2). The symmetrical 
lipospermines synthesis; i.e. those with the same fatty acid chains conjugated to positions N4 
and N9 of the spermine chain, was carried out as described in Chapter 2. For the synthesis of 
the unsymmetrical N4-linoleoyl-N9-oleoylspermine, the primary amine groups of spermine 
were selectively protected with the phthalimide protecting group (2 eq. of N-
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carbethoxyphthalimide in DCM). Then one oleoyl chain was conjugated to one of the free 
secondary amine groups of spermine (1 eq. oleic acid, 1 eq. DCC, and 1 eq. DMAP). 
Purification of the mono-acylated spermine then followed by flash chromatography. The 
second linoleoyl chain was added using DCC coupling of linoleic acid to the 1,12-
diphthalimido-N9-oleoyl-4,9-diazadodecane (1 eq. linoleic acid, 1 eq. DCC, and 1 eq. 
DMAP). Deprotection of the phthalimide protecting groups then followed by refluxing in 
hydrazine monohydrate in DCM/THF 1:1 mixture to obtain N4-linoleoyl-N9-oleoylspermine, 
which was purified by flash chromatography. The guanidinylation of amines typically 
involves an electrophilic amidine group as part of the guanidinylating reagent.211 1,3-Di-Boc-
2-(trifluoromethylsulfonyl)guanidine was used as it can carry out the guanidinylation of 
primary and secondary amines under mild conditions.211, 212 The guanidinylation was carried 
out on the di-acylated spermine derivatives and deprotection of the Boc protected guanidine 
group was carried out using TFA to obtain the trifluoroacetate salts of the synthesized 
compounds (Figure 3).  
 
3.2. Lipoplex particle size and ζ-potential 
The lipoplexes prepared at the cationic lipid/siNC ratios for each guanidinylated lipid 
which resulted in the best reduction in EGFP expression were chosen to be characterized for 
their particle size and ζ-potential (Table 1). Particle size measurement using dynamic light 
scattering showed that the particle size varied from 132-575 nm. The two cationic lipids 3 
and 4 which are acylated with unsaturated C18 fatty acids (dioleoyl and linoleoyl/oleoyl 
respectively) and which showed the best reduction in EGFP expression had the particle size 
of 303 and 158 nm for 3 and 4 respectively. The particle size of the C22 (dierucoyl) 
conjugate 1 was the smallest (132 nm) while the short chain C12 (dilauroyl) conjugate 2 had 
the largest particle size of 575 nm. Lipoplex size has been pointed to be an important factor in 
transfection efficiency though not being the only determinant factor.213 Lipoplexes within size 
range 200-300 nm have been previously reported.214 Although size of lipoplexes will 
determine the main route of entry with smaller lipoplexes (<300 nm) likely to enter via 
clathrin mediated endocytosis, and larger particles (>500 nm) entering cells via caveoli 
mediated endocytosis,214, 215 one recent report suggests that the actual entry route for 
functional siRNA mediated gene silencing is fusion with the plasma membrane rather than 
the endocytosis pathway.171 The ζ-potentials measurements showed that all the lipoplexes had 
positive values within the range 28-50 mV. Cationic lipids 3 and 4 had the similar ζ-potential 
of 45 mV. Positive ζ-potential is important in promoting stability of the prepared lipoplexes 
by enhancing repulsion between the nanoparticles. Although having positive ζ-potential will 
promote interaction between the positively charged lipoplexes and the negatively charged 
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groups present on the cell membrane surface, it was reported that in the presence of serum, 
the lipoplexes actually acquire a negative ζ-potential214 while still maintaining efficient 
transfection efficiency.  
 
3.3. siRNA binding (RiboGreen intercalation assay) 
An siRNA binding assay was used to evaluate the ability of the synthesized 
guanidinylated lipids 1, 2, 3, and 4 to complex and bind siRNA. The loss of fluorescence 
compared to control free siNC indicates its binding to the cationic lipids and hence 
prevention of RiboGreen binding with siNC which leads to reduction of fluorescence 
compared to the control (free) siNC.170, 216 The four cationic lipids 1-4 efficiently bound siNC 
(Table 1) and the normalised fluorescence, relative to free siNC (100%), was reduced to:  5 ± 
2 (1), 12 ± 3 (2), 0 ± 1 (3), and 8 ± 2 (4). These results prove that the guanidinylated lipids 
are able to efficiently bind siNC. 
 
3.4. Transfection with siRNA and evaluating delivery and knock-down 
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Figure 8. Delivery of siEGFP-AF (15 nM, 15 pmol/well) against EGFP (labelled with 
Alexa Fluor 647 at the 3'-position of the sense strand) using 1, 3, and 4. Values are 
presented as means of normalized geometric mean fluorescence of AF647 ± SD (n = 2).  
 
HeLa cells that stably express EGFP were used to evaluate the siEGFP-AF delivery and 
sequence specific knock-down of EGFP expression. The siRNA against EGFP used (siEGFP-
AF) was labelled with Alexa Fluor 647 (AF647) in the 3'-position of the sense strand to 
enable simultaneous tracking of the siRNA delivery and reduction of EGFP expression by 
measuring the fluorescence of the AF647 and the EGFP during the FACS analysis. Healthy 
population of sample cells were gated before recording the fluorescence during FACS.  
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The normalized fluorescence of AF647 measured 48 h post-transfection was measured as 
an estimate for the delivered amount of siRNA. Figure 8 shows that, for each cationic lipid, 
there is a general trend of increasing fluorescence by increasing the amount of the lipid. 
Cationic lipid 2 data are not shown due to the very low siEGFP-AF delivery. With respect to 
1, 3, and 4, there was a significant statistical difference between the geometric mean AF647 
fluorescence measured at 3 and 6 µg/well for each lipid (lipid 4 N/P = 10.7 and 21.4 
respectively) with p < 0.05. There was also a significant statistical difference between the 
amounts of siEGFP-AF delivered (geometric mean fluorescence of AF647) by 3 and 4 (p < 
0.05) with lipoplexes formulated at 6 µg/well (N/P = 21.4). There was no significant 
statistical difference between 1 and 4 at 6 µg/well (p = 0.33). These results show that given 
that 1, 3, and 4 have in common two guanidine head-groups in the form of trifluoroacetate 
salts, the C18 (18:1 and 18:2) unsaturated fatty acids conjugated at positions N4 and N9 of the 
parent spermine provided the optimum chain length for siEGFP-AF delivery compared to the 
C12 (12:0) and C22 (22:1) chains.  
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Figure 9. Reduction in EGFP expression in HeLa cells after transfection with lipoplexes of 1, 
2, 3, and 4 at different cationic lipid/siEGFP-AF ratios. siEGFP-AF concentration is kept 
constant (15 nM, 15 pmol/well). Values are presented as mean ± SD (n = 2). Commercial 
TransIT-TKO (T) is shown for comparison. 
 
Figure 9 shows that the best reduction of EGFP expression was achieved by 4 followed by 
3. At 6 µg/well, EGFP expression was reduced to 26% and 43% for 4 and 3 respectively (p < 
0.05). Lipid 1 did not show any practically significant reduction in EGFP (reduced to 85%) at 
6 µg/well (N/P = 18.8). Lipid 2 resulted in EGFP reduction to 46% at 6 µg/well (N/P = 26.8), 
however, this reduction cannot be evaluated without considering the high toxicity of 2 which 
75 
 
will affect the expression of EGFP as will be discussed in this Chapter (Section 3.6). Lipids 3 
and 4 with C18 (18:1 and 18:2) resulted in the best knock-down of EGFP expression which 
might be attributed to the fusogenic ability of unsaturated fatty acids (in cis-configuration) 
which favours (L to HII) transition as they can promote both membrane fusion and 
endosomal escape.191, 192 The chain length is an important factor that affects the efficiency of 
EGFP knock-down because although the C22 (22:1) has one centre of unsaturation, lipid 1 
resulted in less reduction in EGFP (85%) compared to 3 (43%) and 4 (26%) with significant 
statistical difference between the compared means (p < 0.05) at 6 µg/well. The chain length 
affected siEGFP-AF delivery and knock-down differently, as evident from comparing the 
delivery of 1, 3, and 4 and their EGFP reduction at a concentration of 6 µg/well. Although 1 
and 4 resulted in similar siEGFP-AF delivery efficiencies, lipid 4 was much better than 1 in 
terms of EGFP reduction (to 26% and 85% respectively). These differences in gene silencing 
efficiency compared with lipoplex cellular uptake reflect the multi-step processes of gene 
silencing and/or more than one mechanism of cell entry.171 Also, cationic lipid 3 resulted in 
better EGFP reduction when compared to 1 (to 43% and 85% respectively) despite the fact 
that 1 resulted in higher siEGFP-AF delivery compared to 3 (p < 0.05). The importance of 
chain length and chain unsaturation of cationic lipids has been previously reported to be 
among the most significant factors that affect transfection efficiency because of the effect on 
the hydrophobic volume of lipid and its hydrophilic/lipophilic ratio which will in turn affect 
the properties of the formed lipoplexes.147 When compared to the commercial transfecting 
agent TransIT-TKO, the reduction in EGFP expression obtained with lipoplexes of 4 (26%) 
was the same as that obtained with TransIT-TKO (24%), i.e. there was no significant 
statistical difference (p = 0.30). 
The increases in fluorescence shown in Figure 8 reflect increase in siEGFP-AF delivery 
with increasing concentrations of cationic lipids in the lipoplexes up to a N/P ratio of 18-26 
(6 μg/well). Figure 9 shows the corresponding reduction in EGFP expression. These data 
were obtained from gated FACS analyses of the healthy populations of HeLa cells (parent 
gate), representative examples of which are shown in Figure 10 together with the percentage 
of cells transfected. In order to evaluate siEGFP-AF delivery, the AF647 gate was set-up to 
include cells that have fluorescence signals higher than the auto-fluorescence of control cells 
detected at em = 660 nm. The EGFP gate was set to calculate the geometric mean 
fluorescence of EGFP. 
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Control non-transfected HeLa cells 
 
       
Cells transfected with siEGFP-AF lipoplexes prepared with 3 
 
       
Cells transfected with siEGFP-AF lipoplexes prepared with 4 
 
Figure 10. Gated FACS analysis of delivery of siEGFP-AF (15 nM, 15 pmol/well) 
against EGFP and EGFP expression in HeLa cells 48 h post-transfection with lipoplexes 
of 3 and 4 (6 µg/well) at an siEGFP-AF concentration of 15 pmol/well. The AF647 gate 
(red) shows 75% of parent-gated cells with 3, and 92% of parent-gated cells with 4. The 
EGFP gate (green) shows silencing to ~40% and ~25% respectively measured by 
geometric mean fluorescence relative to control (top line). 
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Figure 11. Scrambled AllStars siRNA (siNC-AF, 15 nM, 15 pmol/well) was 
delivered with cationic lipids 3 and 4 (at 6 g/well). Delivery of tagged siNC-AF 
(left) is expressed as Alexa Fluor 647 normalized geometric mean fluorescence ± 
SD (n = 2). EGFP percentage expression (right, showing absence of silencing as a 
negative control) 48 h post-transfection. 
 
The effects of transfecting HeLa cells using 3 and 4 with the scrambled siNC-AF on 
lipoplex delivery and EGFP expression are shown in Figure 11. Qiagen report that their 
scrambled siRNA lacks any homology to mammalian genes. Figure 11 shows that the EGFP 
expression was practically not affected by the transfection process while the scrambled siNC-
AF was delivered in comparable amounts (i.e. comparable normalized fluorescence) to 
delivery with siEGFP-AF. Thus, cationic lipids 3 and 4 deliver two different siRNAs with 
similar efficiency. These results prove that EGFP reduction after transfection with siEGFP-
AF (shown as averaged data in Figure 9 and as representative examples in Figure 10) is due 
to sequence specific gene silencing and not due to any non-specific effects of the cationic 
lipid vectors.  
 
3.5. Confocal microscopy cell imaging 
Figure 12 shows confocal microscope images of HeLa cells after transfection with 3 and 4 
using siEGFP-AF or scrambled siRNA (siNC-AF) at 6 µg/well of cationic lipid which is the 
amount of lipid that resulted in the best reduction of EGFP expression with respect to each of 
the cationic lipids. 
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         12d          12e              12f 
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Figure 12. Confocal microscopy cell imaging. EGFP fluorescence (green), cell membrane 
stained with WGA-Alexa Fluor 555 (blue), and Alexa Fluor 647 (red) represents tagged 
siRNA delivery. 12a:  non-transfected HeLa cells (control); 12b:  reduction in EGFP 
expression after transfection with siEGFP-AF delivered with 3 (6 µg/well); 12c:  as 12b, but 
only the red channel; 12d:  as 12b, but using the scrambled siNC-AF; 12e:  reduction in 
EGFP expression after transfection with siEGFP-AF delivered with 4 (6 µg/well); 12f:  as 
12e, but using siNC-AF; 12g:  as 12d, but only the red channel; 12h:  as 12e, but only the red 
channel; 12i:  as 12f, but only the red channel.  
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Figure 12a shows negative control HeLa cells. Figures 12b shows the reduction of EGFP 
expression after transfection with siEGFP-AF using 3 at 6µg/well. Figure 12c is the same as 
12b, but only the red channel is turned on to track better the delivery of the AF647 labelled 
siEGFP-AF. It can be seen that the AF647 fluorescence (red) is distributed throughout the 
cell and concentrated in some cell areas. Figure 12d shows that lipoplexes of 3 did not cause 
reduction in EGFP expression when using siNC-AF, which was delivered to HeLa cells 
successfully as shown in Figure 12g. These results prove that the siEGFP-AF was delivered 
successfully to the HeLa cells and that the reduction in EGFP expression is due to sequence 
specific knock-down of EGFP and not due to any non-specified effects of the cationic lipid 
vectors. The same conclusion is drawn when examining the transfection of HeLa cells with 4 
as shown in Figures 12e with 12h, and 12f with 12i. 
 
3.6. Cell viability assay 
Following transfection with cells seeded at a density of 65,000 cells/well in 24-well plates, 
i.e. 65,000 cells/1 mL (Section 3.4), cell viability was assayed in 96-well plates with 6,500 
cells/0.1 mL. The ratio of number of cells to the amount of cationic lipid used (0.6 g 
lipid/0.1 mL), and to siNC (15 nM, 1.5 pmol/well) was exactly the same as the ratio used in 
the transfection experiments in 24-well formats. Figure 13 shows that 1, 3, and 4 resulted in 
more than 64% cell viability. There were no statistical significant difference between the cell 
viability of 3 and 4 (p = 0.32) with cell viabilities of 70% and 64% respectively. The best cell 
viability obtained by 1 (83%) was significantly different (p < 0.05) from the cell viability of 3 
and 4. Whilst diacylated C12 (12:0) 2 is a new compound, the very high toxicity of its parent 
diamine, N4,N9-dilauroylspermine, has been previously reported in both HtTA cells182 and 
HeLa cells (Chapter 2) with scrambled siRNA. There were no significant differences between 
cell viability of TransIT-TKO (76%) and 3 (64%), p = 0.12, or between TransIT-TKO and 4 
(70%), p = 0.41. There is a probability that the counter ion, trifluoroacetate in this case, has a 
contributing negative effect on cell viability as been reported before217 where the presence of 
residual TFA in the concentration range 10-8 to 10-7 M resulted in reduction of cell 
proliferation of osteoblasts , chondrocytes (mature cells found in cartilage), and neonatal 
mice calvariae (bone organ culture).  
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Figure 13. Comparison of cell viability of HeLa cells after transfection with lipoplexes 
at their optimal cationic lipid/siNC ratios and compared with the commercially available 
transfection agent TransIT-TKO (T). Values are presented as mean ± SD (n = 2). 
Experiments were carried out at:  0.6 g/well synthesized cationic lipids, 1.5 pmol 
siRNA/well (15 nM), and 6,500 cells/well.  
 
4. Conclusions 
The four synthesized diguanidinylated diacylated spermine-based cationic lipids were able 
to bind siRNA efficiently and to form particles with sizes in the nanometre range (132-575 
nm). Saturated shorter chain (C12:0) 2 showed relatively high toxicity when compared with 
the longer chain (C18-C22) N1,N12-diamidino-N4,N9-diacylated spermine derivatives. 
Transfection with self-assembled siRNA lipoplexes of 3 and 4 resulted in the sequence 
specific knock-down of EGFP in HeLa cells, exhibiting comparable (low) toxicity to the 
commercial transfecting agent TransIT-TKO. Lipid 4 with one linoleoyl and one oleoyl 
chains acylated on positions N4 and N9 respectively of the N1,N12-diamidinospermine was the 
best transfecting agent. Lipoplexes of lipid 4 showed the same efficiency, in HeLa cells, in 
terms of reduction of EGFP expression as TransIT-TKO. 
In this Chapter, the synthesis of four novel spermine-derived fatty acid amide guanidines 
applied to the self-assembly of siRNA lipoplexes which were then tested in EGFP expressing 
HeLa cells was described. The major endpoints include detection of siRNA complexation in 
the lipoplexes, cellular uptake, toxicity, and gene silencing efficiency even in the presence of 
serum. This is a structure-activity relationship (SAR) study of the cationic head-groups, the 
two primary amine groups of spermine were transformed to guanidine groups. To investigate 
further the SAR regarding the two acylated fatty acids of lipospermines, a series of 
asymmetrical N4,N9-diacylated spermine conjugates will be synthesized and evaluated in 
Chapter 4. 
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Chapter Four  Efficient silencing of EGFP reporter gene with siRNA delivered 
by asymmetrical N4,N9-diacyl spermines 
 
1. Introduction 
 
Since being introduced as non-viral gene delivery vectors in 1987 by Felgner and co-
workers,124 cationic lipids have been widely studied as non-viral gene and siRNA vectors.160, 
196, 218 The majority of phospholipids in mammalian cell membranes are acylated with two 
different fatty acids at the sn-1 and sn-2 positions of the glycerol 3-phosphate.219-223 In this 
Chapter, the design and synthesis of seven new N4,N9-diacylated asymmetrical spermine 
derivatives is reported. The asymmetry is in that they contain two different fatty acid chains 
per spermine residue. The fatty acids are different either in chain length (from C18 to C24) 
and/or in their oxidation state. All seven target compounds have one chain (oleoyl) held 
constant while the other fatty acid chain is varied. This is based on the efficiency of the 
symmetrical DOS in gene silencing which has been established in Chapter 2. The cationic 
group is chosen to be the primary amine. These novel asymmetrical polyamine amides are 
structurally similar to the naturally occurring diacyl lipids that form lipid cellular membranes, 
as the majority of the latter lipids are asymmetrical.219-223 Using the two positive charges from 
the terminal primary amino groups (at the physiological pH 7.4), they are rationally designed 
to form nanoparticles with polynucleotides (e.g. siRNA) by electrostatically binding the 
negatively charged siRNA in aqueous buffered media, and without any pre-formulation steps 
to form liposomes prior to lipoplex formation. This process occurs by the simple mixing of 
the cationic lipids with the polyanionic siRNA enabling the self-assembly of the lipoplexes. 
The asymmetry of the fatty acid chains in these spermine conjugates is hypothesized to 
enhance the efficiency of interaction with the cell membrane phospholipids, leading to better 
mixing or fusion with the membrane lipids, and hence enhancing the siRNA delivery and/or 
gene silencing. Such enhancement was reported previously for DNA lipoplexes with 
asymmetrical lipid components.153  
The synthesized compounds will be used in SAR studies of siRNA delivery and EGFP 
silencing in HeLa cells. Investigating the siRNA delivery and EGFP silencing with selected 
mixtures of symmetrical spermine conjugates is carried out, and compared to the delivery and 
silencing efficiency resulting from using the asymmetrical conjugates which has the same 
type of fatty acids as that in the mixture spermine conjugates, i.e. investigating whether the 
transfection properties of asymmetrical vectors are due to merely using two different types of 
fatty acids regardless of the molecular structure, or the asymmetry itself affects transfection.  
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2. Materials and methods 
 
2.1. Materials and general methods 
All solvents and chemicals were purchased as described in Chapter 2 (Section 2.1). All 
general procedures for preparing anhydrous solvents and purification and characterization of 
the target compounds were carried out as described in Chapter 2 (Section 2.1).  
 
2.2. Synthesis of N4,N9-diacylated spermines 
1,12-Diphthalimido-4,9-diazadodecane. 
To a solution of 1,12-diamino-4,9-diazadodecane (spermine) (2.02 g, 10 mmol) in DCM 
(30 mL) N-carbethoxyphthalimide (4.38 g, 20 mmol) was added. The solution was stirred at 
20 °C for 3 h then evaporated to dryness in vacuo. The residue was purified over silica gel 
(DCM/MeOH 10:1 then 2:1 v/v) to afford the title compound (2.13 g, 46%). 1H NMR, 1.2-
1.4 (m, 4H, H6, H7), 1.4-1.7 (m, 6H, H2, H11, 2 x NH), 2.4-2.5 (m, 8H, H3, H5, H8, H10), 
3.6 (m, 4H, H1, H12), 7.5-7.7 (m, 8H, aromatic protons). 13C NMR, 27.1 (C6, C7), 28.2 (C2, 
C11), 35.5 (C1, C12), 46.3 (C3, C5, C8, C10), 122.7 and 133.6 (aromatic carbons), 168.1 
(C=O). HRMS, found (M+H)+ 463.2354, C26H31N4O4 requires (M+H)+ 463.2340. Often, for 
the synthesis of the following target molecules, the purification of 1,12-diphthalimido-4,9-
diazadodecane can be skipped and the crude product taken on directly into the acylation. 
 
N4,N9-Dioleoyl-1,12-diamino-4,9-diazadodecane (DOS). 
To a solution of 1,12-diphthalimido-4,9-diazadodecane (2.31 g, 5 mmol) in DCM (30 mL) 
and TEA (1.4 mL, 10 mmol) oleoyl chloride (3.3 mL, 10 mmol) was added. The solution was 
stirred for 18 h at 20 °C and then the solvent was evaporated to dryness in vacuo. The residue 
was reacted with hydrazine monohydrate (2 mL) in a mixture of DCM (15 mL) and THF (15 
mL) and heated under reflux for 4 h, cooled to 20 °C, and then the solvent was evaporated in 
vacuo. The residue was purified over silica gel (DCM/MeOH 10:1 v/v then 
DCM/MeOH/NH4OH 10:5:1 v/v/v) to afford the title compound (1.46 g, 40% over two steps). 1H 
NMR, 0.8 (t, J = 7, 6H, H18'), 1.2-1.3 (m, 40H, H4'-H7', H12'-H17'), 1.4-1.8 (m, 12H, H2, H6, 
H7, H11, H3'), 1.9-2.1 (m, 8H, H8', H11'), 2.1-2.3 (m, 4H, H2'), 2.6-2.8 (m, 8H, H1, H12, 2 x 
NH2), 3.2-3.5 (m, 8H, H3, H5, H8, H10), 5.3-5.4 (m, 4H, H9', H10'). 13C NMR, 14.1 (C18'), 
22.6-29.7 (C2, C6, C7, C11, C4'-C8', C11'-C17'), 31.9 (C3'), 33.1 (C2'), 38.9-39.2 (C1, C12), 
42.5-47.4 (C3, C5, C8, C10), 129.8 (C9', C10'), 172.9 (C1'). HRMS, found (M+H)+ 731.7162, 
C46H91N4O2 requires (M+H)+ 731.7137. 
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N4,N9-Dierucoyl-1,12-diamino-4,9-diazadodecane (DEruS). 
To a solution of 1,12-diphthalimido-4,9-diazadodecane (0.46 g, 1 mmol) in DCM (30 mL) 
erucic acid (0.68 g, 2 mmol), DMAP (0.24 g, 2 mmol), and DCC (0.40 g, 2 mmol) were 
added. The solution was stirred at 20 °C for 18 h under an atmosphere of nitrogen, then 
filtered and the filtrate was evaporated to dryness in vacuo. The residue was reacted with 
hydrazine monohydrate (2 mL) in a mixture of DCM (15 mL) and THF (15 mL) and heated 
under reflux for 4 h, cooled to 20 °C, and then the solvent was evaporated in vacuo. The 
residue was purified over silica gel (DCM/MeOH 10:1 v/v then DCM/MeOH/NH4OH 
20:10:1 v/v/v) to afford the title compound (0.34 g, 40% over two steps). 1H NMR, 0.8 (t, J = 
7, 6H, H22'), 1.1-1.3 (m, 60H, H4'-H11', H16'-H21', 2 x NH2), 1.4-1.6 (m, 12H, H2, H6, H7, 
H11, H3'), 1.9 (m, 8H, H12'-H15'), 2.2-2.4 (m, 4H, H2'), 2.5-2.7 (m, 4H, H1, H12), 3.2-3.6 
(m, 8H, H3, H5, H8, H10), 5.2 (m, 4H, H13', H14'). 13C NMR, 14.0 (C22'), 22.6 (C21'), 25.1-
32.8 (C2, C6, C7, C11, C3'-C12', C15'-C20'), 33.1 (C2'), 39.2-39.4 (C1, C12), 42.6-47.4 (C3, 
C5, C8, C10), 129.8 (C13', C14'), 172.8-173.0 (C1'). HRMS, found (M+H)+ 843.8364, 
C54H107N4O2 requires (M+H)+ 843.8389; found (M+Na)+ 865.8194, C54H106N4O2Na requires 
(M+Na)+ 865.8208. 
 
N4,N9-Dilinoleoyl-1,12-diamino-4,9-diazadodecane (DLinS). 
To a solution of 1,12-diphthalimido-4,9-diazadodecane (0.46 g, 1 mmol) in DCM (30 mL) 
linoleic acid (0.56 g, 2 mmol), DMAP (0.24 g, 2 mmol), and DCC (0.40 g, 2 mmol) were 
added. The solution was stirred at 20 °C for 18 h under an atmosphere of nitrogen, then filtered 
and the filtrate was evaporated to dryness in vacuo. The residue was reacted with hydrazine 
monohydrate (2 mL) in a mixture of DCM (15 mL) and THF (15 mL) and heated under reflux 
for 4 h, cooled to 20 °C, and then the solvent was evaporated in vacuo and the residue purified 
over silica gel (DCM/MeOH 10:1 v/v then DCM/MeOH/NH4OH 20:10:1 v/v/v) to afford the 
title compound (0.29 g, 40% over two steps). 1H NMR, 0.8 (t, J = 7, 6H, H18'), 1.2-1.3 (m, 
28H, H4'-H7', H15'-H17'), 1.4-1.8 (m, 16H, H2, H6, H7, H11, H3', 2 x NH2), 1.9-2.0 (m, 8H, 
H8', H14'), 2.0-2.3 (m, 4H, H2'), 2.5-2.7 (m, 8H, H1, H12, H11'), 3.2-3.4 (m, 8H, H3, H5, H8, 
H10), 5.2-5.3 (m, 8H, H9', H10', H12', H13'). 13C NMR, 14.0 (C18'), 22.4 (C17'), 25.0-33.0 
(C2, C6, C7, C11, C2'-C8', C11', C14'-C16'), 39.0-39.3 (C1, C12), 42.4-47.6 (C3, C5, C8, 
C10), 127.8-130.0 (C9', C10', C12', C13'), 172.7-173.0 (C1'). HRMS, found (M+H)+ 727.6851, 
C46H87N4O2 requires (M+H)+ 727.6824. 
 
1,12-Diphthalimido-N4-oleoyl-4,9-diazadodecane. 
To a solution of 1,12-diphthalimido-4,9-diazadodecane (2.31 g, 5 mmol) in DCM (30 mL) 
oleic acid (1.6 mL, 5 mmol), DMAP (610 mg, 5 mmol), and DCC (1.03 g, 5 mmol) were 
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added. The solution was stirred at 20 °C for 20 h then filtered and the filtrate was evaporated 
to dryness in vacuo. The residue was purified over silica gel (DCM/MeOH 20:1 v/v) to afford 
the title compound (1.34 g, 37%). 1H NMR, 0.9 (t, J = 7, 3H, H18'), 1.3 (m, 20H, H4'-H7', 
H12'-H17'), 1.5-1.6 (m, 8H, H6, H7, H11, H3'), 1.9-2.0 (m, 7H, H2, H8', H11', 1 x NH), 2.1-
2.3 (m, 2H, H2'), 2.7-2.8 (m, 4H, H8, H10), 3.2-3.5 (m, 4H, H3, H5), 3.6-3.8 (m, 4H, H1, 
H12), 5.3 (m, 2H, H9', H10'), 7.7-7.8 (m, 8H, aromatic). 13C NMR, 14.1 (C18'), 22.6 (C17'), 
25.1-31.8 (C2, C6, C7, C11, C3'-C8', C11'-C16'), 33.1 (C2'), 35.3-35.9 (C1, C12), 45.2-50.6 
(C3, C5, C8, C10), 123.1-123.3 and 131.8-134.1 (aromatic carbons), 129.7-129.9 (C9', C10'), 
168.2-168.4 (C=O phthalimide), 173.0 (C1'). HRMS, found (M+H)+ 727.4774, C44H63N4O5 
requires (M+H)+ 727.4793. 
 
N4-Linoleoyl-N9-oleoyl-1,12-diamino-4,9-diazadodecane (LinOS). 
To a solution of 1,12-diphthalimido-N4-oleoyl-4,9-diazadodecane (0.72 g, 1 mmol) and 
TEA (0.14 mL, 1 mmol) in DCM (30 mL) linoleoyl chloride (0.33 mL, 1 mmol) was added. 
The solution was stirred at 20 °C for 18 h then the solvent was evaporated to dryness in 
vacuo. The residue was reacted with hydrazine monohydrate (2 mL) in a mixture of DCM (15 
mL) and THF (15 mL) and heated under reflux for 4 h, cooled to 20 °C, and then the solvent 
was evaporated in vacuo. The residue was purified over silica gel (DCM/MeOH 10:1 v/v then 
DCM/MeOH/NH4OH 10:5:1 v/v/v) to afford the title compound (0.27 g, 37% over two 
steps). 1H NMR, 0.9 (t, J = 7, 6H, H18', H18"), 1.2-1.4 (m, 34H, H4'-H7', H15'-H17', H4"-
H7", H12"-H17"), 1.4-1.7 (m, 12H, H2, H6, H7, H11, H3', H3"), 1.8-2.0 (m, 12H, H8', H14', 
H8", H11", 2 x NH2), 2.0-2.3 (m, 4H, 2', 2"), 2.6-2.8 (m, 6H, H1, H12, H11'), 3.2-3.4 (m, 8H, 
H3, H5, H8, H10), 5.3 (m, 6H, H9', H10', H12', H13', H9", H10"). 13C NMR, 14.0 (C18', 
C18"), 22.4 (C17', C17"), 25.0-26.8 (C2, C6, C7, C11, C11') , 27.1-27.2 (8', 14', 8", 11") , 
29.1-29.6 (4'-7', 15'-17', 4"-7", 12"-17"), 30.9-32.9 (C3', C16', C3", C16"), 33.0-36.7 (C2', 
C2"), 38.9-39.3 (C1, C12), 42.4-47.6 (C3, C5, C8, C10), 127.8-130.0 (C9', C10', C12', C13', 
C9", C10"), 172.7-173.0 (C1', C1"). HRMS, found (M+H)+ 729.6980, C46H89N4O2 requires 
(M+H)+ 729.6986. 
 
N4-Oleoyl-N9-stearoyl-1,12-diamino-4,9-diazadodecane (OSS). 
To a solution of 1,12-diphthalimido-N4-oleoyl-4,9-diazadodecane (0.72 g, 1 mmol) and 
TEA (0.14 mL, 1 mmol) in DCM (30 mL) stearoyl chloride (0.34 mL, 1 mmol) was added. 
The solution was stirred at 20 °C for 18 h then the solvent evaporated to dryness in vacuo. 
The residue was reacted with hydrazine monohydrate (2 mL) in a mixture of DCM (15 mL) 
and THF (15 mL) and heated under reflux for 4 h, cooled to 20 °C, and then the solvent was 
evaporated in vacuo. The residue was purified over silica gel (DCM/MeOH 10:1 v/v then 
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DCM/MeOH/NH4OH 10:5:1 v/v/v) to afford the title compound (0.31 g, 43% over two 
steps). 1H NMR, 0.8 (t, J = 7, 6H, H18', H18"), 1.2-1.4 (m, 48H, H4'-H7', H12'-H17', H4"-
H17"), 1.4-1.8 (m, 16H, H2, H6, H7, H11, H3', H3", 2 x NH2), 1.9-2.0 (m, 4H, H8', H11'), 
2.1-2.3 (m, 4H, H2', H2"), 2.6-2.8 (m, 4H, H1, H12), 3.2–3.4 (m, 8H, H3, H5, H8, H10), 5.3 
(m, 2H, H9', H10'). 13C NMR, 14.3 (C18', C18"), 22.9 (C17', C17"), 25.4-29.6 (C2, C6, C7, 
C11, C4'-C8', C11'-C15', C4"-C15"), 31.4, 32.9 (C3', C3"), 32.1 (C16', C16"), 33.3 (C2', 
C2"), 39.4 (C1, C12), 42.7-47.6 (C3, C5, C8, C10), 130.0 (C9', C10'), 173.1 (C1', C1"). 
HRMS, found (M+Na)+ 755.7112, C46H92N4O2Na requires (M+Na)+ 755.7118. 
 
General Procedure for the synthesis of asymmetrical acyl spermine derivatives using 
DCC coupling. The required carboxylic acid (1 mmol), DMAP (122 mg, 1 mmol), and DCC 
(206 mg, 1 mmol) were added to a solution of 1,12-diphthalimido-N4-oleoyl-4,9-
diazadodecane (726 mg, 1 mmol) in DCM (15 mL). The solution was stirred at 20 °C for 20 h 
then filtered and the filtrate was evaporated to dryness in vacuo. The residue was reacted with 
hydrazine monohydrate (2 mL) in a mixture of DCM (10 mL) and THF (10 mL) and heated 
under reflux for 4 h, cooled to 20 °C, and then the solvent was evaporated in vacuo. The 
residue was purified over silica gel (DCM/MeOH 10:1 v/v then DCM/MeOH/NH4OH 
100:10:1 v/v/v) to afford the title compound. 
 
N4-Arachidonoyl-N9-oleoyl-1,12-diamino-4,9-diazadodecane (AOS). 
According to the General Procedure, arachidonic acid (304 mg, 1 mmol) was reacted to 
afford the title compound (301 mg, 40% over two steps). 1H NMR, 0.9 (m, 6H, J = 7, H20', 
H18"), 1.2-1.8 (m, 42H, H2, H6, H7, H11, H3', H17'-H19', H3"-H7", H12"-H17", 2 x NH2), 
2.0-2.2 (m, 8H, H4', H16', H8", H11"), 2.2-2.4 (m, 4H, 2', 2"), 2.6-2.8 (m, 10H, H1, H12, 
H7', H10', H13'), 3.2-3.4 (m, 8H, H3, H5, H8, H10), 5.3-5.4 (m, 10H, H5', H6', H8', H9', 
H11', H12', H14', H15', H9", H10"). 13C NMR, 14.1 (C20', C18"), 22.5-22.6 (C19', C17"), 
25.3-27.2 (C4', C7', C10', C13', C16', C8", C11"), 29.2-32.7 (C2, C6, C7, C11, C3', C17', 
C18', C3"-C7", C12"-C16"), 33.1 (C2', C2"), 39.0-39.4 (C1, C12); 42.5-47.3 (C3, C5, C8, 
C10), 127.5-130.5 (C5', C6', C8', C9', C11', C12', C14', C15', C9", C10"), 172.6-172.8 (C1', 
C1"). HRMS, found (M+H)+ 753.6982, C48H89N4O2 requires (M+H)+ 753.6980. 
 
N4-Eicosenoyl-N9-oleoyl-1,12-diamino-4,9-diazadodecane (EicOS). 
According to the General Procedure, eicosenoic acid (310 mg, 1 mmol) was reacted to 
afford the title compound (273 mg, 36% over two steps). 1H NMR, 0.9 (t, J = 7, 6H, H20', 
H18"), 1.2-1.3 (m, 44H, H4'-H9', H14'-H19', H4"-H7", H12"-H17"), 1.4-1.8 (m, 12H, H2, 
H6, H7, H11, H3', H3"), 2.0 (m, 8H, H10', H13', H8", H11"), 2.2-2.4 (m, 8H, H2', H2", 2 x 
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NH2), 2.6-2.8 (m, 4H, H1, H12), 3.2-3.45 (m, 8H, H3, H5, H8, H10), 5.3-5.4 (m, 4H, H11', 
H12', H9", H10"). 13C NMR, 14.1 (C20', C18"), 22.7 (C19', C17"), 25.1-32.6 (C2, C6, C7, 
C11, C3'-C10', C13'-C18', C3"-C8", C11"-C16"), 33.1 (C2', C2"), 38.8-39.4 (C1, C12), 42.5-
47.5 (C3, C5, C8, C10), 129.8 (C11', C12', C9", C10"), 172.9-173.4 (C1', C1"). HRMS, 
found (M+H)+ 759.7450, C48H95N4O2 requires (M+H)+ 759.7455. 
 
N4-Erucoyl-N9-oleoyl-1,12-diamino-4,9-diazadodecane (EruOS). 
According to the General Procedure, erucic acid (339 mg, 1 mmol) was reacted to afford 
the title compound (268 mg, 34% over two steps). 1H NMR, 0.9 (t, J = 7, 6H, H22', H18"), 
1.2-1.4 (m, 48H, H4'-H11', H16'-H21', H4"-H7", H12"-H17"), 1.4-1.7 (m, 16H, H2, H6, H7, 
H11, H3', H3", 2 x NH2), 2.0 (m, 8H, H12', H15', H8", H11"), 2.3 (m, 4H, H2', H2"), 2.8 (m, 
4H, H1, H12), 3.2-3.4 (m, 8H, H3, H5, H8, H10), 5.3 (m, 4H, H13', H14', H9", H10"). 13C 
NMR, 14.1 (C22', C18"), 22.6 (C21', C17"), 25.1-27.2 (C2, C6, C7, C11, C12', C15', C8", 
C11"), 29.1-32.7 (C3'-C11', C16'-C20', C3"-C7", C12"-C16"), 33.1 (C2', C2"), 39.1-39.4 (C1, 
C12), 42.4-47.3 (C3, C5, C8, C10), 129.7-129.9 (C13', C14', C9", C10"), 172.8-173.0 (C1', 
C1"). HRMS, found (M+H)+ 787.7763, C50H99N4O2 requires (M+H)+ 787.7768. 
 
N4-Lignoceroyl-N9-oleoyl-1,12-diamino-4,9-diazadodecane (LigOS). 
According to the General Procedure, lignoceric acid (369 mg, 1 mmol) was reacted to 
afford the title compound (310 mg, 38% over two steps). 1H NMR, 0.9 (t, J = 7, 6H, H24', 
H18"), 1.2-1.4 (m, 64H H4'-H23', H4"-H7", H12"-H17", 2 x NH2), 1.4-1.7 (m, 12H, H2, H6, 
H7, H11, H3', H3"), 2.0 (m, 4H, H8", H11"), 2.2-2.3 (m, 4H, 4H, H2', H2"), 2.6-2.8 (m, 4H, 
H1, H12), 3.2-3.4 (m, 8H, H3, H5, H8, H10), 5.3 (m, 2H, H9", H10"). 13C NMR, 14.1 (C24', 
C18"), 22.6 (C23', C17"), 25.1-27.2 (C2, C6, C7, C11, C8", C11"), 29.2-32.7 (3'-22', 3"-7", 
12"-16"), 33.1 (C2', C2"), 39.2-39.4 (C1, C12), 42.5-47.3 (C3, C5, C8, C10), 129.7-129.9 
(C9", C10"), 172.8-173.0 (C1', C1"). HRMS, found (M+H)+ 817.8232, C52H105N4O2 requires 
(M+H)+ 817.8238. 
 
N4-Nervonoyl-N9-oleoyl-1,12-diamino-4,9-diazadodecane (NOS). 
According to the General Procedure, nervonic acid (367 mg, 1 mmol) was reacted to afford 
the title compound (302 mg, 37% over two steps). 1H NMR, 0.9 (t, J = 7, 6H, H24', H18"), 
1.2-1.4 (m, 52H, H4'-H13', H18'-H23', H4"-H7", H12"-H17"), 1.4-1.8 (m, 12H, H2, H6, H7, 
H11, H3', H3"), 2.0 (m, 8H, H14', H17', H8", H11"), 2.2-2.4 (m, 4H, H2', H2"), 2.6-2.8 (m, 
4H, H1, H12), 3.2-3.4 (m, 12H, H3, H5, H8, H11, 2 x NH2), 5.3 (m, 4H, H15', H16', H9", 
H10"). 13C NMR, 14.1 (C24', C18"), 22.6 (C23', C17"), 25.5-27.2 (C2, C6, C7, C11, C14', 
C17', C8", C11"), 29.1-32.8 (C3'-C13', C18'-C22', C3"-C7", C12"-C16"), 33.1 (C2', C2"), 
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39.0-39.5 (C1, C12), 42.5-47.6 (C3, C5, C8, C10), 129.8 (C15', C16', C9", C10"), 172.7-172.8 
(C1', C1"). HRMS, found (M+H)+ 815.8076, C52H103N4O2 requires (M+H)+ 815.8081. 
 
2.3. Transfection studies of HeLa cells stably expressing EGFP 
On the day of transfection, cells were trypsinized (0.25% trypsin, 3-4 min) at a confluency 
of 80-90% and were counted under inverted light microscope by means of haemocytometer 
using trypan blue (0.4%) to exclude the dead cells, then seeded at a density of 100,000 
cells/well in 24-well plates. The lipoplexes were prepared by mixing the specified amounts of 
the transfection reagent in Opti-MEM serum-free medium (50 L) with siRNA (15 L, 1 M 
working solution) in Opti-MEM serum-free medium. Lipofectamine 2000 (2 L/well) and 
TransIT-TKO (4 L/well) were used in accordance with the manufacturers’ instructions, both 
were used in the presence of 10% FCS. The solutions were vortex-mixed for 2-3 s, and added 
to wells containing DMEM (10% FCS, and without G418), within 0.5 h of seeding, to make 
the final volume in each well 1 mL (siRNA final concentration 15 nM). The plates were then 
incubated for 48 h at 37 °C in 5% CO2. N/P ratios (defined as the ratio of cationic lipid 
ammonium ions to RNA phosphate anions) were calculated as:   
siRNAdsinphosphatesofnumbertotalsiRNAofmolesofnumber
lipidcationicofmolesofnumberPN



0.2/  
 
2.4. Cell viability assay 
HeLa cells were trypsinized (0.25% trypsin, 3-4 min) at a confluency of 80-90% and 
counted under inverted light microscope by means of haemocytometer using trypan blue 
(0.4%) to exclude the dead cells, then seeded at a density of either 6,500 (transfection after 24 
h) or 4,000 (transfection after 0.5 h) cells per well of 96-well plates. The transfection was 
carried out using the same protocol as transfecting the 24-well plates with the exception of 
reducing the amount of lipoplexes such that each well contains 1.5 pmol siRNA in a final 
volume of 100 L/well of DMEM containing 10% FCS. After incubation for 44 h at 37 °C in 
5% CO2, alamarBlue (10 L) was added to each well. After incubation for 3.5 h at 37 °C in 
5% CO2, the absorbance of each well was measured at 570 nm and 600 nm using a 
microplate-reader (VERSAmax), and the calculation of the amount of alamarBlue reduced 
measured at 570 nm was carried out according to the standard protocol provided by the 
alamarBlue supplier (Invitrogen). Percentage viability was calculated as: 
100% 
cellscontrolofalamarBlueofreducedamount
cellssampleofalamarBlueofreducedamountviability  
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2.5. Experimental Protocols 
Flow cytometry (FACS analysis) was carried out as described above in Chapter 2 (Section 
2.5). Confocal microscopy cell imaging was carried out as described in Chapter 2 (Section 
2.6). Particle size and -potential measurements were carried out as described in Chapter 2 
(Section 2.8). siRNA binding (RiboGreen intercalation assay) was carried out as described in 
Chapter 2 (Section 2.9). Statistical analysis was carried out as described in Chapter 2 (Section 
2.10). 
 
3. Results and discussion 
 
Spermine (1,12-diamino-4,9-diazadodecane or N,N′-bis(3-aminopropyl)-1,4-
diaminobutane) has two terminal primary amine groups at carbons 1 and 12, and two 
secondary amine groups with their nitrogen atoms numbered 4 and 9. In order to conjugate 
two different fatty acids at the N4 and N9 positions, first, the two terminal primary amines 
were protected with phthalimide, then one fatty acid (oleic, 18:1) was acylated on position N4 
using oleic acid/DCC/DMAP to conjugate in a 1:1 stoichiometry with an oleoyl chain (Figure 
1). The purified mono-acylated product, 1,12-diphthalimido-N4-oleoyl-4,9-diazadodecane, 
was then conjugated with the second long-chain fatty acid using DCC/DMAP or acid 
chloride/TEA. This method avoids using orthogonal protection of the primary and secondary 
amino groups with different protecting groups (e.g. phthalimide for the primary amines and 
then Boc for the secondary amines) and hence the target products were obtained in fewer 
reactions. Keeping one fatty acid chain constant as oleic acid (18:1), the free secondary amine 
group of 1,12-diphthalimido-N4-oleoyl-4,9-diazadodecane was acylated with:  arachidonic 
(20:4), eicosenoic (20:1), erucic (22:1), lignoceric (24:0), linoleic (18:2), nervonic (24:1), and 
stearic (18:0) acids. Whilst all the other molecules are named with the oleoyl group at N9, N4-
oleoyl-N9-stearoyl-1,12-diamino-4,9-diazadodecane (OSS) is named as such to reflect the 
alphabetical order of oleoyl-stearoyl (IUPAC nomenclature), but this does not alter the 
relative structures within the diacylated-spermine series. Thus, seven asymmetrical spermine 
derivatives were synthesised (Figure 2), purified to homogeneity, and then characterized by 
NMR and HRMS. All of the spermine fatty acid conjugates in this Chapter were obtained as 
the free bases. 
Spermine requires orthogonal protection to synthesize unsymmetrical N4,N9-diacylated 
lipospermines.  One approach is to protect the primary amine functional groups as 
phthalimides, followed by Boc protection of only one secondary amine (by using 1.0 eq). 
HRMS, found (M+H)+  563.2853, C31H39N4O6 requires (M+H)+  563.2864.  The first fatty 
acid could be introduced by DCC/DMAP coupling to the free secondary amine (Figure 1). 
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Figure 1. Synthesis of the asymmetrical spermine fatty acid conjugates by two possible 
routes. (a) Nefkens’ reagent, DCM (Chapter 2, Section 2.2); (b) DCC/DMAP, R1COOH 
(oleic acid), DCM; (c) DCC/DMAP, R2COOH, DCM; (d) Boc-O-Boc, MeOH; (e) TFA, 
DCM, DCM/ aqueous NaHCO3.  
 
Boc deprotection and obtaining the free base after extraction with DCM from aq. NaHCO3 
solution then conjugation of the secondary amine functional group with the second long-
chain fatty acid (e.g. arachidonic, eicosenoic, erucic, linoleic, lignoceric, nervonic, and stearic 
acids).  Another practical approach uses DCC/DMAP to conjugate stoichiometrically only 
one fatty acid to the diphthalimido protected spermine then after purification conjugating the 
second fatty acid, thus avoiding Boc introduction and TFA-mediated Boc deprotection.  In 
the current work, the synthetic scheme of sequential stoichiometric conjugation of fatty acids 
to diphthalimido protected spermine (reaction steps a, b, and c) was used to synthesize the 
asymmetrical lipospermines as it resulted in a higher yield of the mono oleoyl diphthalimido 
spermine in fewer reaction steps compared to the synthetic route involving a Boc-protected 
intermediate (Figure 1).  
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1,12-Diphthalimido-4,9-diazadodecane 
 
 
N4,N9-Dioleoyl-1,12-diamino-4,9-diazadodecane (DOS) C18:1 9 and C18:1 9 
N
NNH2
NH2
O
O  
 
N4,N9-Dierucoyl-1,12-diamino-4,9-diazadodecane (DEruS) C22:1 13 and C22:1 13 
 
 
N4,N9-Dilinoleoyl-1,12-diamino-4,9-diazadodecane (DLinS) C18:2 9,12 and C18:2 9,12 
 
 
1,12-Diphthalimido-N4-oleoyl-4,9-diazadodecane 
N
N
N
N
H
O
O
O
O
O
 
 
N4-Arachidonoyl-N9-oleoyl-1,12-diamino-4,9-diazadodecane (AOS) C20:4 5,8,11,14 and C18:1 9 
NH2 N
N NH2
O
O  
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N4-Eicosenoyl-N9-oleoyl-1,12-diamino-4,9-diazadodecane (EicOS) C20:1 11 and C18:1 9 
O
N
NH2 N
NH2
O
 
N4-Erucoyl-N9-oleoyl-1,12-diamino-4,9-diazadodecane (EruOS) C22:1 13 and C18:1 9 
NH2N
O
NNH2
O
 
 
N4-Lignoceroyl-N9-oleoyl-1,12-diamino-4,9-diazadodecane (LigOS) C24:0 and C18:1 9 
O
N
NH2 N
NH2
O
 
 
N4-Linoleoyl-N9-oleoyl-1,12-diamino-4,9-diazadodecane (LinOS) C18:2 9,12 and C18:1 9 
O
NH2 N
N NH2
O  
 
N4-Nervonoyl-N9-oleoyl-1,12-diamino-4,9-diazadodecane (NOS) C24:1 15 and C18:1 9 
N
NH2N
O
NH2
O
 
 
N4-Oleoyl-N9-stearoyl-1,12-diamino-4,9-diazadodecane (OSS) C18:1 9 and C18:0 
O
O
N
NNH 2
NH 2
 
 
Figure 2. Target asymmetrical and symmetrical N4,N9-diamides of spermine. 
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The HRMS shown in Figure 3 is of 1,12-diphthalimido-N4-oleoyl-4,9-diazadodecane. 
Figure 4 shows the 1H NMR (upper) and HMQC (lower) assignments of 1,12-diphthalimido-
N4-oleoyl-4,9-diazadodecane. The numbering convention is that the spermine residue is the 
parent residue, and the oleoyl carbon numbers are primed. The most important features 
essential to identify the target compound include: (a) the presence of the double bonds 
protons of the oleoyl chain (2 protons at δ = 5.3, H9', H10'); (b) 3 protons at δ = 0.9 (3H, 
H18') representing the terminal methyl group of the oleoyl chain; (c) the presence of 4 
protons at δ = 3.2-3.5 (m, 4H, H3, H5), which are deshielded because they are next to the 
nitrogen atoms of the amide group at N4, indicating presence of one amide bond, and the 
successful conjugation of the fatty acids to spermine N4 position; (d) The two protons at δ = 
2.1-2.3 (m, 2H, H2') which are deshielded because they are next to the carbonyl group of the 
amide, proving the conjugation of the oleoyl residue to spermine; (e) the presence of 4 
protons at δ = 2.7-2.8 (m, 4H, H8, H10) which are deshielded because they are next to the 
free secondary amine group at position N9; (f) 4 protons at δ = 3.6-3.8 (m, 4H, H1, H12), 
deshielded because they are next to the imide groups of the protected terminal amines; (g) the 
aromatic protons of the phthalimide protecting groups at δ = 7.7-7.8 (8 protons). The HMQC 
shows: (a) the cross-peak of H2' proton with C2' carbon at δ = 33.1, which is the δ of the 
carbon next to amide carbonyl (b) the cross-peak of H1' and H12' protons with C1 and C12 
carbons at δ = 35.3-35.9, which is δ of carbons next to imide carbonyls (c) the cross-peak of 
H3, H5, H8, and H10 protons with C3, C5, C8, C10 carbons at δ = 45.2-50.6, which are the 
chemical shifts of carbons next to amide and amine groups. Taken together with the HRMS 
shown in Figure 3 of 1,12-diphthalimido-N4-oleoyl-4,9-diazadodecane, these results prove 
that the target compound was synthesized successfully. 
 
 
 
Figure 3. HRMS of protonated (M+H)+ 1,12-Diphthalimido-N4-oleoyl-4,9-diazadodecane 
C44H63N4O5 with m/z = 727.4774.  
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Figure 4. Upper: 1H NMR of 1,12-diphthalimido-N4-oleoyl-4,9-diazadodecane. Lower: 
HMQC NMR. The number of protons (peak integration) and the numbering of the associated 
carbons are shown in 1H NMR chart. The numbering of the assigned carbons is shown in 
HMQC chart next to each cross-peak.  
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The HRMS of LinOS is shown in Figure 5. Figure 6 shows the 1H NMR (upper) and 
HMQC (lower) assignments of LinOS. The numbering convention is that the spermine 
residue is the parent residue, the linoleoyl carbon numbers are primed, and the oleoyl carbon 
numbers are double primed, which is the IUPAC convention for numbering side chains 
(alphabetical priority for side chains). The most important features necessary to identify the 
target compound include: (a) the presence of the double bonds protons (6 protons at δ = 5.3, 
H9', H10', H12', H13', H9", H10") which correspond to the two double bonds of the linoleoyl 
chain and the one double bond of the oleoyl chain; (b) the presence of 8 protons at δ = 3.2-3.4 
(8H, H3, H5, H8, H10), which are deshielded because they are next to the nitrogen atoms of 
the amide groups, indicating the successful conjugation of the fatty acids to the spermine N4 
and N9; (c) 6 protons at δ = 0.9 (6H, H18', H18") representing the two terminal methyl groups 
of the two conjugated fatty acids; (d) 4 protons at δ = 2.6-2.8 (4H, H1, H12) representing 
protons of two CH2 groups deshielded because they are next to an amine group, indicating 
that the primary amine groups are deprotected; (e) the total proton integration which fits the 
formulae of LinOS, including the four protons of the amine groups at δ = 1.8-2.0.  
 
 
 
 
Figure 5. HRMS of LinOS C46H88N4O2. The upper spectrum shows the protonated LinOS, 
C46H89N4O2, (M+H)+ with m/z = 729.6980. The lower spectrum shows the doubly protonated 
LinOS C46H90N4O2 (M+2H)2+ with m/z = 365.3533.  
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Figure 6. Upper: 1H NMR of LinOS. Lower: HMQC NMR of LinOS. The number of protons 
(peak integration) and the numbering of the associated carbons are shown in 1H NMR chart. 
The numbering of the assigned carbons is shown in HMQC chart next to each cross-peak.  
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Figure 6 (lower) shows the HMQC of LinOS. The assignments of 1H-NMR and 13C-NMR 
of LinOS can be verified, as seen from the cross-peaks representing the protons H1 and H12 
with carbons C1 and C12 at δ = 38.9-39.3. The cross-peaks of protons of H3, H5, H8, and 
H10 to the carbons at δ = 42.4-47.6, as well as the cross-peaks of protons H2' and H2" and 
the carbons at δ = 33.0-36.7, indicate the presence of the amide groups and the conjugation of 
the fatty acids to the parent spermine. The absence of any cross-peaks of the NH2 protons at δ 
= 1.8-1.9 (1H-NMR) verifies the presence of the deprotected terminal primary NH2 protons. 
Taken together, in addition to the HRMS results shown in Figure 5, it can be concluded that 
the target compound (LinOS) has been synthesised successfully. 
 
3.1. Transfection studies of HeLa cells stably expressing EGFP 
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Figure 7. siEGFP-AF delivery to HeLa cells expressed as the normalized values of the 
AF647 geometric mean fluorescence (AF fluorescence) 48 h post-transfection of HeLa cells 
with the lipoplexes prepared with seven asymmetrical spermine fatty acid conjugates and 
symmetrical DOS. The amount of siEGFP-AF was kept constant at 15 pmol/well (15 nM). 
 
Figure 7 shows siRNA siEGFP-AF delivery to HeLa cells as evaluated by the normalized 
geometric mean fluorescence of AF647 covalently bound to siEGFP. The amount of siRNA 
delivered (at 6 g cationic lipid/well) as measured by AF647 fluorescence was 30, 17, and 10 
for the C18 fatty acid conjugates OSS, DOS, and LinOS respectively which was related 
inversely to increases in the number of C=C double bonds in the C18 fatty acids. Increasing 
the number of unsaturation sites in C24 fatty acids also decreased siRNA delivery (at 6 g 
cationic lipid/well, N/P = 21.4) normalized AF647 fluorescence was 50 and 23 for LigOS and 
><urls><related-urls><url>&lt;Go to ISI&gt;://WOS:A1996UF04900016</url></rel one to 
EicOS and AOS respectively, resulted in a decrease in siRNA delivery, from 19 to 10 at 6 g 
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cationic lipid/well (p = 0.0001), and from 18 to 14 at 3 g/well (p = 0.0163) for EicOS and 
AOS respectively. Increasing the chain length (EruOS, 22:1 and NOS, 24:1), while keeping 
the number of C=C double bonds constant, caused an increase in siRNA delivery compared 
to shorter DOS 18:1 and EicOS 20:1. At a cationic lipid concentration of 6 g/well, AF647 
fluorescence was 17, 19, 35, and 23; and at 3 g/well:  14, 18, 31, and 24 for DOS, EicOS, 
EruOS, and NOS respectively. Comparing saturated LigOS (with lignoceroyl chain, 24:0) 
and OSS (with stearoyl chain 18:0) shows that an increase in the chain length from C18 
(OSS) to C24 (LigOS) resulted in an increase in AF647 fluorescence from 30 to 50 
respectively (p < 0.0001). 
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Figure 8. EGFP expression percentage calculated 48 h post-transfection of HeLa cells with 
the lipoplexes prepared with seven asymmetrical spermine fatty acid conjugates and 
symmetrical DOS. The amount of siEGFP-AF was kept constant at 15 pmol/well (15 nM). 
 
Figure 8 shows the reduction of EGFP expression in HeLa cells 48 h post-transfection 
with lipoplexes of siEGFP and the synthesized asymmetrical fatty acid derivatives of 
spermine. C18 fatty acids with one or two unsaturation sites resulted in better reduction in 
EGFP expression. Thus, LinOS (3 g/well, N/P = 11.9) gave 24% EGFP expression, DOS (6 
g/well, N/P = 23.8) gave 27% EGFP, compared to OSS (with one stearoyl 18:0) which at 
3g/well gave 38% EGFP and at 6 g/well gave 38% EGFP. Increasing the number of 
unsaturation sites in C20 fatty acids resulted in better reduction in EGFP expression (down to 
37% and 29% at 6 g/well, p < 0.0001; 52% and 34% at 3 g/well; p < 0.0001 for EicOS and 
AOS respectively). There was no significant statistical difference (p > 0.05) between LigOS 
and NOS with respect to their effects on EGFP expression. Increasing the chain length of the 
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fatty acid spermine derivatives from C18 to C24 while keeping number of C=C double bonds 
constant generally resulted in higher levels of EGFP across the series of compounds, with 
EGFP expression reduced to 26%, 38%, 51%, and 54% at 6 g/well of DOS, EicOS, EruOS, 
and NOS respectively. There were no differences between EicOS and EruOS at 0.75, 1.5, and 
3 g/well. Increasing the chain length from C18 to C24 in OSS and LigOS respectively 
resulted in higher levels of EGFP expression at different concentrations of lipids. At 6 
g/well, OSS resulted in EGFP expression of 38% while LigOS resulted in EGFP expression 
of 56% (p < 0.0001). The efficiency of gene silencing achieved with LinOS (76%, 
corresponding to 24% EGFP percentage expression), DOS (73%), and OSS (62%) is 
comparable to that of commercially available reagents TransIT-TKO (4 L/well, 75%) and 
Lipofectamine 2000 (2 L/well, 69%) used in the presence of serum (10% FCS) and in 
accordance with the manufacturers’ instructions for optimal efficiency. The quantitative 
FACS data (Figures 7 and 8) are better illustrated by the flow cytometric graphs comprised of 
individual histograms (Figure 9). 
Representative FACS results (Figure 9) are shown with the typical graphs:  forward 
scatter/side-scatter (FSC/SSC) dot graph showing the gating of the healthy cell population, 
the profile with the AF647 gate, and the profile with the EGFP gate. These data are 
representative in that they are typical and reflect a single delivery and gene silencing 
experiment (from 1 of 9 wells). The conditions shown are without (as a control) and with 
siEGFP-AF. A qualitative analysis of the control cells (Figure 9a) shows a healthy and 
homogeneous population of EGFP fluorescing cells, with weak autofluorescence excluded 
out of the AF647 gate. Delivery of siEGFP-AF (15 nM, 15 pmol/well) was 6-fold greater 
with LigOS (6 µg/well) than with LinOS (3 µg/well). However, gene silencing was greater 
with LinOS lipoplexes than with those prepared with LigOS (shown in Figure 9 and statistics 
in Figure 8). Thus, these flow cytometry experiments are also good representatives of 
cationic lipids showing high delivery with low gene silencing (LigOS), and low delivery with 
good silencing (LinOS). The commercial transfection reagents TransIT-TKO and 
Lipofectamine 2000 show very high delivery, but their silencing is no better than that 
achieved with LinOS (3 µg/well) (Figure 9). Clearly, intracellular delivery and gene silencing 
are controlled by different processes and therefore functional siRNA delivery is affected by 
lipoplexes of different cationic lipids to varying extents.171  
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(9a) Control 
 
     
(9b) LigOS 
 
     
(9c) LinOS 
 
   
(9d) TransIT-TKO 
100 
 
   
(9e) Lipofectamine 2000  
 
Figure 9. Gated FACS analysis of delivery of siEGFP-AF (15 nM, 15 pmol/well) and EGFP 
expression in HeLa cells (compared to control) 48 h post-transfection with lipoplexes of 
LigOS (6 µg/well) and LinOS (3 µg/well). Positive controls come with the commercial 
transfection reagents TransIT-TKO and Lipofectamine 2000. The AF647 gate (red) typically 
shows >95% of parent-gated cells with delivery of siEGFP-AF lipoplexes prepared with 
asymmetrical spermine fatty acid conjugates. The EGFP gate (green, values measured by 
geometric mean fluorescence relative to control) shows silencing to ~20% with LinOS 
lipoplexes, and to ~55% with LigOS lipoplexes even though delivery is essentially 
quantitative with the latter. 
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Figure 10. EGFP expression percentage (dark grey bars) calculated 48 h post-transfection of 
HeLa cells with the lipoplexes prepared with asymmetrical spermine fatty acid conjugates 
and siNC-AF (15 pmol/well, 15 nM). siNC-AF fluorescence shows siRNA delivery (white 
bars). Cationic lipid amounts used were those that resulted in the best reduction in EGFP 
expression:  AOS (6 g/well), EicOS (6 g/well), EruOS (6 g/well), LigOS (6 g/well), 
LinOS (3 g/well), NOS (6 g/well), and OSS (6 g/well). 
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The EGFP expression and siNC-AF delivery are shown in Figure 10. The amounts of lipids 
used were those which resulted in the best reduction in EGFP expression with respect to each 
cationic lipid (Figure 8). The data show that while the delivery of siNC-AF for each cationic 
lipid, at the specified concentration, was with comparable efficiency to the delivery results of 
siEGFP-AF (Figure 7), there was no significant effect (a maximum of 10% reduction) on EGFP 
expression percentage. Thus, the reduction in EGFP expression after transfection with siEGFP-
AF lipoplexes is mainly due to sequence-specific EGFP knock-down mediated by the delivered 
siEGFP-AF, and not due to any cationic lipid-related effects, e.g. toxicity. 
 
Figure 11. siEGFP-AF delivery to HeLa cells expressed as the normalized values of the 
geometric mean fluorescence of AF647 48 h post-transfection of HeLa cells with the 
mixtures of lipoplexes prepared with DOS/DLinS or DOS/DEruS at different molar ratios 
(total lipid weight 3 g/well). The amount of siEGFP-AF was kept constant at 15 pmol/well 
(15 nM). 
 
Mixtures of cationic lipids have been reported to enhance DNA transfection through 
synergy.224 Figure 11 shows siEGFP-AF delivery with lipoplexes of mixtures of DOS/DLinS 
and DOS/DEruS at different molar ratios of the symmetrical spermine derivatives, as well as 
comparing their siEGFP-AF delivery with the delivery by the asymmetrical LinOS and 
EruOS. DOS lipoplexes resulted in AF647 fluorescence of 14 (normalized) and DLinS 
resulted in delivery of 3. The mixtures of DOS/DLinS of molar ratio 4:1 to 1:4, resulted in 
AF647 fluorescence of intermediate values between those of DOS and DLinS. When 
compared to LinOS, the siEGFP-AF delivery with the DOS/DLinS 1:1 lipoplexes resulted in 
lower AF647 delivery (7 and 12 for DOS/DLinS 1:1 and LinOS respectively, p < 0.0001). 
The mixtures of DOS/DEruS of molar ratio 4:1 to 1:4, resulted in AF647 fluorescence of 
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intermediate values between those of DOS (14) and DEruS (82). There was no statistical 
significant difference between DOS/DEruS 1:1and EruOS (33 and 31 respectively, p = 0.64). 
The mixtures mostly behave in a way which reflects the behaviour of the individual 
components (Figure 11). DLinS shows the lowest uptake, consistent with the results (Figure 
11) where lipids containing more double bonds show lower uptake. DEruS has the highest 
uptake, also consistent with the results in Figure 11 where the longer and more saturated lipid 
chains, EruOS, LigOS, and NOS show higher uptake. However, these mixtures of cationic 
lipids displayed no synergy in siEGFP-AF delivery as found with DNA transfection.224 
 
Figure 12. EGFP expression percentage measured 48 h post-transfection of HeLa cells with 
the lipoplexes prepared with mixtures of DOS/DLinS or DOS/DEruS at different molar ratios 
(total lipid weight 3 g/well). The amount of siEGFP-AF was kept constant at 15 pmol/well 
(15 nM). 
 
Figure 12 shows the reduction in EGFP expression 48 h post-transfection with lipoplexes 
of mixtures of DOS/DLinS and DOS/DEruS at different molar ratios of the symmetrical 
spermine derivatives, as well as the EGFP expression resulting from transfection with 
lipoplexes of the asymmetrical LinOS and EruOS. The mixtures of DOS/DLinS of molar 
ratio 4:1 to 1:4, resulted in EGFP expression of intermediate values between those of DOS 
and DLinS, with EGFP expression increasing with the increase in DLinS content in the 
mixture. When compared to LinOS, the EGFP expression with the DOS/DLinS 1:1 
lipoplexes resulted in EGFP expression of 34% compared to LinOS 24% (3 g/well, p < 
0.0001). The mixtures of DOS/DEruS of molar ratio 4:1 to 1:4, resulted in EGFP expression 
of intermediate values between those of DOS and DEruS. Contrary to the results obtained 
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with DOS/DLinS 1:1 and LinOS, EruOS resulted in higher EGFP expression (47%) 
compared to the DOS/DEruS 1:1 mixture (31%, p < 0.0001). The gene silencing of 
lipoplexes composed solely of DLinS (55%), and of DEruS (57%) show limited inhibition of 
EGFP expression (Figure 12). The mixtures mostly show gene silencing dominated by DOS 
rather than reflecting the percentage composition of the individual components. This is also 
found in the covalent binding of erucoyl and oleoyl chains in the spermine conjugate EruOS 
(gene silencing to 47%), but incorporating two different C18 acyl chains in the asymmetrical 
LinOS, linoleoyl and oleoyl, affords the best gene silencing (24%). 
 
3.2. Confocal microscopy cell imaging 
Figure 13a shows non-transfected (control) HeLa cells expressing EGFP (green) within 
the cell membrane (blue). Figures 13b and 13d show HeLa cells only 4 h post-transfection 
with lipoplexes of siEGFP-AF and LinOS (3 µg/well). Figure 13b shows that while siEGFP-
AF (red) has been delivered, EGFP is still strongly expressed throughout the cell. In Figure 
13d, the green channel was turned-off to better visualize the red colour representing siEGFP-
conjugated dye AF647 (siEGFP-AF). Note that the lower cell shows higher uptake compared 
to the upper cell. In Figure 13c, EGFP (green) is barely detectable at 48 h post-transfection, 
compared to the control untransfected cells shown in Figure 13a. Scattered red dots indicate 
that siEGFP-AF is still present 48 h post-transfection. Taken together, the photomicrographs 
shown in Figure 13 demonstrate the apparent efficient uptake of lipoplexes of siEGFP-AF 
and LinOS (3 µg/well) and the subsequent very dramatic reduction (knock-down) of EGFP 
expression, at least up to 48 h post-transfection. Of interest is that LinOS (at 3 and even at 6 
µg/well, Figure 7) shows the lowest siRNA delivery, but with siEGFP-AF held constant at 15 
pmol/well (15 nM), LinOS (3 µg/well) forms the most efficient lipoplexes for gene silencing 
(Figure 8) even though this high efficacy is not reflected in high delivery. 
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  (13a)      (13b) 
   
  (13c)      (13d) 
 
Figure 13. Confocal photomicrographs of HeLa cells before and after transfection of siEGFP-
AF with LinOS (3 µg/well). The cell membrane is stained with Alexa Fluor 555 (blue). 
Representative pictures are shown. (13a) Untransfected HeLa cells stably expressing EGFP 
(green). (13b) Detection of siEGFP-AF (red dots), only 4 h post-transfection. (13c) EGFP 
expression with the green channel on as in (13a) and (13b), monitored 48 h post-transfection. 
EGFP expression is largely reduced (cf FACS data, Figure 13b). (13d) as (13b) with the FACS 
green and blue channels turned off for clarity. 
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Figure 14. A Z-stack confocal photomicrograph gallery of photomicrographs representing 12 
Z-sections in HeLa cells transfected with lipoplexes of LinOS (3 g/well) and siEGFP-AF 
(15 pmol). EGFP fluorescence (green), cell membrane stained with WGA-Alexa Fluor 555 
(blue), and Alexa Fluor 647 (red) represents tagged siRNA delivery. 
 
In order to further highlight the intracellular detection of siEGFP-AF monitored 48 h post-
transfection (Figure 13c) where there is almost no detectable EGFP expression (with the 
green channel turned on), a Z-stack gallery was recorded through a monolayer of transfected 
HeLa cells (Figure 14). Z-Stacks are a series of successive optical sections acquired at 
different positions along the Z-axis (in 1.0 m slices). The first optical section was taken 
slightly lower than the surface of the cells attached to the cover slip, then the sections were 
recorded while slicing through to the opposite surface. Figure 14 shows that majority of the 
red colour (representing siRNA delivery) is present inside the cell, the blue colour 
representing cell membrane is only present at the perimeter of the cells, and occasionally the 
red colour is present simultaneously with the blue colour indicating Alexa Fluor 647 (red) 
(bound to siRNA) within the membrane. While slicing along the Z-axis, there is no blue 
colour in the middle of the cells where there is red. Minko and co-workers have recently 
reported the use of Z-stack photomicrographs to determine the orientation of the delivered 
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siRNA, where a NuLight DY-547 fluorophore tagged siRNA was delivered to A2780 human 
ovarian cancer cells by surface neutral, but internally cationic polyamidoamine dendrimers.225  
 
3.3. Particle size, zeta-potential measurements, and siRNA binding (RiboGreen intercalation 
assay) 
 
Table 1. Particle diameter, ζ-potential, and siRNA binding assay of fatty acid amides of 
spermine measured at the cationic lipid/siRNA ratios that showed best knock-down of EGFP 
(all shown as mean ± SD). 
Cationic 
lipid 
Diameter 
(nm) 
ζ-potential 
(mV) 
% fluorescence 
of RiboGreen 
AOS 292 ± 36 49 ± 1 4 ± 1 
EicOS 273 ± 11 55 ± 2 2 ± 1 
EruOS 286 ± 29 51 ± 2 2 ± 1 
LigOS 241 ± 26 59 ± 6 1 ± 1 
LinOS 225 ± 20 53 ± 3 4 ± 1 
NOS 291 ± 26 40 ± 4 1 ± 1 
OSS 145 ± 7 56 ± 2 5 ± 1 
 
DLS was used to measure the particle sizes (Table 1) of the lipoplexes prepared at the 
cationic lipid/siRNA ratio that resulted in the largest reduction in EGFP expression. The size 
range is 145-292 nm (OSS to AOS respectively) which is in agreement with the size range of 
lipoplexes previously reported to transfect successfully in cell culture.214 The particle size 
could determine the main route of cellular entry, with lipoplexes <300 nm likely to enter via 
clathrin-mediated endocytosis, and lipoplexes >500 nm entering cells via caveoli-mediated 
endocytosis.214, 215 However, the entry route for functional siRNA delivery might be by fusion 
with the cell membrane rather than via an endocytic pathway, as demonstrated using selective 
inhibitors.171 The ζ-potentials of the prepared lipoplexes (Table 1) are all positive (40-59 
mV). Such a net positive charge on the lipoplex surface is important in promoting lipoplex-
lipoplex repulsion, thus preventing aggregation. The RiboGreen siRNA binding assay results 
(Table 1) show that the asymmetrical spermine conjugates are able to bind siRNA almost 
completely, with the fluorescence of RiboGreen dye reduced to values of 1-5% of the control. 
The two free terminal primary amine groups of the acylated spermine conjugates are 
practically fully protonated at physiological pH 7.4.  
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3.4. Cell viability assays 
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Figure 15. Cell viability (alamarBlue assay) 48 h post-transfection of HeLa cells with the 
lipoplexes prepared with spermine fatty acid conjugates, using 6,500 cells/well, and 
transfection with lipoplexes was 24 h after seeding the cells. The amount of siNC was kept 
constant (1.5 pmol/well, 15 nM) and amounts of lipids were adjusted accordingly to the same 
cationic lipid/siRNA ratio that resulted in the best reduction in EGFP expression:  AOS (0.6 
g/well), EicOS (0.6 g/well), EruOS (0.6 g/well), LigOS (0.6 g/well), LinOS (0.3 
g/well), NOS (0.6 g/well), and OSS (0.6 g/well); compared with DOS (0.6 g/well), 
Lipofectamine 2000 (Lipof, 0.2 L/well), and TransIT-TKO (0.4 L/well). 
 
For pragmatic cell viability assays, the transfection conditions in 24-well format were 
downscaled to 96-well format, after establishing that 4,000-6,500 cells/well was an optimal 
range for reproducible results and in order to avoid problems of overconfluency. To keep the 
ratios and concentrations the same, the cell number, weight of cationic lipid, and amount of 
siRNA were each reduced to one tenth of their original values. The two cell viability assay 
conditions employed reflect the experimental conditions used in gene silencing (0.5 h 
between seeding and transfection) and in confocal microscopy where the time after seeding 
was 24 h to allow the cells to attach well and distribute evenly on the cover slips. In 
comparison, when using FACS to quantify gene silencing, there was no requirement for a 
long time between seeding and transfection as there was no requirement for better attachment 
to cover slips.  
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For the experiments whose results are shown in Figure 15, the weight of lipid chosen was 
based on the ratio of lipid/siEGFP-AF that resulted in the best reduction in EGFP expression 
as seen in Figure 8. The percentage cell viabilities, shown in Figure 14, indicate that 
transfection of HeLa cells with lipoplexes of siRNA and the synthesized asymmetrical 
spermine derivatives resulted in cell viabilities above 74%, with LinOS (0.3 g/well) 
resulting in 88% viability and DOS 85% viability (0.6 g/well) which is comparable to 
TransIT-TKO (81%) and better than Lipofectamine 2000 (62%).  
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Figure 16. Cell viability (alamarBlue assay) 48 h post-transfection of HeLa cells with the 
lipoplexes prepared with spermine cationic lipids using 4,000 cells/well and transfection 0.5 h 
after seeding. The amount of siRNA (siNC) was kept constant at 1.5 pmol/well (15 nM) and 
amounts of cationic lipids were adjusted accordingly. 
 
Figure 16 shows the cell viabilities after transfection of HeLa cells using a lower number 
of cells (4,000 cell/well in 96-well format) and carrying out the transfection within 0.5 h of 
seeding the cells, aiming to make the transfection conditions harsher for the cells, such that 
individual differences between each of the cationic lipids at their different concentrations can 
be compared. Figure 16 also shows that increasing the amounts of lipids per well from 0.075 
to 0.6 g resulted in a decrease in cell viability. The viabilities resulting from transfection 
with lipoplexes of LinOS and DOS (the cationic lipids that showed the best reduction in 
EGFP expression as shown in Figure 8) were reduced from 96% to 84% to 65% to 52% 
(LinOS) and from 95% to 77% to 50% to 33% (DOS) at 0.075, 0.15, 0.3, and 0.6 g/well 
respectively. The lowest cell viabilities were due to transfection with EruOS lipoplexes (from 
94%, 53%, 26%, and 14% at 0.075, 0.15, 0.3, and 0.6 g/well of EruOS respectively). 
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In this Chapter, seven asymmetrical lipopolyamines based on spermine, possessing two 
primary amines were designed, synthesized, purified, and tested in a variety of physico-
chemical and cell biological assays. These are novel divalent cationic lipids. Assessment 
using both flow cytometry and fluorescence microscopy in human HeLa cells, measuring 
both delivery of the fluorescently tagged siRNA and silencing the EGFP signal in a stably 
transfected cell line, allowed quantitation of the differences between asymmetrical cationic 
lipids, selected mixtures of their symmetrical counterparts, and comparison with 
commercially available non-viral delivery agents. In this Chapter, the design of this series of 
novel spermine based cationic lipids involved making variations in the hydrophobic domain 
by changing the type of fatty acids conjugated to the parent spermine molecule. Koynova et 
al. reported the impact of changing the hydrophobic moiety of cationic lipids on DNA 
transfection efficiency.147 Data from 20 cationic phosphatidylcholine (PC) derivatives show 
that the chain saturation state and chain length, representing hydrophobic volume and cationic 
lipid hydrophilic-lipophilic balance (HLB), are major factors that determine DNA 
transfection efficiency, with variations in efficiency by more than two orders of magnitude, 
and also that lipid chain asymmetry has a strong impact on DNA transfection efficiency while 
keeping the HLB of cationic lipids constant.147 
Non-viral DNA vectors prepared from cationic lipids that are composed of asymmetrical 
fatty acid chains have been reported to have higher in vitro153 and/or in vivo226 efficiencies in 
comparison with their symmetrical counterparts. Several hypotheses have been put forward to 
explain the superior DNA transfection efficiency of asymmetrical cationic lipids. Ali et al. 
reported that fatty chain asymmetry in membrane lipids affects the physical environment of 
liquid-crystalline bilayers.223 PCs showing a relatively large difference in chain length (larger 
asymmetry, e.g. 18:0/8:0 or 18:0/10:0 PCs) resulted in 20-25% greater in-plane elasticity 
compared to PCs with less asymmetry (16:0-18:1 PCs) and to symmetrical PCs (di18:1). 
Heyes et al.153 suggested that the difference in length between the fatty chains allows for 
better overlapping within biological lipid bilayers following the work of Balasubramaniam et 
al. who proposed that asymmetrical lipids have increased fusogenicity.227  
The effect on DNA transfection efficiency of changing the saturation state in one chain 
was reported by Koynova et al.228 Comparing two asymmetric cationic phospholipid 
derivatives, oleoyldecanoylethyl-PC (C18:1/C10:0) and stearoyldecanoylethyl-PC 
(C18:0/C10:0), resulted in the former compound with the oleoyl chain showing 50-fold more 
DNA transfection efficiency than the latter with the saturated stearoyl chain. This DNA 
transfection efficiency result was attributed to the enhanced fusibility of the (C18:1/C10:0) 
lipid with cellular lipid membranes, and to the facilitated release of DNA due to phase 
reorganization, lamellar to non-lamellar transitions, and extensive phase coexistence as a 
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result of lipid mixing at physiological temperatures.228 The processes of siRNA lipoplex 
delivery (uptake) and gene silencing are different from each other and different from DNA 
transfection. The results of EGFP expression gene-silencing show that siRNA lipoplexes self-
assembled with lipopolyamines possessing one or two centres of unsaturation in the acyl 
chains (e.g. DOS, LinOS) lead to more gene silencing compared to similar lipoplexes 
containing saturated chains of the same length (e.g. stearoyl in OSS). siRNA uptake was 
highest with the symmetrical DEruS.  
Synergistic effects of mixtures of cationic lipids have also been reported to enhance DNA 
transfection. However, mixtures of N-[1-(2,3-dimyristoyloxy)propyl]-N,N,N-
trimethylammonium (DMTAP) and N-[1-(2,3-dioleoyloxy)propyl]-N,N,N-
trimethylammonium (DOTAP) show intermediate values of DNA transfection efficiencies 
compared to using pure parent lipids as a linear function of lipid mixture composition.224 
Enhanced DNA transfection following the use of lipid mixtures is possibly due to the change 
of the hydrophobic volumes of the lipids, related to the average hydrophobicity of the 
mixture and/or the heterogeneous distribution of the hydrophobic domains of the mixtures. 
Also, the presence of more than one lipid results in an increase in the degrees of freedom of 
lipoplex-membrane interactions eventually leading to better fusogenicity.224 siRNA lipoplex 
formation and delivery do not necessarily follow the same constraints as those of DNA 
lipoplexes due to the significant structural differences between DNA and siRNA regarding 
molecular weight and rigidity. Thus, the aforementioned hypotheses regarding DNA self-
assembled lipoplexes should be applied cautiously to siRNA lipoplexes. 
The use of mixtures e.g. DOS/DLinS and DOS/DEruS, at different molar ratios of the 
symmetrical spermine derivatives, afforded similar or lower siEGFP-AF delivery in comparison 
with their related asymmetrical cationic lipids (LinOS and EruOS). Reduction in EGFP 
expression 48 h after transfection with lipoplexes prepared from mixtures of these symmetrical 
cationic lipids was poorer than that achieved with the related asymmetrical cationic lipid 
LinOS, but better than that achieved with EruOS. In the alamarBlue assay, cell viability of 
LinOS lipoplexes was 88%. LinOS is an excellent, efficient, non-toxic cationic lipid in HeLa 
cells, comparable or superior to commercially available reagents TransIT-TKO and 
Lipofectamine 2000. 
The amount of siEGFP-AF delivered to HeLa cells was lower with more C=C double 
bonds in the lipid moiety. Increasing the chain length, while keeping the number of C=C 
constant, caused an increase in siRNA delivery. C18 fatty acids with one or two unsaturation 
sites resulted in better reduction in EGFP expression and increasing the number of 
unsaturation sites in C20 fatty acids also resulted in better reduction in EGFP expression in 
HeLa cells 48 h post-transfection. Increasing the chain length of the fatty acid spermine 
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derivatives from C18 to C24 while keeping the number of C=C double bonds constant was 
generally less efficient for gene silencing. It is shown that reduction in EGFP expression after 
transfection with siEGFP-AF lipoplexes was due to sequence-specific EGFP knock-down 
mediated by the delivered siEGFP-AF, and not due to any cationic lipid-related effects, e.g. 
toxicity. It is concluded that the effects of different hydrophobic domains are not equal on 
intracellular delivery of siRNA and on gene silencing by siRNA. Control of these processes 
can be achieved with different N4,N9-diacyl spermines where gene silencing is efficiently 
demonstrated using lipoplexes of LinOS, and relatively higher siEGFP-AF delivery is 
demonstrated using LigOS. 
 
4. Conclusions 
 
In this Chapter, seven asymmetrical N4,N9-diacyl spermine conjugates were designed, 
synthesized, characterized by NMR and HRMS, and investigated in vitro in HeLa cells for 
siEGFP-AF delivery and EGFP gene knock-down. One oleoyl chain was kept constant in all 
the asymmetrical conjugates while the other fatty acid chain was varied in length and/or 
saturation state. The SAR study revealed that asymmetrical conjugates with longer fatty acid 
chains (e.g. in LigOS and NOS), results in more siEGFP-AF intracellular delivery compared 
to conjugates with less chain length (e.g. LinOS). Also, the spermine conjugates with one 
saturated chain (e.g. OSS) resulted in better siEGFP-AF delivery compared to their 
unsaturated analogues (LinOS). Interestingly, EGFP silencing did not essentially directly 
relate to the amount of siEGFP-AF delivered. LinOS lipoplexes resulted in reduction of 
EGFP expression to 24% (3 g lipid/well) and LigOS reduced EGFP expression to 56% (6 
g lipid/well), while LigOS resulted in 4-fold more delivery than LinOS. The SAR study 
showed that generally having one or two double bonds in the conjugated fatty acid chains 
enhance the resultant gene-silencing of the delivered siEGFP-AF when compared to saturated 
chains of same length. The cell viability 48 h post-transfection was above 74%, with LinOS 
at the best lipid/siNC ratio resulting in 88% cell viability.  
In the next Chapter, coformulating asymmetrical LinOS with the neutral lipids cholesterol 
and DOPE will be investigated, aiming to enhance the amount of siEGFP-AF delivered to the 
cells, and evaluating the subsequent reduction of EGFP expression. These coformulation 
approaches will be carried out while maintaining the simple procedure for preparing the 
lipoplexes, i.e. lipid mixtures will be prepared without carrying out the traditional liposomal 
preparation protocols.  
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Chapter Five  Quantitative silencing of EGFP reporter gene by self-assembled siRNA 
lipoplexes of mixtures of LinOS or DOS with either cholesterol or DOPE 
 
1. Introduction 
 
Small (or short) interfering RNA (siRNA) is a double-stranded RNA (dsRNA), typically 
21-25 nucleotides per strand. Sequence-specific post-transcriptional gene silencing by siRNA 
has many potential therapeutic applications1 as well as being an important tool in the study of 
functional genomics. 
Gene silencing mediated by siRNA requires that the siRNA is protected from various 
exo- and endo-nucleases44 and is delivered intact to the cytoplasm of the target cell.39 The 
negative charges of the siRNA phosphate backbone must be masked to facilitate the siRNA-
vector complex (lipoplex) binding to the cell membrane which is then followed by cellular 
entry of the lipoplex mainly via endocytosis and to a lesser extent by membrane fusion.171 
Thus, a vector is needed to fulfil these requirements. Non-viral vectors used for gene delivery 
(DNA based) and gene silencing by siRNA or shRNA include lipid-based vectors, polymer-
based vectors e.g. polyethylenimine, carbohydrate-based polymers e.g. cyclodextrin and 
chitosan, dendrimers e.g. polyamidoamine225 and polypropylenimine, and polypeptides.82, 229-
231 Lipid-based non-viral vectors are widely used for siRNA delivery.196, 198, 218 Fatty acid 
derivatives of spermine (symmetrical N1,N12-diacyl and N4,N9-diacyl) were previously 
synthesized and tested for their ability to deliver non-silencing siRNA in vitro,170, 182, 216 while 
in Chapter 4, the novel asymmetrical LinOS showed high gene-silencing efficiency.  
In this Chapter, the formulations of the new spermine diacyl fatty acid derivative N4-
linoleoyl-N9-oleoyl-1,12-diamino-4,9-diazadodecane (LinOS) are characterized in preparing 
self-assembled lipoplexes with siRNA either on its own (without a helper lipid) or in co-
formulae with cholesterol or DOPE, and without pre-formulation of liposomes. The prepared 
lipoplexes were evaluated for their efficiency in delivering siRNA, in mediating gene-
silencing, and for their effects on cell viability. 
 
2. Material and methods 
 
2.1. Materials and general methods 
Chemicals were purchased from Sigma-Aldrich (Gillingham, UK) and solvents were 
purchased from Fisher Scientific UK (Loughborough, UK). All chemicals and cell culture 
media were purchased as described in Chapter 2 (Section 2.1). HeLa cells stably expressing 
EGFP were obtained from the Cell Service at Cancer Research UK (CRUK, London 
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Research Institute, Clare Hall Laboratories, South Mimms, London, UK). The high resolution 
(HR) time-of-flight mass spectra (MS) were obtained on a Bruker Daltonics micrOTOF mass 
spectrometer using electrospray ionisation (ESI). AllStars negative control siRNA (siNC) and 
it tagged with Alexa Fluor 647 (siNC-AF) at the 3'-position were purchased from Qiagen 
(Crawley, UK) as was siRNA against EGFP labelled with Alexa Fluor 647 (siEGFP-AF) at 
the 3'-position of the sense strand. 
 
2.2. N4-Linoleoyl-N9-oleoyl-1,12-diamino-4,9-diazadodecane (LinOS) and N4,N9-dioleoyl-
1,12-diamino-4,9-diazadodecane (DOS) 
The authenticity of N4-linoleoyl-N9-oleoyl-1,12-diamino-4,9-diazadodecane (LinOS) was 
confirmed (HRMS, found (M+H)+ 729.6980, C46H89N4O2 requires (M+H)+ 729.6986) and 
N4,N9-dioleoyl-1,12-diamino-4,9-diazadodecane (DOS) (HRMS, found (M+H)+ 731.7162, 
C46H91N4O2 requires (M+H)+ 731.7137) by the HRMS of homogenous samples.  
 
2.3. siRNA lipoplex preparation 
LinOS, DOS, cholesterol, and DOPE were prepared as ethanolic solutions. For LinOS 
and DOS mixtures with cholesterol and DOPE, the required volumes of the ethanolic 
solutions of the single lipids were mixed together. To prepare the lipoplexes, two working 
liquids A and B were prepared. Liquid A was prepared by adding the required amount of 
siRNA (siEGFP-AF, siNC-AF, or siNC) to OptiMEM I media, such that the concentration of 
siRNA was adjusted to 1 pmol/µL. Liquid B was prepared by adding the required volume of 
lipid ethanolic solution to OptiMEM I media, such that the final concentration of LinOS or 
DOS was 0.75 µg/µL followed by mixing on a vortex mixer for 3 s. Liquid A was added to 
liquid B and they were mixed on a vortex mixer for 3 s. The lipoplex preparation was then 
simply allowed to stand for 20 min at 20 °C to allow lipoplex formation by charge 
neutralization and equilibration. TransIT-TKO was prepared according to the supplier’s 
(Mirus) instructions.  
 
2.4. Experimental Protocols 
Transfection experiments were carried out on HeLa cells stably expressing EGFP using 
the protocol described in Chapter 2 (Section 2.4). Flow cytometry (FACS analysis) was 
carried out as described in Chapter 2 (Section 2.5). Confocal microscopy cell imaging was 
carried out as described in Chapter 2 Section 2.6. Cell viability assay was carried out as 
described in Chapter 2 (Section 2.7). Particle size and -potential measurements were carried 
out as described in Chapter 2 (Section 2.8). Statistical analysis was carried out as described in 
Chapter 2 (Section 2.10). 
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2.8. Cryo-transmission electron microscopy (Cryo-TEM) 
siNC lipoplexes were prepared with LinOS/Chol 1:2 (0.75 g LinOS per 3.75 pmol siNC, 
N/P = 11.9) in 10 mM HEPES buffer. Cryo-transmission electron microscopy (Cryo-TEM) 
was kindly performed by J. M. Mantell (School of Biochemistry and Wolfson Bioimaging 
Facility, University of Bristol, Bristol BS8 1TD,). A sample (5 μL) was pipetted onto a 
previously glow discharged, lacy carbon-coated copper grid (Electron Microscopy Services). 
The excess was blotted and the sample plunge frozen into liquid ethane using a Vitrobot 
plunge freezer (FEI Company). The sample was transferred to a Gatan 626 Cryotransfer 
holder and the lipoplexes were examined at a temperature of approximately −170 °C in a FEI 
Tecnai 20 Transmission Electron Microscope operating at 200kV.  
 
3. Results and discussion 
 
    
(1a)      (1b)  
 
   
  (1c)      (1d) 
Figure 1. (a) N4-Linoleoyl-N9-oleoyl-1,12-diamino-4,9-diazadodecane (LinOS), (b) N4,N9-
dioleoyl-1,12-diamino-4,9-diazadodecane (DOS), (c) cholesterol, (d) 1,2-dioleoyl-sn-glycero-
3-phosphoethanolamine (DOPE). 
 
The lipid dispersions in Opti-MEM media were prepared by addition of ethanolic 
solutions of the single lipids (Figure 1) or lipid mixtures to Opti-MEM followed by brief 
mixing on a vortex mixer. This simple procedure avoids the use of sonication or extrusion 
techniques which are used to prepare single lamellar vesicles and/or reduce the size of the 
prepared lipid vesicles. This procedure can be considered as an even more direct method than 
the ethanol injection vesicle protocol.232, 233 
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Figure 2 shows the effect of changing the N4-linoleoyl-N9-oleoyl-1,12-diamino-4,9-
diazadodecane/ cholesterol (LinOS/Chol) molar ratio on the delivery of siEGFP-AF or siNC-
AF in the transfected HeLa cells measured by flow cytometry (FACS). The highest siEGFP-
AF delivery was achieved with lipoplexes having a LinOS/Chol molar ratio of 1:2, as these 
lipoplexes resulted in normalized Alexa Fluor 647 (AF647) fluorescence of 250. The 
difference between the value obtained by lipoplexes of LinOS/Chol 1:2 and the closest value 
of 165 of lipoplexes of LinOS/Chol 1:3 was statistically significant (p = 0.0005). Decreasing 
the molar ratio of LinOS/Chol from 3:1 to 1:2, i.e. increasing the amount of cholesterol in the 
mixtures, resulted in an increase in the AF647 fluorescence from 11 to 250 respectively. Co-
formulation with cholesterol in the lipoplexes of LinOS/Chol 1:2 resulted in a significant 
increase of AF647 fluorescence when compared with lipoplexes of LinOS only, from 6 with 
LinOS lipoplexes to 250 with LinOS/Chol 1:2 lipoplexes which means a ~42-fold increase in 
siEGFP-AF delivery. The cholesterol data column (Chol) shows that cholesterol alone did not 
result in any significant siEGFP-AF delivery. Lipoplexes of siNC-AF and LinOS/Chol 1:2 
resulted in comparable delivery of siNC-AF when compared with lipoplexes of siEGFP-AF 
and LinOS/Chol 1:2, Alexa Fluor 647 fluorescence of 268 and 250 respectively (p = 0.28). 
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Figure 2. siEGFP-AF delivery to HeLa cells expressed as the normalized values of the 
geometric mean fluorescence intensity of Alexa Fluor 647 (AF fluorescence) 48 h post-
transfection of HeLa cells with the lipoplexes prepared with LinOS/Chol and either siEGFP-
AF at different LinOS/Chol ratios or siNC-AF at LinOS/Chol 1:2 (per well, the amounts of 
LinOS, siEGFP-AF, and siNC-AF were kept constant at 0.75 µg, 15 pmol, and 15 pmol 
respectively, N/P = 3.0). The LinOS/Chol ratio is the molar ratio. Light grey columns 
represent lipoplexes prepared with siEGFP-AF, the black column represents lipoplexes of 
LinOS/Chol 1:2 with siNC-AF. 
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Figure 3 shows the effect of changing the LinOS/Chol molar ratio from 3:1 to 1:3 on the 
percentage expression of EGFP in the transfected HeLa cells measured by FACS. The best 
lipoplexes were those having LinOS/Chol ratio of 1:2, as they resulted in a reduction of 
EGFP percentage expression to 20%, statistically significant when compared to the reduction 
of EGFP obtained by lipoplexes of LinOS/Chol 1:3 (26%, p = 0.0024) and LinOS/Chol 1:1 
(27%, p = 0.0001) which were the second best in terms of EGFP expression reduction. Co-
formulation with cholesterol in lipoplexes of LinOS/Chol 1:2 resulted in reducing the EGFP 
percentage expression from 32% for lipoplexes of LinOS only to 20% (p = 0.0001). The 
cholesterol data column (Figure 3) shows that siEGFP-AF only formulated with cholesterol 
did not have any significant effect on EGFP expression (100% ± 5). Lipoplexes of siNC-AF 
and LinOS/Chol 1:2 likewise did not result in any reduction in EGFP expression (105% ± 5). 
Transfection of siEGFP-AF with the commercial reagent TransIT-TKO resulted in EGFP 
expression of only 20%. There was no statistically significant difference between the 
percentage reductions of EGFP expression due to transfection with lipoplexes of LinOS/Chol 
1:2 and TransIT-TKO (p > 0.05).  
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Figure 3. EGFP percentage expression calculated 48 h post-transfection of HeLa cells with the 
lipoplexes prepared with LinOS/Chol and either siEGFP-AF at different LinOS/Chol ratios or 
siNC-AF at LinOS/Chol 1:2 (per well, the amounts of LinOS, siEGFP-AF, and siNC-AF were 
kept constant at 0.75 µg, 15 pmol, and 15 pmol respectively, N/P = 3.0). Light grey columns 
represent lipoplexes prepared with siEGFP-AF, the black column represents lipoplexes of 
LinOS/Chol 1:2 with siNC-AF. 
 
LinOS/Chol 1:2 lipoplexes with siEGFP-AF resulted in both highest siRNA delivery and 
most efficient reduction of EGFP (from 100% to 20%). The reduction of EGFP with 
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LinOS/Chol lipoplexes having different LinOS/Chol ratios is affected by the amount of 
siEGFP-AF delivered. However, it can be seen that although siRNA delivery with lipoplexes 
of LinOS/Chol of molar ratio 1:2 and 3:1 was 250 and 11 respectively (~23-fold), the 
reduction of EGFP was to 20% and to 46% (~2-fold). Thus, it is difficult to predict the 
functional biological activity of siRNA based solely on the amount delivered. One 
explanation is that siRNA lipoplexes might be delivered via different cellular internalization 
pathways such as clathrin- or caveolin-mediated endocytosis and/or membrane fusion. A 
recent report showed that the functional delivery of siRNA lipoplexes is not necessarily via 
endocytic pathways, but rather might be due to another cellular internalization mechanism 
such as membrane fusion.171 Although the amounts of siRNA delivered might vary largely, 
the resultant reduction in EGFP may not correspond exactly with that same large variation.  
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Figure 4. siEGFP-AF delivery to HeLa cells expressed as the normalized values of the 
geometric mean fluorescence intensity of AF647 48 h post-transfection with the lipoplexes 
prepared with LinOS/DOPE and siEGFP-AF at different LinOS/DOPE ratios (per well, the 
amounts of LinOS and siEGFP-AF were kept constant at 0.75 µg and 15 pmol respectively, 
N/P = 3.0). Light grey columns represent lipoplexes prepared with siEGFP-AF, the black 
column represents lipoplexes of LinOS/DOPE 1:1 with siNC-AF. 
 
Figure 4 shows the effect of changing the LinOS/1,2-dioleoyl-sn-glycero-3-
phosphoethanolamine (DOPE) molar ratio from 1:3 to 3:1 on the delivery of siEGFP-AF or 
siNC-AF in the transfected HeLa cells. Co-formulation with DOPE in the lipoplexes of 
LinOS/DOPE resulted in a significant increase of normalized AF647 fluorescence when 
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compared with lipoplexes of LinOS only, from 6 with LinOS only to 85 and 78 respectively 
(p = 0.24) for lipoplexes of LinOS/DOPE 1:3 and 1:1 which gave the highest AF647 
fluorescence. Lipoplexes of LinOS/DOPE 1:2 and 2:1 (molar ratios) resulted in AF647 
fluorescence of 48 and 21 respectively (p = 0.0001). The DOPE data column shows that 
siEGFP-AF formulation with DOPE only did not result in any significant siEGFP-AF 
delivery. Lipoplexes of siNC-AF and DOPE/Chol 1:1 resulted in AF647 fluorescence of 51.  
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Figure 5. EGFP percentage expression calculated 48 h post-transfection of HeLa cells with 
the lipoplexes prepared with LinOS/DOPE and siEGFP-AF at different LinOS/DOPE ratios 
(per well, the amounts of LinOS and siEGFP-AF were kept constant at 0.75 µg and 15 pmol 
respectively, N/P = 3.0). Light grey columns represent lipoplexes prepared with siEGFP-AF, 
the black column represents lipoplexes of LinOS/DOPE 1:1 with siNC-AF. 
 
Figure 5 shows the effect of changing the LinOS/DOPE molar ratio from 1:3 to 3:1on the 
percentage expression of EGFP in the transfected HeLa cells. There were very little 
differences between the percentage expressions of EGFP after transfection with the 
LinOS/DOPE lipoplexes at all LinOS/DOPE ratios, with LinOS/DOPE 1:1 lipoplexes 
resulting in EGFP percentage expression of 21%, and no statistically significant difference 
was found between any of the EGFP percentage expressions resulting from the transfection 
with the LinOS/DOPE lipoplexes. Co-formulation with DOPE in the lipoplexes of 
LinOS/DOPE 1:1 resulted in reducing the EGFP percentage expression from 32% for 
lipoplexes of LinOS to 21% (p = 0.0001). The DOPE data column shows that formulating 
siEGFP-AF with DOPE only did not result in any significant effect on EGFP expression 
(105% ± 3). Lipoplexes of siNC-AF and LinOS/DOPE 1:1 did not result in any reduction in 
119 
 
EGFP expression (101% ± 3). There was no statistically significant difference between the 
percentage expressions of EGFP after transfection with lipoplexes of LinOS/DOPE 1:1 and 
TransIT-TKO (p = 0.49). Although the amount of delivered siEGFP-AF increased markedly 
with the addition of DOPE, the differences in the delivered amount did not reflect significant 
differences in the reduction of EGFP corresponding to the differences in the delivered 
amount. For example, lipoplexes of LinOS/DOPE 1:1 and 3:1 delivered siEGFP-AF with 
values of 78 and 12 respectively, and reduced EGFP (from 100%) to 21% and 23% 
word><keyword>ohese data, as discussed above with LinOS/Chol lipoplexes, reflect the 
possibility of the presence of a specific functional mechanism which results in the required 
specific gene silencing.171 
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Figure 6. siEGFP-AF delivery to HeLa cells 48 h post-transfection with the lipoplexes 
prepared with LinOS/Chol 1:2 or DOS/Chol 1:2 at N/P = 3.0 or N/P = 11.9 (per well, the 
amounts of LinOS and DOS were kept constant at 0.75 µg). Lipoplexes names ending in 15 
and 3.75 represent lipoplexes prepared with 15 pmol and 3.75 pmol respectively of siEGFP-
AF or siNC-AF. Light grey columns represent lipoplexes prepared with siEGFP-AF, black 
columns represent lipoplexes prepared with siNC-AF. 
 
Figure 6 shows the effect of changing the N/P charge ratio from 3.0 to 11.9 by means of 
reducing the amount of siEGFP-AF (or siNC-AF) from 15 pmol/well of 24-well plates to 
3.75 pmol/well, on the normalized AF647 fluorescence in the transfected cells. A comparison 
between the LinOS/Chol 1:2 lipoplexes and N4,N9-dioleoyl-1,12-diamino-4,9-
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diazadodecane/cholesterol (DOS/Chol) 1:2 lipoplexes at N/P = 3.0 and 11.9 is also shown. 
The AF647 fluorescence is significantly higher in the case of lipoplexes prepared with 15 
pmol siEGFP-AF or siNC-AF when compared to the lipoplexes prepared with 3.75 pmol 
siEGFP-AF or siNC-AF at N/P = 11.9. siEGFP-AF lipoplexes LinOS/Chol 15 and 
LinOS/Chol 3.75 resulted in AF647 fluorescence of 250 and 41 respectively and p = 0.0001, 
siNC-AF lipoplexes LinOS/Chol 15 and LinOS/Chol 3.75 resulted in AF647 fluorescence of 
151 and 23 respectively and p = 0.0001. siEGFP-AF lipoplexes of DOS/Chol 15 and 
DOS/Chol 3.75 resulted in AF647 fluorescence of 144 and 48 respectively and p = 0.0001, 
siNC-AF lipoplexes of DOS/Chol 15 and DOS/Chol 3.75 resulted in AF647 fluorescence of 
106 and 32 respectively and p = 0.0001. Lipoplexes of LinOS/Chol 15 showed the highest 
AF647 fluorescence. The delivery of AF647 results from transfecting HeLa cells with 
lipoplexes co-formulated with cholesterol were significantly higher than those achieved on 
transfection with only DOS or LinOS lipoplexes (DOS 15, DOS 3.75, LinOS 15, and LinOS 
3.75, Figure 6 the four columns on the right) of siEGFP-AF. 
Figure 7 shows the effect of changing the N/P charge ratio from 3.0 to 11.9 by reducing the 
amount of siEGFP-AF (or siNC-AF) from 15 pmol/well to 3.75 pmol/well (24-well plates), on 
the percentage of EGFP expression in the transfected HeLa cells (48 h post-transfection) 
investigated together with a comparison between LinOS/Chol 1:2 lipoplexes and DOS/Chol 1:2 
lipoplexes at N/P = 3.0 and 11.9. The amounts of LinOS and DOS were kept constant at 0.75 
µg. Transfecting HeLa cells with lipoplexes of siEGFP-AF and LinOS/Chol 1:2 did not show a 
significant decrease in the efficiency of transfection on decreasing the amount of siEGFP-AF 
from 15 pmol/well to 3.75 pmol/well. Thus, lipoplexes of LinOS/Chol 15 and LinOS/Chol 3.75 
resulted in EGFP percentage expression of 20% and 21% respectively with p = 0.42. Lipoplexes 
of DOS/Chol 1:2 showed a significant change of EGFP percentage expression from 21% for 
DOS/Chol 15 to 28% for DOS/Chol 3.75 lipoplexes (with siEGFP-AF 15 pmol and 3.75 pmol 
respectively). There were no statistically significant differences between the EGFP percentage 
expression on transfection with lipoplexes of siEGFP-AF with either DOS/Chol 15 or 
LinOS/Chol 15 (21% and 20% respectively, p = 0.42). However, transfection with lipoplexes of 
LinOS/Chol 3.75 resulted in a lower EGFP percentage expression (21%) compared to 
lipoplexes of DOS/Chol 3.75 (28%), p = 0.0001. Transfection with lipoplexes of siNC-AF (15 
pmol or 3.75 pmol) with DOS/Chol 1:2 or LinOS/Chol 1:2 did not result in any significant 
reduction of the EGFP expression. However, delivery of siEGFP-AF in co-formulations of DOS 
or LinOS with cholesterol led to statistically significant enhancement of gene silencing, i.e. a 
large reduction in EGFP percentage expression in the transfected HeLa cells:  DOS/Chol 15, 
DOS/Chol 3.75, LinOS/Chol 15, and LinOS/Chol 3.75 were 21%, 28%, 20%, and 21% (each ± 
2%) respectively, compared to DOS 15, DOS 3.75, LinOS 15, and LinOS 3.75 lipoplexes which 
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resulted in EGFP percentage expressions of 37%, 38%, 32%, and 35% (each ±5%) respectively, 
showing significant improvements in the gene silencing on mixing with cholesterol (p = 0.0001 
for all four respectively). With EGFP having a half-life of ~24 h,234 gene silencing to 20% (48 h 
post-transfection) is essentially quantitative as the fluorescence which equates to 20% EGFP 
expression is the residual EGFP after two half-lives. 
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Figure 7. EGFP percentage expression 48 h post-transfection with lipoplexes prepared with 
LinOS/Chol 1:2 or DOS/Chol 1:2 at N/P = 3.0 or N/P = 11.9 (per well, the amounts of LinOS 
and DOS were kept constant at 0.75 µg). Lipoplex names followed by 15 and 3.75 represent 
lipoplexes prepared with 15 pmol and 3.75 pmol respectively of siEGFP-AF or siNC-AF. 
Light grey columns represent lipoplexes prepared with siEGFP-AF. Black columns represent 
lipoplexes prepared with siNC-AF. 
 
Figure 6 shows that the amount of siEGFP-AF delivered with either DOS/Chol or 
LinOS/Chol lipoplexes prepared with 15 pmol siEGFP-AF was higher by ~3-fold and 5-fold 
respectively when compared to lipoplexes prepared with 3.75 pmol siEGFP-AF. However, the 
reduction in EGFP expression (Figure 7) of the DOS/Chol or LinOS/Chol lipoplexes prepared 
with either 15 pmol or 3.75 pmol only varied slightly.  
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Table 1. Effect of formulation on the particle size, polydispersity index (PDI), and ζ-potential 
of lipoplexes of LinOS, DOS, DOS/Chol, LinOS/Chol, and LinOS/DOPE mixtures. All 
lipoplexes were prepared with either 15 pmol siNC (N/P = 3.0) or 3.75 pmol siNC (N/P = 
11.9) except for LinOS/DOPE which was prepared with 15 pmol siNC only (N/P = 3.0). The 
cationic lipid/helper lipid ratios which resulted in the best reduction in EGFP expression post-
transfection with siEGFP-AF lipoplexes were selected (Figures 3, 5, and 7) (n = 2, triplicates 
of duplicates). 
 
Lipoplex formulation 
Particle size (nm) 
Mean ± SD 
PDI 
Mean ± SD 
ζ-Potential (+mV) 
Mean ± SD 
DOS/Chol 1:2 15 pmol siNC 106 ± 19 0.35 ± 0.04 58 ± 4 
DOS/Chol 1:2 3.75 pmol siNC 127 ± 8 0.37 ± 0.02 60 ± 5 
LinOS/Chol 1:2 15 pmol siNC 113 ± 13 0.34 ± 0.05 60 ± 4 
LinOS/Chol 1:2 3.75 pmol siNC 118 ± 6 0.35 ± 0.06 56 ± 1 
DOS 15 pmol siNC 356 ± 37 0.48 ± 0.06 56 ± 2 
DOS 3.75 pmol siNC 192 ± 10 0.32 ± 0.05 52 ± 4 
LinOS 15 pmol siNC 294 ± 25 0.41 ± 0.06 53 ± 3 
LinOS 3.75 pmol siNC 194 ± 9 0.33 ± 0.04 60 ± 3 
LinOS/DOPE 1:1 15 pmol siNC 685 ± 83 0.66 ± 0.08 64 ± 4 
 
Self-assembled lipoplexes of siRNA and cholesterol co-formulations with DOS or LinOS 
resulted in particle size in the range of 106-127 nm. There were a slight increase in particle 
size in lipoplexes of DOS/Chol 1:2 from 106 nm to 127 nm upon decreasing the amount of 
siRNA from 15 pmol to 3.75 pmol (increasing N/P charge ratio from 3.0 to 11.9), p = 0.0317. 
There was no statistically significant difference between the particle sizes of lipoplexes of 
LinOS/Chol 1:2 with either 15 or 3.75 pmol (p = 0.41). The type of cationic lipid used (DOS 
or LinOS) in the cholesterol mixtures did not have a significant effect on the resulting particle 
size at the same N/P charge ratio (same amount of siRNA), where DOS/Chol and 
LinOS/Chol lipoplexes at N/P = 3.0 (15 pmol siRNA) resulted in particle size of 106 and 113 
respectively (p = 0.47), and DOS/Chol and LinOS/Chol lipoplexes at N/P = 11.9 (3.75 pmol 
siRNA) resulted in particle size of 127 and 118 respectively (p = 0.05). Lipoplexes prepared 
with siRNA and either DOS or LinOS, without any helper lipid, have a particle size in the 
range of 192-356 nm. There was a statistically significant difference between the DOS and 
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the LinOS lipoplex particle sizes (356 and 294 respectively, p = 0.0068) at N/P = 3.0 (15 
pmol siRNA). At N/P = 11.9, the type of cationic lipid did not affect the particle size, with 
lipoplexes of DOS and LinOS having particle sizes of 192 and 194 respectively (p = 0.72). 
Increasing the N/P charge ratio to 11.9 (lowering the siRNA amount from 15 to 3.75 pmol) 
reduced the lipoplexes particle size from 356 to 192 nm (DOS, p = 0.0001) and 294 to 194 
nm (LinOS, p = 0.0001). Co-formulation with cholesterol resulted in significant reduction of 
the prepared lipoplexes size, when comparing the lipoplexes of each cationic lipid with or 
without cholesterol. The particle sizes of DOS/Chol 15, DOS/Chol 3.75, LinOS/Chol 15 , 
LinOS/Chol 3.75 (106, 127, 113, and 118 nm respectively) are significantly reduced 
compared to DOS 15, DOS 3.75, LinOS 15, and LinOS 3.75 (356 nm; p = 0.0001, 192 nm; p 
= 0.0001, 294 nm; p = 0.0001, and 194 nm; p = 0.0001 respectively). The lipoplexes of 
LinOS/DOPE 1:1 and 15 pmol siRNA (N/P =3.0) had the relatively larger particle size of 685 
nm compared to the other lipoplex formulations. 
The ζ-potentials of the prepared lipoplexes were all positive and in the range 53-64 mV. 
There was no significant effect of the co-formulation with cholesterol on the ζ-potentials of 
their prepared lipoplexes compared to the lipoplexes of their cationic lipids without 
cholesterol. The presence of DOPE caused no or only a very slight increase in the lipoplex ζ-
potential (+64 mV) when compared to the other lipoplexes prepared with the same amount of 
siRNA (15 pmol) at the same N/P = 3.0. 
Lipoplex size is an important factor in transfection efficiency though it is not the only 
determinant factor.213 Cationic cholesterol derivatized liposomes complexed with siRNA 
have a size range of 150-500 nm,172 where selected siRNA lipoplexes were used either to 
deliver fluorescently tagged scrambled siRNA to different cell lines including HeLa cells, or 
to deliver siRNA silencing GFP in a 293T cell line that stably expresses GFP. Lipoplex size 
affects the main route of cellular entry where smaller lipoplexes (diameter < 300 nm) are 
likely to enter by clathrin-mediated endocytosis, while larger particles (diameter > 500 nm) 
enter cells by caveoli-mediated endocytosis.214, 215 Also, the entry route that results in 
functional siRNA mediated gene knock-down might be by fusion with the plasma membrane 
rather than the endocytosis pathway.171 In a report earlier this year, functional delivery of 
lipoplexes of oligonucleotides in two cell lines, including a HeLa S3 cell line, was found to 
be by membrane fusion.235 The authors concluded that lipoplexes internalized in cells by 
direct membrane fusion improve the functional delivery of oligonucleotide cargoes because 
they might avoid the endosomal escape step which is the rate-limiting step for many pDNA 
and siRNA delivery vectors. However, the lipoplex size used in that study was 869 nm.235 
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Figure 8. (a) Particle size distribution (DLS) for LinOS/Chol 1:2 lipoplexes prepared with 
3.75 pmol siNC (N/P = 11.9), the hydrodynamic diameter is 117 nm (polydispersity index, 
PDI = 0.31). (b) Particle size distribution (DLS) for LinOS (only) lipoplexes prepared with 
3.75 pmol siNC (N/P = 11.9), the hydrodynamic diameter is 187 nm (PDI = 0.38) for the 
shown lipoplexes. 
 
Shown in Figure 8 are monomodal populations of LinOS/Chol 1:2 and LinOS (only) 
lipoplexes. The polydispersity indices (PDI) of the lipoplexes (Table 1) prepared with LinOS 
or DOS cholesterol mixtures were 0.35-0.37. There was no effect of changing the siRNA 
amount in the LinOS/Chol or DOS/Chol lipoplexes on the PDI. The PDI of lipoplexes 
prepared with the cationic lipids only varied from 0.32–0.48. Decreasing the amount of 
siRNA (thus increasing N/P from 3.0 to 11.9) in LinOS or DOS lipoplexes resulted in a 
decrease in the PDI from 0.48 to 0.32 and 0.41 to 0.33 respectively (p = 0.0217 and 0.0005). 
The lipoplexes of LinOS/DOPE 1:1 resulted in a higher PDI of 0.66. 
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Figure 9. Confocal photomicrographs. EGFP fluorescence (green), cell membrane stained with 
WGA-Alexa Fluor 555 (blue), and Alexa Fluor 647 (red) shows tagged siEGFP-AF delivery. 
(a) Control non-transfected HeLa cells, (b) HeLa cells 48 h post-transfection with lipoplexes of 
LinOS/Chol 1:2 and siEGFP-AF (3.75 pmol), (c) as (d) with the red channel only, (d) and (e) 
magnified HeLa cells 48 h post-transfection, as in (b) and (c) respectively. 
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Confocal photomicrographs show control non-transfected HeLa cells, Figure 9a the EGFP 
(green colour) contained within the cell membrane (blue colour). Post-transfection (48 h) with 
siEGFP-AF, the EGFP expression was reduced (Figure 9b 63x objective, scan zoom 1.0) as the 
green colour largely faded away and the red colour represents the delivered siEGFP-AF. Figure 
9c is as Figure 9b with the red channel only turned on for better visualization of the delivered 
siEGFP-AF. Figure 9d is a zoomed photomicrograph (63x objective, 1.7 scan zoom), and Figure 
9e is as Figure 9d with the red channel only turned on. Figure 9b and Figure 9d show the 
reduction of EGFP expression compared to control cells, with the red colour of delivered 
siEGFP-AF. The photomicrographs in Figure 9 prove that siEGFP-AF was delivered to the 
EGFP-stably transfected HeLa cells, and also that EGFP gene expression was silenced.  
Z-Stacks are a series of successive optical sections acquired at different positions across 
the Z-axis defining the thickness of the sample perpendicular to the sample’s horizontal XY 
plane and therefore they are useful for visualizing three-dimensional structures. To 
characterize the intracellular delivery of siEGFP-AF further, Z-stack photomicrographs were 
recorded through a monolayer of transfected HeLa cells (Figure 10). In order to record such a 
stack, the experiment was set up such that the first optical section was recorded slightly lower 
than the surface of the cells attached to the cover slip, then the sections were recorded while 
slicing through to the opposite surface. This arrangement allows to identify whether the red 
colour (representing siRNA delivery) is present inside the cell, where there will be no blue 
colour (representing cell membrane) associated with the red colour, or the red colour is 
present on/in the cell membrane, in this case the red colour will be present simultaneously 
with the blue colour of the cell membrane. It can be seen in the series of Z-stack 
photomicrographs starting from the top left (Figure 10), that the red colour appears in the 
centre of the cells, the blue colour is present only in the perimeter of the cells, and there is no 
simultaneous blue colour in the middle of the cells where there is red. Thus, it is concluded 
that the majority of the delivered siRNA is present inside the HeLa cells. Minko and co-
workers have reported the use of Z-stack photomicrographs to characterize the orientation of 
the delivered siRNA, where a siRNA tagged with NuLight DY-547 fluorophore was 
delivered to A2780 human ovarian cancer cells by surface neutral while internally cationic 
polyamidoamine dendrimers.225  
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Figure 10. Z-Stack confocal photomicrographs. EGFP fluorescence (green), cell membrane 
stained with WGA-Alexa Fluor 555 (blue), and Alexa Fluor 647 (red) represents tagged 
siRNA delivery. A Z-stack series of photomicrographs representing 20 Z-sections in HeLa 
cells transfected with lipoplexes of LinOS/Chol 1:2 and siEGFP-AF (3.75 pmol). 
 
 
 
Figure 11. Cryo-TEM of LinOS/Chol (1:2) siRNA lipoplexes. 
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Lipoplexes prepared with LinOS/Chol 1:2 and siRNA form spherical multilamellar 
arrangements (Figure 11) with a size of ~100 nm which is in good agreement with the particle 
size measured by DLS (Table 1) of the same lipoplexes. The constant distance between lamellar 
repeats is ~6 nm, with the electron-dense layers fitting a monolayer of siRNA. Recent cryo-
TEM photomicrographs of lipidic aminoglycoside derivatives/siRNA self-assembled lamellar 
complexes show concentric onion-like structures with the distance between the lamellar repeats 
being 7 nm.236 Such siRNA lipoplexes promote efficient siRNA delivery and RNA interference. 
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Figure 12. Viability of transfected HeLa cells measured using the alamarBlue assay 48 h 
post-transfection with lipoplexes prepared with siNC and either LinOS/Chol or LinOS/DOPE 
at different LinOS/neutral lipid ratios. All were assayed at 1.5 pmol siNC/well (15 nM), 
6,500 cells/well, except LinOS/Chol 1:2 3.75 which had only 0.375 pmol siNC/well (3.75 
nM). 
 
Transfection of HeLa cells with lipoplexes of LinOS/Chol and LinOS/DOPE at different 
molar ratios and 1.5 pmol siRNA in 96-well plates (Figure 12), N/P = 3.0, resulted in cell 
viabilities of 81-95% of the control cells. The viability resulting from transfection using 
LinOS (only) lipoplexes was 96% at N/P = 3.0. Transfection with LinOS/Chol 1:2 3.75 
resulted in viability of 94%, higher than that of LinOS/Chol 1:2 (89%, p = 0.0205). These 
values are significantly higher than the cell viability on transfection with TransIT-TKO (82%, 
p = 0.0001 for both). There were small differences in viabilities between LinOS/Chol 
lipoplexes (81-95%) and LinOS/DOPE lipoplexes (84-87%). Although the amount of 
lipoplexes chosen in this assay was only one tenth that used in the 24-well plate assays (for 
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delivery and gene silencing experiments), the siRNA concentration was kept constant in the 
culture medium in all experiments, i.e. either 15 nM or 3.75 nM.  
In this Chapter, the efficiency of both siRNA delivery and the gene silencing by siRNA 
lipoplexes prepared from mixtures of LinOS or DOS with either cholesterol or DOPE neutral 
helper lipids was evaluated. LinOS and DOS are derivatives of the naturally occurring 
polyamine, spermine, that has been conjugated to the naturally occurring C18 unsaturated 
fatty acids:  oleic acid (18:1) and/or linoleic acid (18:2). The design of LinOS and DOS is 
based on the hypothesis that using such natural moieties as the building blocks in the 
synthetic lipid will result in more benign (less toxic) cationic lipids and that better 
interactions (mixing) with bilayers of both the cell membrane and the endosomal membranes 
of target cells will increase cellular delivery efficiency and endosomal escape. 
Cholesterol and DOPE are widely used as helper lipids in DNA liposome and lipoplex 
preparations,237 mainly due to their ability to promote non-lamellar lipid arrangements and 
thus facilitate membrane fusion upon cellular internalization. Herein is reported an important 
increase in both siRNA delivery and the resultant gene silencing efficiency with an increase in 
the cholesterol content of the lipoplexes (Figure 2 and Figure 3). Cholesterol enhances 
transfection with DNA lipoplexes by increasing DNase resistance and cholesterol 
nanodomains are known to form in lipoplexes having ≥ 52% of molar cholesterol content. 238, 
239 The presence of cholesterol domains in the lipoplexes prepared with ≥ 60% molar 
cholesterol content was suggested to result in an increasing resistance to lipoplex aggregation 
in the presence of 50% serum, and decreased albumin binding to the lipoplexes led to better 
interaction (fusion) with the cell membrane.239 Cholesterol and DOPE facilitate the 
conversion of the lipoplex lamellar phase (L) into the non-lamellar inverted hexagonal (HII) 
and cubic phases which play an important role in membrane fusion.237, 240, 241 In early and 
elegant siRNA SNALP delivery studies, MacLachlan and co-workers reported on the 
importance of the saturation of C=C along the lipids chains.158 They found that, in an series of 
symmetrical 1,2-dialkyloxy-N,N-dimethyl-3-aminopropane analogues, as C=C saturation 
increased, lamellar phase (L) to non-lamellar inverted hexagonal (HII) phase transition 
temperatures increased, an indicator of decreasing fusogenicity, and that less fusogenic 
particles are more readily internalized by cells, but with lower gene silencing efficiency. They 
also argued that as electrostatic binding is a precursor to uptake, the pKa values of the cationic 
lipid will be important. Their results support an siRNA transfection model in which 
endosomal release, mediated by fusion with the endosomal membrane, results in cytoplasmic 
translocation of the siRNA payload.158 Whilst fully agreeing with their argument, in addition 
to the two (different) unsaturated acyl chains (18:2 and 18:1) of LinOS, cholesterol, a known 
membrane fusogen242 was also incorporated in the efficient lipoplex formulations. 
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Lipoplexes containing LinOS/DOPE showed enhanced gene silencing (Figure 5) 
compared to LinOS lipoplex formulations lacking any helper lipid. However, LinOS/DOPE 
lipoplexes showed less siEGFP-AF delivery (Figure 4) when compared to LinOS/Chol 
lipoplexes (Figure 2). Lipoplexes containing cholesterol have also been found to be more 
effective in vivo than those containing DOPE.243-247 The particle size of LinOS/Chol 
lipoplexes that resulted in the best balance between gene silencing and siEGFP-AF delivery 
were measured (Table 1). These LinOS/Chol lipoplexes were much smaller than the 
LinOS/DOPE lipoplexes (Table 1). DOPE containing lipoplexes reportedly showed 
immediate loss of integrity in the presence of serum which might explain the higher 
efficiency of cholesterol containing lipoplexes in vivo.246 Thus, lipoplexes of LinOS/Chol at 
1:2 ratio resulted in the best siEGFP-AF delivery and gene silencing. Further investigation 
with respect to the effect of decreasing the amount of complexed siRNA from 15 pmol to 
3.75 pmol at LinOS/Chol 1:2 ratio showed the amount of siEGFP-AF delivered was down to 
20-33%. The symmetrical spermine conjugate DOS, which was demonstrated to form siRNA 
lipoplexes that efficiently silence EGFP (Chapter 2), was chosen to prepare lipoplexes with 
the DOS/Chol ratio of 1:2, experimentally determined to be the best for LinOS/Chol, to 
investigate the effect of changing the cationic lipid on the siEGFP-AF delivery and EGFP 
knock-down. Figure 6 shows that both LinOS and DOS mixtures with cholesterol markedly 
increased siEGFP-AF delivery, with LinOS/Chol lipoplexes resulting in more enhanced 
siEGFP-AF delivery. The reduction of EGFP expression was essentially the same at both 
siEGFP-AF concentrations used and for both formulae. Although lipoplexes prepared with 
3.75 pmol siEGFP-AF have a lower amount of siRNA, they therefore have a higher N/P 
charge ratio, N/P = 11.9 compared with N/P = 3.0 for lipoplexes prepared with 15 pmol 
siEGFP-AF which may play a role in the interactions with cell membranes hence promoting 
gene silencing. The differences seen between lipoplexes of LinOS/Chol and DOS/Chol can 
be attributed to the difference between the fatty acids in LinOS and DOS. LinOS contains one 
oleoyl chain (18:1, one Z-double bond) and one linoleoyl (18:2, two Z-double bonds) while 
DOS contains two oleoyl chains. The differences in the hydrophobic volume of these cationic 
lipids will affect the transfection efficiency of lipoplexes,147, 226, 227 and LinOS lipoplexes were 
better than DOS lipoplexes in EGFP silencing in HeLa cells. Lipoplexes prepared with 
scrambled siNC-AF had good delivery efficiency, but they did not result in any significant 
gene silencing, therefore the reduction in EGFP expression on transfection with siEGFP-AF 
lipoplexes is due to sequence specific gene silencing, and not due to any off target or lipid 
related effects e.g. toxicity. The cell viability (Figure 12) shows that the lipoplexes were well 
tolerated by HeLa cells with viabilities ≥ 81%, and the best viability (94%) for lipoplexes 
containing cholesterol was achieved with LinOS/Chol 1:2 prepared with 0.375 pmol siRNA.  
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4. Conclusions 
 
The new cationic lipid LinOS was characterized and evaluated for its ability to deliver 
siRNA to HeLa cells, and for its effect on gene silencing efficiency. LinOS was used to 
prepare self-assembled lipoplexes with siRNA, either alone, or in a co-formula with 
cholesterol or DOPE at various ratios of the cationic lipid/helper lipid. The lipoplexes co-
formulated with cholesterol resulted in particle size that is smaller than the particle size of 
lipoplexes co-formulated with DOPE. The lipoplexes co-formulated with either cholesterol or 
DOPE were superior to those without cholesterol in terms of efficiency of siRNA delivery, 
with the lipoplexes having LinOS/Chol ratio 1:2 resulting in the highest delivery. These 
lipoplexes resulted in better gene silencing than the lipoplexes of LinOS, and comparable to 
the commercial transfecting agent TransIT-TKO in the presence of 10% FCS in the HeLa cell 
culture media. The self-assembled lipoplexes resulted in cell viability that is larger than 80% 
in HeLa cells. LinOS/Chol 1:2, without any liposomal pre-formulation steps, achieves siRNA 
delivery to ~100% of cells, best gene silencing, and with up to 94% cell viability. These 
results show that LinOS/Chol forms self-assembled lipoplexes with siRNA, and LinOS/Chol 
(1:2) is a promising non-viral non-toxic non-viral vector for siRNA. 
The importance of the different mechanisms of lipoplex cell entry is now a key topic for 
investigation. Earlier this year, Juliano and co-workers reported functional delivery of 
oligonucleotide lipoplexes was by membrane fusion.235 This route of entry brought improved 
functional delivery of oligonucleotide cargoes. However, Langer and co-workers have 
reported that there are at least two routes of entry. The well-established endocytic pathway 
and membrane fusion.171 Therefore, there is a need to optimise the delivery of siRNA cargoes 
and to uncover aspects of the mechanisms of cellular entry. 
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Chapter Six  On consideration of mechanisms 
 
1. Introduction 
 
In Chapters 2-5, a series of fatty acid spermine conjugates and fatty acid guanidinylated 
spermine conjugates were synthesized, characterized, and evaluated in vitro as non-viral 
vectors for siRNA delivery. In order to enhance the efficiency of the lipoplexes and to 
investigate the underlying mechanisms affecting the efficiency of siRNA delivery and EGFP 
knock-down, a series of ‘proof of concept’ experiments was designed and carried-out. The 
contribution of endosomal escape to the delivery and gene silencing efficiency, the packing 
of the lipoplexes, the effect of using more than one helper lipid in the lipoplex formulation, 
and changing the type of the cationic head-group from amine to guanidine in the lipoplexes 
containing cholesterol are key variables. Among different pathways for intracellular delivery 
of lipoplexes, endocytosis and the subsequent escape of the lipoplexes were studied 
extensively.215, 237, 248-251 In the field of lipid mediated DNA delivery, endocytosis was found 
to be a determinant factor in the efficiency of the transgene expression.250 Lipoplexes may 
enter cells via another independent pathway (in addition to endocytosis), which may be by 
lipid mixing which itself depends on the lipoplex structure.252 Related to siRNA delivery and 
endosomal escape, the use of a neutral helper lipid that enhances the fusogenicity of the 
lipoplexes is one possible approach to improve the outcome of transfection. The effect of 
using a cholesterol and DOPE mixture in the same lipoplex preparation on the transfection 
process is also worth investigating. Another strategy is to facilitate endosomal escape by 
using a molecule that responds to the decrease in pH in the endosome, e.g. cholesteryl 
hemisuccinate (CHS) which shows pH-dependent release characteristics in liposomes.253  
The properties of the cationic head-group affect its behaviour with respect to nucleic acid 
binding, its interaction with different anionic groups extracellularly and on the cell 
membrane, lipid polymorphism and its endosomal escape characteristics.125, 153, 254 In order to 
differentiate between endocytic and non-endocytic (e.g. membrane fusion) intracellular 
delivery pathways, decreasing the temperature to 4-6 °C is known to block the various 
endocytic pathways (clathrin and caveolin dependent).171 More importantly, as it has been 
shown in the previous Chapters, as delivery is not necessarily related to the subsequent gene 
silencing quantitatively, and while various intracellular delivery pathways might be involved 
in the internalization process, not all of them are essentially involved in the resulting gene 
silencing.171 Thus, preventing endocytosis by decreasing the transfection temperature should 
allow us to differentiate between the contribution of endocytosed lipoplexes and lipoplexes 
internalized by other mechanisms such as membrane fusion.  
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2. Materials and methods 
 
Dextran sulfate (DS) (molecular weight > 500,000 Da) and cholesteryl hemisuccinate 
(CHS) were purchased from Sigma-Aldrich. All solvents and other chemicals were purchased 
as described in Chapter 2 (Section 2.1). 
 
2.1. Experimental protocols 
The lipoplexes containing individual cationic lipids were prepared as described above in 
Chapter 2 (Section 2.4). The lipoplexes containing individual cationic lipids/Chol mixtures 
were prepared as described in Chapter 5 (Section 2.3), with the cationic lipid/Chol 1:2 molar 
ratio and the cationic lipid amount 0.75 g/well kept constant. 
 
2.2. Preparation of lipoplexes containing Chol/DOPE 
Ethanolic solutions of the individual cationic lipids, cholesterol, and DOPE were mixed to 
result in the required molar ratio of cationic lipid/Chol/DOPE. Two liquid preparations (A 
and B) were then prepared. Liquid A was prepared by adding the ethanolic solution 
containing the lipid mixture to Opti-MEM serum free medium in an Eppendorf microtube, 
and then mixed on a vortex mixer for 2-3 s. Liquid B was prepared by adding the required 
volume of siRNA master solution to serum free Opti-MEM medium in an Eppendorf 
microtube, and then mixing briefly. The lipoplexes were prepared by adding the required 
volumes of liquid B to liquid A containing the required amounts of lipids in an Eppendorf 
microtube, followed by mixing on a vortex mixer for 2-3 s, and then left for 20 min at 20 °C 
for the lipoplexes to form. 
 
2.3. Preparation of lipoplexes containing CHS 
Ethanolic solutions of the individual cationic lipids, cholesterol, and CHS were mixed to 
yield the required molar ratio of either cationic lipid/CHS or cationic lipids/CHS/Chol. Two 
liquid preparations (A and B) were then prepared. Liquid A was prepared by adding the 
ethanolic solution containing the lipid mixture to Opti-MEM serum free medium in an 
Eppendorf microtube, and then was mixed on a vortex mixer for 2-3 s. Liquid B was prepared 
by adding the required volume of siRNA master solution to serum free Opti-MEM medium in 
an Eppendorf microtube, and then mixing briefly. The lipoplexes were prepared by adding 
the required volumes of liquid B to liquid A containing the required amounts of lipids in an 
Eppendorf microtube, followed by mixing on a vortex mixer for 2-3 s, and then left for 20 
min at 20 °C for the lipoplexes to form. 
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2.4. Preparation of lipoplexes containing DS 
Ethanolic solutions of the individual cationic lipids and cholesterol were mixed to result in 
the required molar ratio of cationic lipid/Chol. Two liquid preparations (A and B) were then 
prepared. Liquid A was prepared by adding the ethanolic solution containing the lipid 
mixture to Opti-MEM serum free medium in an Eppendorf microtube, and then mixed on a 
vortex mixer for 2-3 s. Liquid B was prepared by adding the required volumes of master 
solutions of siRNA and DS to serum free Opti-MEM medium in an Eppendorf microtube, 
and mixing briefly. The lipoplexes were prepared by adding the required volumes of liquid B 
to liquid A containing the required amounts of the lipids in an Eppendorf microtube, followed 
by mixing on a vortex mixer for 2-3 s, and leaving for 20 min at 20 °C for the lipoplexes to 
form. 
 
2.5. Cell culture and transfection experiments in the presence of 10% or 50% serum 
The cell culture and transfection experiments in 10% serum were carried out as described 
in Chapter 2 (Section 2.4). The cell culture and transfection experiments in 50% serum were 
carried out as described in Chapter 2 (Section 2.4), except that on day of transfection, the 
medium in each well was aspirated and replaced with DMEM containing 50% FCS. The 
lipoplexes were then added to each well and the plates were incubated for 4 h in 5% CO2 at 
37 °C. The cell culture medium from each well was then removed, and replaced with DMEM 
containing 10% FCS, and the plates were incubated for a further 44 h in 5% CO2 at 37 °C.  
 
2.6. Cell culture and transfection experiments at different temperatures 
Cells were trypsinized at a confluency of 80-90% and seeded at a density of 65,000 
cells/well in 24-well plates and were then incubated for 24 h at 37 °C, 5% CO2. Prior to 
transfection, the plates were incubated for 1 h at 37, 22, or 6 °C. The lipoplex solutions were 
then added to wells containing DMEM (10% FCS) such that the final volume in each well 
was 1 mL, and the plates were incubated at 37, 22, or 6 °C for 4 h to allow for the 
intracellular delivery. The media from each well were then aspirated and the cells were 
washed twice with PBS. DMEM (10% FCS) was then added to each well (1 mL) and all the 
plates were incubated at 37 °C for 44 h prior to FACS analysis. 
 
2.7. FACS analysis 
Preparation of the cells for FACS analysis and measurement of delivery and gene silencing 
were carried out as described in Chapter 2 (Section 2.5). 
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3. Results and discussion 
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Figure 1. siEGFP-AF delivery 48 h post-transfection with lipoplexes prepared using mixtures 
of LinOS with cholesterol and DOPE. Delivery was compared to that of LinOS without any 
helper lipids. The N/P ratio of 3.0 was kept constant by using 0.75 µg LinOS and 15 pmol 
siEGFP-AF constant in all lipoplex formulations while varying the Chol/DOPE mixture 
molar ratio with respect to LinOS, and Chol/DOPE molar ratio was kept constant at 2:1 in all 
experiments. 
 
Figure 1 shows the effect of preparing the lipoplexes with LinOS/Chol/DOPE mixtures. 
The molar ratio of Chol/DOPE was kept constant at 2:1 while the amount of LinOS was 
varied. The LinOS/Chol/DOPE is the molar ratio of the three lipids in the mixture. The 
Chol/DOPE ratio was preliminary chosen based on the previous results which showed that 
LinOS/Chol 1:2 and LinOS/DOPE 1:1 were the best in terms of siEGFP-AF delivery among 
LinOS/Chol and LinOS/DOPE mixtures respectively. All the LinOS/Chol/DOPE lipoplexes 
resulted in increased siEGFP-AF delivery, with LinOS/Chol/DOPE 1:2:1 lipoplexes resulting 
in the best delivery, showing ~20-fold increase compared to LinOS only lipoplexes. 
However, the delivery of siEGFP-AF with LinOS/Chol 1:2 (Chapter 5, Figure 2) resulted in 
an ~40-fold increase in siEGFP-AF delivery compared to LinOS lipoplexes, i.e. better than 
LinOS/Chol/DOPE.  
 
136 
 
0
10
20
30
40
50
EG
FP
 %
 e
xp
re
ss
io
n
Cationic lipid formulation
 
Figure 2. EGFP percentage expression 48 h post-transfection with lipoplexes prepared using 
mixtures of LinOS with cholesterol and DOPE. EGFP percentage expression was compared 
to that of LinOS without any helper lipids. The N/P ratio of 3.0 was kept constant by using 
0.75 µg LinOS and 15 pmol siEGFP-AF constant in all lipoplex formulations while varying 
the Chol/DOPE weight. Chol/DOPE molar ratio was kept constant at 2:1. 
 
Figure 2 shows the effect of preparing the lipoplexes with LinOS/Chol/DOPE mixtures on 
EGFP expression. The molar ratio of Chol/DOPE was kept constant at 2:1 while the amount 
of LinOS was varied. The Chol/DOPE ratio was preliminary chosen based on the previous 
results (Chapter 5) which showed that LinOS/Chol 1:2 and LinOS/DOPE 1:1 were the best in 
terms of EGFP silencing among LinOS/Chol and LinOS/DOPE mixtures respectively. 
Compared to LinOS (37% EGFP expression), all LinOS/Chol/DOPE mixtures resulted in 
enhanced reduction in EGFP expression (reduced to 23-26%), except 2:2:1 lipoplexes which 
resulted in 34% EGFP percentage expression.  
The rationale of using Chol/DOPE mixtures was to evaluate the combining of the roles of 
both helper lipids. The results in Figures 1 and 2 taken together, show that while using 
LinOS/Chol/DOPE mixtures resulted in significant enhancement of siEGFP-AF delivery and 
reduction in EGFP expression, there was no advantage found on using the Chol/DOPE 
mixture over using the LinOS/Chol 1:2 mixture (Chapter 5, Figures 2 and 3).  
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Figure 3. siEGFP-AF and siNC-AF delivery 48 h post-transfection with lipoplexes prepared 
using DOSdiG/Chol 1:2 and LinOSdiG/Chol 1:2 mixtures (0.75 µg/well cationic lipid). Light 
grey bars represent siEGFP-AF delivery, black bars represent siNC-AF delivery. Lipoplex 
formulae suffixed with 15 are prepared with 15 pmol of siRNA (N/P = 2.7), while those 
suffixed with 3.75 are prepared with 3.75 pmol siRNA (N/P = 10.7). 
 
siEGFP-AF delivery (Figure 3) with lipoplexes prepared with DOSdiG/Chol and 
LinOSdiG/Chol 1:2 mixtures. siEGFP-AF amount was 15 or 3.75 pmol, with the N/P = 2.7 
and 10.7 respectively. The cationic lipid/Chol ratio was chosen based on the efficiency of 
LinOS/Chol 1:2 lipoplexes (Chapter 5). The results show that using 15 pmol siEGFP-AF 
resulted in more delivery compared to 3.75 pmol siEGFP-AF. Compared to using DOSdiG 
and LinOSdiG 0.75 µg/15 pmol siEGFP-AF (Chapter 3, Figure 8), there is a clear 
enhancement of delivery of ~20-fold. The black bars show that the delivery of siNC-AF 
lipoplexes is comparable with that of the siEGFP-AF lipoplexes (grey bars).  
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Figure 4. EGFP percentage expression 48 h post-transfection with lipoplexes prepared using 
DOSdiG/Chol and LinOSdiG/Chol mixtures. Light grey bars represent siEGFP-AF delivery, 
while black bars represent siNC-AF delivery. Lipoplex formulae suffixed with 15 are 
prepared with 15 pmol of siRNA (N/P = 2.7), while those suffixed with 3.75 are prepared 
with 3.75 pmol siRNA (N/P = 10.7).  
 
EGFP percentage expression is shown in Figure 4, 48 h post-transfection with lipoplexes 
prepared with DOSdiG/Chol and LinOSdiG/Chol 1:2 mixtures, siEGFP-AF amount was 15 
or 3.75 pmol. The results show that there was a significant reduction of EGFP expression by 
using the cholesterol mixtures (expression reduced to 25-33%) when compared to DOSdiG or 
LinOSdiG 0.75 µg/15 pmol siEGFP-AF (Chapter 3, Figure 9) lipoplexes which resulted in 
EGFP percentage expression of 50-65%. Lowering the amount of siEGFP-AF in the 
lipoplexes from 15 to 3.75 pmol resulted in decreasing the efficiency of EGFP silencing 
(expression only reduced to 39-48%). Using 15 pmol siEGFP-AF, there was no significant 
difference between DOSdiG/Chol and LinOSdiG/Chol lipoplexes (p = 0.06). Transfection 
with siNC-AF lipoplexes showed that there is no significant change in EGFP expression. 
Using the guanidine conjugates DOSdiG/Chol and LinOSdiG/Chol, in comparison to using 
DOS/Chol and LinOS/Chol in Chapter 5, was to investigate if changing the type of the 
cationic head-group (from amine to guanidine), which hypothetically affects the packing of 
the cationic lipid due to changing the size of the polar head-group relative to the hydrophobic 
portion, would have an effect on the delivery and/or gene silencing. The results show that 
although formulation with cholesterol enhanced both delivery and transfection, the DOS/Chol 
and LinOS/Chol 1:2 mixtures (Chapter 5, Figure 6) were significantly better in delivery (at 
15 pmol siEGFP-AF, DOS/Chol, DOSdiG/Chol, LinOS/Chol, and LinOSdiG/Chol resulted 
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in 169, 117, 250, and 81 AF647 fluorescence respectively) and also better in gene silencing 
especially at 3.75 pmol siEGFP-AF (DOS/Chol, DOSdiG/Chol, LinOS/Chol, and 
LinOSdiG/Chol resulted in 29, 39, 23, and 48% EGFP expression respectively). Thus, the 
results show that using the guanidine conjugates did not offer any significant advantage over 
using the polyamine conjugates with respect to delivery and/or gene silencing. 
 
 
Figure 5. Upper:  bidentate hydrogen bonding of guanidinium group (left) vs. electrostatic 
interaction of the ammonium group both interacting with a phosphate group. Lower:  LinOS 
showing electrostatic binding to 5'-3' CUG found in the sense strand of siEGFP. 
 
In contrast to the protonated amine group which interacts electrostatically with the 
phosphate groups, the guanidinium group forms bidentate hydrogen bonds, and the 
electrostatic interaction between the positively charged guanidinium and the negatively 
charged phosphate (Figure 5).201 Although this interaction of guanidinium functional groups 
in the bulk of aqueous buffers can be weak, it is strong upon approaching cell membranes, 
and thus guanidine groups have the advantage of enhancing the binding to negatively charged 
cell membranes.201, 255, 256 Guanidine groups are also known to have a negligible hydration 
shell in contrast to ammonium groups.257, 258 Cationic lipid hydration state, which is in part 
affected by the cationic head hydration and bulkiness, was related to the efficiency of 
transfection in vivo in mouse lungs.132  
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More efficient transfection was achieved with the lipids that had polar head-groups 
resulting in closer polar domain association and less hydration (e.g. due to H-bonds), in 
addition to having acyl cis-unsaturated fatty chains conjugated to the polar head-groups. 
These lipids had the greatest imbalance between the polar head-groups and the hydrophobic 
domain’s cross-sectional area. The hydration of the head group as well as the hydrocarbon 
tail packing also determines the stability of the interaction of the cationic lipid with 
polynucleotides.160 In addition, changing the type of the polar head-group will affect the 
shape parameter of the lipid. The lipid shape parameter (also known as the packing 
parameter) is defined by the equation: 
OHC
HC
AL
VS
.
   
where S is the shape parameter, VHC the volume of hydrophobic hydrocarbon chain, LHC 
the length of the hydrocarbon chain, and AO the surface area of the polar head-group. Lipids 
that have S ≤ 0.5 are cone-shaped and tend to form micelles in aqueous media. A value of 0.5 
≤ S ≤ 1 indicates cylindrical shape and tendency towards formation of lipid bilayers. When S 
≥ 1, this suggests inverted cone shape and a tendency to form inverted structures such as 
reversed micelles or hexagonal phases (Figure 6).125 The formation of inverted hexagonal 
phases (HII) is known to enhance membrane fusion, whether upon intracellular delivery 
and/or during lipoplex endosomal escape.125 Decreased head-group hydration results in 
reducing the space available to water and so reduces the cross-sectional area of the polar 
head-group, and resulting in S > 1. Conjugating unsaturated fatty acids also increases the 
tendency to form inverted structures (and S > 1).  
 
   
Figure 6. Shape (packaging) parameter of cationic lipids. 
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The difference between DOS/DOSdiG and LinOS/LinOSdiG is in the cationic head-
groups. Although the guanidine group was reported previously to increase transfection 
efficiency,204, 206 it is the effect of the guanidine group on the lipid’s hydration and shape as a 
whole that is important in determining its efficiency, and hence the advantages gained by 
guanidinylation were not evident in DOSdiG and LinOSdiG in comparison with their amine 
counterparts. 
 
 
Cholesterol 
 
 
 
 
Cholesteryl hemisuccinate  
(non-ionized) 
 
 
 
 
 
Cholesteryl hemisuccinate  
(ionized) 
 
Figure 7. Cholesteryl hemisuccinate can take either an ionized or non-ionized form. At acidic 
pH = pKa ~4.3, 50% of the CHS population is ionized and 50% is non-ionized. 
 
CHS is used as a fusogenic lipid in some liposomal preparations259 because it promotes 
phase change from lamellar/bilayer to the inverted hexagonal phase HII, in the endosomal 
compartment due to the decreasing pH, typically at pH ≤ 4.3 which is approximately the pKa 
of succinic acid.260 As shown in Figure 7, as the acidity increases in endosomes towards pH 
~4.3, the CHS ionized form which is predominant at physiological pH 7.4 starts to change to 
the non-ionized form. This change affects the shape of the CHS molecule, as the ionized form 
has a polar head and adopts a cylindrical shape promoting bilayer formation.260 The non-
ionized form lacks the polar head, while the hydrophobic steroid part is unchanged and 
adopts an inverted cone shape (Figure 6), thus promoting HII phase formation which enhances 
the fusogenic characteristic of CHS. During formulation of the lipoplexes and during 
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H
O
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O
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H
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intracellular entry, the pH is approximately 7.4 and thus CHS is ionized (deprotonated), 
promoting bilayer formation in the lipoplexes. Once the lipoplexes are in the endosomes and 
the pH starts to decrease (towards 5.5), CHS starts to be protonated changing to the non- 
ionized form which enhances fusogenicity. Therefore, CHS was used to prepare mixtures 
with LinOS and LinOS/Chol, aiming to enhance endosomal escape of the lipoplexes and the 
release of the siEGFP-AF cargo of the lipoplexes into the cytoplasm. 
 
   
(8a) Control 
 
   
(8b) LinOS/CHS/Chol 1:1:1 (7.5 pmol siEGFP-AF) 
 
   
(8c) LinOS/CHS 1:1 (7.5 pmol siEGFP-AF) 
 
Figure 8. FACS data for (a) control non-transfected cells, and transfected cells with (b) 
LinOS/CHS/Chol 1:1:1 and (c) LinOS/CHS 1:1 (molar ratios) (at 7.5 pmol siEGFP-AF) 
showing siEGFP-AF delivery (middle column) and EGFP silencing (right column). LinOS is 
0.75 g/well. 
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The representative FACS data in Figure 8 show the effect of formulating the lipoplexes 
with CHS. Relative to control cells (Figure 8a), there was an increase in both siEGFP-AF 
delivery and efficiency of EGFP silencing with the lipoplexes of LinOS/CHS/Chol 1:1:1 and 
LinOS/CHS 1:1 (molar ratios) (Figure 8b and 8c respectively). There was better delivery with 
LinOS/CHS/Chol relative to LinOS/CHS (Figure 8b and 8c, middle column). The EGFP 
silencing was slightly better with LinOS/ CHS/Chol lipoplexes compared to lipoplexes of 
LinOS/CHS only (Figure 8b and 8c, right column). 
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Figure 9. siEGFP-AF delivery 48 h post-transfection with lipoplexes prepared using LinOS 
and LinOS mixtures with cholesterol and/or CHS. Molar ratios are used, lipoplexes suffixed 
15 and 7.5 are prepared with 15 and 7.5 pmol of siEGFP-AF respectively (LinOS is 0.75 
g/well). 
 
siEGFP-AF delivery is shown in Figure 9 48 h post-transfection with lipoplexes of LinOS, 
LinOS/CHS 1:1 and LinOS/CHS/Chol 1:1:1 (molar ratios). Also shown is the effect of 
decreasing the siEGFP-AF amount from 15 to 7.5 pmol for LinOS/CHS 1:1 lipoplexes. 
Preparing the lipoplexes with LinOS/CHS 1:1 resulted in a significant increase of siEGFP-AF 
delivery (~6-9-fold) compared to LinOS only. Lowering the amount of siEGFP-AF from 15 
to 7.5 pmol in LinOS/CHS 1:1 lipoplexes resulted in a slight significant increase in delivery 
(from 42 to 50, p = 0.03). Lipoplexes of LinOS/CHS/Chol 1:1:1 clearly resulted in the best 
delivery (Figure 8). 
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Figure 10. EGFP percentage expression 48 h post-transfection with lipoplexes prepared 
using LinOS and LinOS mixtures with cholesterol and/or CHS. Lipoplexes suffixed with 15 
and 7.5 are prepared with 15 and 7.5 pmol of siEGFP-AF respectively (LinOS is 0.75 
g/well). 
 
The EGFP percentage expression 48 h post-transfection with LinOS, LinOS/CHS, and 
LinOS/CHS/Chol lipoplexes are shown in Figure 10. Compared to LinOS lipoplexes (0.75 
µg, 15 pmol siRNA), all lipoplexes containing CHS resulted in an enhanced reduction of 
EGFP expression. The lipoplexes of LinOS/CHS/Chol 1:1:1 resulted in the best gene 
silencing, reducing EGFP expression to 18%, compared to 23% with TransIT-TKO (p = 
0.0001, formulated with 15 pmol siEGFP-AF).  
The molar ratio LinOS/CHS/Chol 1:1:1 was chosen to be as close as possible to that of the 
efficient lipoplexes LinOS/Chol 1:2. LinOS/CHS 1:1 lipoplexes were prepared to investigate 
if the effect of LinOS/CHS/Chol 1:1:1 is solely due to CHS or cholesterol is contributing to 
the effects on delivery and gene silencing. It is clear that adding cholesterol to the lipoplexes 
formulation enhanced delivery and gene knock-down. A formula of LinOS/CHS 1:2 was not 
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prepared (in analogy to the efficient LinOS/Chol 1:2) because each CHS molecule at pH 7.4 
carries one negative charge, while LinOS carries 2 positive charges at the same pH, thus the 
LinOS/CHS 1:2 will be neutral with no excess of positive charges to bind electrostatically the 
siRNA or to promote stability of the lipoplexes (due to a positive -potential). 
 
 
Figure 11. DS is a polymer (n = 1-~500) of α-1,6-linked D-glucopyranose modified with 
side-chains (branches) of D-glucopyranose with (α-1,3) linkages to the parent chain and an 
average length of 3 units of glucose. DS has approximately 17% sulfur (~2.3 sulfate groups 
per glucose unit). 
 
DS (Figure 11) is a highly negatively charged polymer, due to its sulfated glucose units. 
DS has approximately 2 sulfate units per glucose unit and therefore two pKa values. The first 
has a negative pKa value and the other has pKa < 2,261 which makes the DS practically and 
essentially 100% ionized at pH 7.4. Thus, because DS is a polymer, it is rationalized that the 
packing of siRNA lipoplexes will be changed in the presence of DS, which will affect 
lipoplex stability, the distribution of the siRNA cargo within the lipoplex, and/or transfection 
efficiency. In two recent reports, adding additional DNA cargo to siRNA lipoplexes resulted 
in enhanced gene silencing both in vivo 262 and in vitro to mouse melanoma cell lines.168 The 
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addition of the DNA (a negatively charged biopolymer) was found to enhance gene silencing 
of lipid/liposomal delivery systems but not polymer based systems, a difference which was 
attributed to the different physicochemical characteristics of lipoplexes and polyplexes, e.g. 
polyplexes do not form lamellar structures. Adding DNA cargo resulted in more homogenous 
distribution of the nucleic acids (DNA and siRNA) within the lipid matrix of the polyplexes, 
and also resulted in better release characteristics (i.e. less stability) when the lipoplexes were 
challenged in vitro with anionic heparan sulfate. As DNA and DS are both highly negatively 
charged polymers, DS was chosen to investigate its effects on lipoplex formulation. 
Interestingly, during the progress of the current work, a recent paper by the same research 
group mentioned above using various anionic polymers to formulate siRNA lipoplexes was 
published.263 The lipoplexes containing the anionic polymers (including dextran sulfate) were 
evaluated in vitro in mouse melanoma cells (B16-Luc) stably expressing luciferase, and in 
vivo in female C57BL/6 mice.263  
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Figure 12. siEGFP-AF delivery (grey bars) 48 h post-transfection with lipoplexes prepared 
using LinOS and LinOS mixtures with cholesterol and/or dextran sulfate (DS). Lipoplexes 
suffixed with 15 and 3.75 are prepared with 15 and 3.75 pmol of siEGFP-AF. Black bars 
represent siNC-AF delivery. 
 
Although the DNA remained the most efficient cargo, the most efficient anionic polymer, 
polyglutamate, showed marked efficiency compared to the lipoplexes without any anionic 
polymer. In the current work, DS showed an enhancement in delivery and slight enhancement 
of gene silencing, which is evidence, as a proof of concept, of the potential for improvement 
of LinOS/Chol lipoplexes. 
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The effect of adding dextran sulfate (DS) to LinOS/Chol lipoplexes on siEGFP-AF 
delivery is shown in Figure 12. The LinOS/Chol ratio was 1:2, and the amount of DS used 
was such that it provides an equal number of negative charges as 15 pmol/well siRNA. Thus, 
the N/P ratio of these lipoplexes will be half that of the lipoplexes without DS. There was an 
enhancement in delivery with the lipoplexes containing DS. Interestingly, delivery with 15 
pmol siEGFP-AF was lower than that with 3.75 pmol. This might be due to the higher 
positive charge (N/P = 2.4) of the LinOS/Chol/DS 3.75 lipoplexes, while the LinOS/Chol/DS 
15 lipoplexes will have a lower N/P ratio (N/P = 1.5) with the presence of the highly 
negatively charged DS, which will in turn affect the latter lipoplex’s ability to bind to the 
negatively charged cell membranes. The black columns show that the delivery of siNC-AF 
lipoplexes was comparable to that of the siEGFP-AF lipoplexes (grey columns). 
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Figure 13. EGFP percentage expression 48 h post-transfection with siEGFP-AF lipoplexes 
(grey bars) and siNC-AF (black bars) prepared using LinOS and LinOS mixtures with 
cholesterol and/or dextran sulfate (DS). Lipoplexes suffixed with 15 and 3.75 are prepared 
with 15 and 3.75 pmol of siRNA. 
 
The effect of adding DS to LinOS/Chol lipoplexes on EGFP expression 48 h post-
transfection is shown in Figure 13. The addition of DS resulted in slight enhancement of gene 
silencing compared to the LinOS/Chol 1:2 lipoplexes. LinOS/Chol/DS and LinOS/Chol 
lipoplexes prepared with 3.75 pmol siEGFP-AF reduced EGFP expression to 18 and 21, p = 
0.03. The EGFP expression was not practically affected with transfection with siNC-AF 
lipoplexes, showing that the EGFP silencing with siEGFP-AF lipoplexes is not related to 
non-specific effects of LinOS/Chol/DS formulation. Figure 14 shows representative FACS 
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data where the addition of DS to LinOS/Chol 1:2 (at 3.75 pmol siEGFP-AF) caused an 
enhanced delivery (Figure 14b, middle column) relative to the lipoplexes without DS (Figure 
14c, middle column).  
 
   
       (14a) Control HeLa cells 
 
   
 (14b) LinOS/Chol 1:2 3.75 pmol siEGFP-AF + DS 
 
   
 (14c) LinOS/Chol 1:2 3.75 pmol siEGFP-AF 
Figure 14. Representative data showing siEGFP-AF (3.75 pmol) delivery and EGFP-AF 
silencing of LinOS/Chol 1:2, (a) control HeLa cells, (b) with and (c) without DS. 
 
There was efficient EGFP silencing compared to control non-transfected cells (Figure 14a, 
right column), and adding DS to the lipoplex formulation caused a marked increase in the 
delivery of siEGFP-AF as shown in Figure 14b and 14c (middle column).  
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   (15a)     (15b) 
 
Figure 15. LinOS (3 g/well) and LinOSdiG (6 g/well) transfection in the presence of 50% 
or 10% FCS, at 15 nM siEGFP-AF (a) siEGFP-AF delivery and (b) EGFP expression 
percentage, 48 h post-transfection. The transfection duration was 4 h in the presence of 50% 
FCS and was 48 h in the presence of 10% FCS. 
 
The presence of serum in the cell culture medium, commonly 10-15% and up to 50% of 
the culture medium, during transfection with lipoplexes was found to decrease the 
transfection efficiency.264-266 Figure 15 shows the effect of increasing the serum content of the 
cell culture medium (DMEM) from 10% to 50% on siEGFP-AF delivery and EGFP 
silencing. The percentage of 50% v/v serum in DMEM was chosen based on the fact that 
approximately half of human blood is serum by percentage, thus 50% serum in the 
transfection medium is one step further on towards investigating the expected lipoplexes 
performance in vivo. Practically, 50% serum is considered by some research groups as 100% 
serum, i.e. 100% relative to the percentage of serum in blood.267 LinOS (3 g/well) and 
LinOSdiG (6 g/well) were chosen as LinOS was the best asymmetrical lipospermine, and 
LinOSdiG was the best among the guanidinylated conjugates. The two cationic lipids also 
were chosen to have different cationic head-groups (amine and guanidine), as this may affect 
the interaction with the increased content of serum. Increasing the amount of serum to 50% 
increased the stress on the lipoplex stability, in a similar manner to the destabilizing factors 
that can be present in vivo, where serum is known to affect negatively transfection efficiency, 
with the exception of pulmonary delivery which can benefit from an increase in lipoplex 
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size.109, 246, 268 Serum contains proteins (e.g. albumin and fibrinogen), heparin, and 
lipoproteins that can bind to cationic lipids, causing aggregation of lipoplexes, resulting in 
size changes and changes in the zeta-potential from positive to negative values.246, 269 
siEGFP-AF delivery was higher with LinOS than with LinOSdiG (p = 0.02). EGFP 
expression was reduced to 24% with LinOS, which is approximately similar to the reduction 
of EGFP expression in the presence of only 10% FCS serum at the same concentration of 
LinOS (Chapter 4, Figure 7). LinOSdiG reduced the expression to only 59%, and the 
difference from LinOS was statistically significant (p = 0.001). It is clear that while the 
transfection duration lasted 4 h before replacing the culture media with fresh media, LinOS 
retained its activity in 50% serum, while LinOSdiG showed reduced gene-silencing compared 
to that obtained in 10% FCS (Chapter 3, Figure 9). Thus, LinOS is a good candidate for 
future in vivo experiments. 
The EGFP half-life (t1/2) is reported to be ~24 h,234, 270-272 (t1/2  is the time required for the 
fluorescence of a given amount of EGFP to be reduced to 50% ), thus the fluorescence will be 
reduced to ~25% of its original value after two half-lives (48 h). Therefore, lipoplexes 
showing reduction of EGFP expression to values ≤ 25% 48 h post-transfection (e.g. Figures 
10, 13, and 15) completely inhibit EGFP expression (100% gene silencing). 
The effects of carrying out transfection at different temperatures (37, 22, and 6 °C) on 
siEGFP-AF delivery are shown in Figure 16. The amounts of siEGFP-AF and LinOS were 
kept constant at 15 pmol and 0.75 µg respectively. The delivery of both LinOS and 
LinOS/Chol 1:2 lipoplexes was significantly decreased at 22 °C and 6 °C compared to 
delivery at 37 °C. At 6 °C, the delivery was decreased to values of 1 and 3 of LinOS and 
LinOS/Chol lipoplexes respectively, as compared to values of 6 and 34 respectively at 37 °C. 
Figure 17 shows the EGFP expression 48 h post-transfection with LinOS and LinOS/Chol 
1:2 siEGFP-AF lipoplexes. The results show that the gene silencing efficiency of both LinOS 
and LinOS/Chol decreased with decreasing temperature, from 24 and 21 at 37 °C to 64 and 
40 at 6 °C respectively. At 22 °C, the LinOS lipoplexes were affected more than LinOS/Chol 
lipoplexes (EGFP expression reduced to 59% and 21% respectively). Lowering the 
temperature during the experimental work on cells in culture is a known method for 
inhibiting temperature dependent (and thereby energy dependent) endocytosis.171, 252, 273 
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Figure 16. siEGFP delivery 48 h post-transfection with lipoplexes of either LinOS (6 µg/15 
pmol siEGFP-AF) represented as grey bars, or lipoplexes of LinOS/Chol 1:2 (LinOS 0.75 
µg/15 pmol siEGFP-AF) represented as black bars. Transfection was carried out at 37, 22, 
and 6 °C for 4 h. 
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Figure 17. EGFP percentage expression 48 h post-transfection with lipoplexes of either 
LinOS (6 µg/15 pmol siEGFP-AF) represented as grey bars, or lipoplexes of LinOS/Chol 1:2 
(LinOS 0.75 µg/15 pmol siEGFP-AF) represented as black bars. Transfection was carried out 
at 37, 22, and 6 °C for 4 h. 
 
These results suggest that only a tiny fraction of the delivered siRNA is responsible for the 
gene silencing effect. For example, the delivery of LinOS/Chol lipoplexes was decreased by 
~ 10-fold by changing the temperature from 37 to 6 °C, while EGFP expression changed only 
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from 21% to 40% at 37 and 6 °C respectively. While gene silencing is sensitive to 
temperature change, endocytosis and the mechanism responsible for functional siRNA 
delivery are different. These results agree with the results recently reported171 by Lu et al., 
where the functional delivery of siRNA lipoplexes, prepared with the cationic lipid 
commercial transfection reagent DharmaFECT 1, was found to be temperature sensitive, but 
independent on different endocytic pathways. They also reported that even though the 
majority of siRNA lipoplexes reside in the endosomes, membrane fusion is the major 
functional siRNA lipoplex delivery mechanism. 
 
 
 
Figure 18. siEGFP-AF lipoplexes of LinOS/Chol 1:2 48 h post transfection in HeLa cells. 
 
The cellular internalization and distribution of lipoplexes of LinOS/Chol 1:2 prepared 
with siEGFP-AF in HeLa cells 48 h post transfection is shown in Figure 18. Two population 
of siEGFP-AF appear. One population appears as relatively larger red dots, indicating an 
increased localization in specific areas inside the cells. The second population appears as a 
homogenous distribution of a less bright-red colour which might be located in the 
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nuclear/perinuclear areas. The presence of such two different populations suggests that either 
they result from two or more different internalization mechanisms, or they resulted from 
different intracellular distribution processes after being uptaken by the cells. Taken together 
with the effect of lowering temperature during the transfection process (shown in Figures 16 
and 17), Figure 18 further points to the possibility of the existence of more than one 
internalization mechanism for these lipoplexes. 
 
4. Conclusions 
 
In this Chapter, different approaches to understanding the molecular mechanisms with a 
view to improving the efficiency of delivery and/or gene silencing of the lipoplexes prepared 
with selected spermine conjugates have been considered. The selection of the conjugates and 
their mixtures with helper lipids was based on their high efficiency (e.g. LinOS/Chol 1:2) or 
specific property (e.g. guanidine head-groups in DOSdiG and LinOSdiG). Mixing cholesterol 
and DOPE did not result in a significant enhancement of delivery or gene silencing relative to 
LinOS/Chol 1:2 lipoplexes, although the mixture resulted in a significant increase in 
efficiency compared to LinOS lipoplexes. Cholesterol mixtures with DOSdiG and LinOSdiG 
were much more efficient than lipoplexes prepared with the cationic lipids only, however, no 
significant advantage of changing the nature of the head-group, from amine to guanidine, was 
observed. The inclusion of the pH sensitive CHS in the formulation resulted in enhancement 
of gene silencing. Formulating the lipoplexes with the anionic polymer DS resulted in a slight 
increase of silencing efficiency. Both CHS and DS formulation approaches are promising for 
further optimization of the lipoplexes. Investigating the cellular entry of siRNA lipoplexes by 
carrying out transfection at decreasing temperatures showed that delivery was significantly 
decreased (10-fold) and that whilst the subsequent silencing was also decreased, this was by a 
much lesser extent. Therefore, it is concluded that a temperature sensitive mechanism, aside 
from endocytosis, is responsible for the majority of functional siRNA delivery.  
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Conclusions 
 
In this thesis, a focussed and critical overview of siRNA delivery, the need for siRNA 
studies of non-viral vectors, and the potential for siRNA lipoplexes in difficult-to-treat 
diseases was presented. Five discrete sets of experiments were carried out in order to answer 
SAR and mechanism-of-action questions with regard to siRNA delivery and gene silencing. 
Firstly, five symmetrical lipospermines were prepared by conjugating fatty acids of 
various chain length and oxidation state (C12:0, C18:0, C18:1 9, C18:2 9,12, C22:1 13) to 
the naturally occurring polyamine, spermine (1,12-diamino-4,9-diazadodecane). They were 
evaluated for their siRNA delivery, gene knock-down efficiency, and effect on cell viability. 
siRNA delivery could not be related directly to gene silencing efficiency as N4,N9-dierucoyl 
spermine (DES) resulted in higher siRNA delivery compared to N4,N9-dioleoyl spermine 
(DOS). EGFP silencing in HeLa cells stably expressing EGFP showed that the unsaturated 
fatty acid conjugates are more efficient than the saturated fatty acid ones, with DOS resulting 
in the most efficient gene silencing in the presence of 10% FCS. The alamarBlue cell 
viability assay showed that the symmetrical spermine conjugates resulted in good cell 
viability (75%-85% compared to the commercial controls Lipofectamine 2000 and TransIT-
TKO), except N4,N9-dilauroyl spermine (DLauS) which resulted in low cell viability (50% at 
3 g DLauS/well). Thus, unsaturated fatty acid conjugates of spermine are efficient and non-
toxic non-viral vectors for siRNA mediated gene silencing. The best gene silencing was with 
the symmetrical conjugates that have two C18 chains with one double bond on each chain 
(oleoyl, silencing EGFP to 19%), followed by linoleoyl chains with two double bonds per 
chain (silencing EGFP to 28%). 
The effect of changing the type of the cationic head-group from a primary amine to a 
guanidine group was investigated by synthesizing four guanidine derivatives of selected 
N4,N9-diacylated spermines. These guanidine-containing cationic lipids bound siRNA 
efficiently and formed lipoplexes with lipoplex diameters in the nanometre size-range. Two 
cationic lipids with C18 unsaturated chains, N1,N12-diamidino-N4,N9-dioleoylspermine and 
N1,N12-diamidino-N4-linoleoyl-N9-oleoylspermine, were more efficient in terms of EGFP 
gene silencing compared to cationic lipids with shorter C12 (12:0, lauroyl) and very long C22 
(22:1 13, erucoyl) chains. N1,N12-Diamidino-N4-linoleoyl-N9-oleoylspermine (LinOSdiG) 
siRNA lipoplexes resulted in EGFP gene silencing to 26%, in the presence of 10% FCS, and 
satisfactory cell viability (64%). The EGFP gene silencing was comparable with that obtained 
with TransIT-TKO (down to 23%). Changing the cationic head-group to the guanidine did 
not offer a significant advantage in siRNA delivery or in EGFP gene silencing over the 
lipospermines with terminal primary amine groups. Guanidinylated N4,N9-diacylated 
155 
 
spermines that have fatty chains 18:1/18:1 (symmetrical) or 18:1/18:2 (asymmetrical) are 
good candidates for non-viral delivery of siRNA to HeLa cells using self-assembled 
lipoplexes, but they do not show any significant advantages despite their increased basicity 
and the formation of double the number of salt-bridges (four compared to two primary 
amines) to the siRNA and cell membrane anionic groups. 
The symmetrical spermine conjugates with two 18:1 chains showed the best balance 
between siRNA delivery, EGFP gene silencing to 19%, and high cell viability (78%). Thus, 
seven asymmetrical N4,N9-diacyl spermines were synthesized and one oleoyl chain was 
chosen to be held constant. These lipospermines were evaluated as siRNA non-viral vectors, 
and were compared to molar mixtures of selected symmetrical N4,N9-diacyl spermines, 
keeping the total weight of the cationic lipid constant (3 g/well). These lipospermines bound 
siRNA efficiently and formed lipoplexes with particle diameters in the nanometre size-range. 
Intracellular delivery of siRNA and EGFP gene silencing differ with varying the fatty acid 
chain lengths and saturation state. N4-Linoleoyl-N9-oleoyl-1,12-diamino-4,9-diazadodecane 
(LinOS) resulted in the best gene silencing, while LigOS (with one lignoceroyl 24:0 chain 
and one oleoyl) resulted in the best siRNA delivery. Lipospermines with two unsaturated 
fatty chains generally resulted in better EGFP gene silencing, while the conjugates with one 
saturated chain resulted in better siRNA delivery. Increasing the lipid chain-length also 
resulted in increased siRNA delivery. LinOS EGFP gene silencing (24 % with 3 g/well, 
compared to 27% with 6 g DOS under same experimental conditions of transfection) was 
comparable with or superior to that achieved with the commercially available non-viral 
vectors TransIT-TKO (25%) and Lipofectamine 2000 (31%), although siRNA delivery was 
much higher with these two commercial reagents. Thus, delivery and gene silencing are 
governed by significantly different factors. The asymmetrical lipospermines were well 
tolerated by the HeLa cells under the normal transfection conditions (cell viabilities typically 
>74%, LinOS 88%).  
The use of the mixtures DOS/DLinS and DOS/DEruS at different molar ratios did not 
enhance siRNA delivery when compared to the corresponding asymmetrical cationic lipids 
LinOS and EruOS. EGFP gene silencing with LinOS was better than any of the DOS/DLinS 
mixtures, while the mixture of 1:1 DOS/DEruS resulted in better EGFP gene expression 
reduction. Thus, although no definitive rule can describe the superiority of using mixtures 
over asymmetrical lipospermines or vice versa, it is clear that both approaches can offer an 
advantage in terms of the resulting gene silencing. These results can be compared and 
contrasted with the use of mixtures for DNA delivery (gene delivery/gene therapy) where 
synergy was observed.  
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It is concluded that not only are siRNA delivery and siRNA mediated gene silencing 
controlled by different factors, but also that DNA delivery has different vector requirements. 
It is clear that siRNA delivery and gene silencing are not the same, and the facile comparison 
with DNA delivery i.e. “all polynucleotides are similar” is precisely that, facile. 
siRNA lipoplexes were prepared by the direct mixing of siRNA and mixtures of LinOS 
with either cholesterol or DOPE (as a neutral lipid) at various molar ratios of the lipids. The 
effects of varying the lipid formulation and changing of the N/P ratio on the intracellular 
delivery of siRNA to HeLa cells and on the EGFP gene silencing were evaluated. The 
presence of either cholesterol or DOPE in the mixture resulted in a significant increase in 
siRNA delivery, as well as enhanced EGFP silencing. LinOS/Chol mixture (1:2) resulted in 
the highest siRNA delivery, as well as the best gene EGFP silencing (reduced to 20%) at an 
N/P ratio of 3.0. Decreasing the amount of siRNA from 15 pmol to 3.75 pmol while keeping 
the LinOS/Chol amount constant, thus increasing the N/P ratio to 11.9, resulted in decreasing 
the amount of delivered siRNA, while the reduction of EGFP was comparable to that 
obtained with 15 pmol (N/P = 3.0) of siRNA. Cholesterol mixtures with the symmetrical 
cationic lipid DOS at 1:2 DOS/Chol, N/P = 3.0 (15 pmol siRNA) resulted in less efficient 
siRNA delivery than with LinOS/Chol 1:2, and comparable delivery at N/P = 11.9 (3.75 pmol 
siRNA). The EGFP gene silencing was comparable with 1:2 mixtures of either LinOS or 
DOS with cholesterol (lipoplexes prepared with 15 pmol siRNA), but LinOS/Chol mixture 
showed better EGFP gene silencing when the siRNA amount was reduced to 3.75 pmol. 
Particle size determination by DLS showed that the lipoplex diameters for cholesterol 
mixtures were in the range 106-118 nm, compared to 194-356 nm for the lipoplexes prepared 
with the spermine conjugates only, and to 685 nm for the 1:1 LinOS/DOPE mixture.  
Confocal microscopy showed successful siRNA delivery and EGFP knock-down, and Z-
stack photomicrographs showed that the delivered siRNA is distributed intracellularly. Cell 
viability assay (alamarBlue) showed that the prepared lipoplexes resulted in cell viabilities ≥ 
81%, with LinOS/Chol (1:2) resulting in viability of 85% and 94% at siRNA amounts 15 
pmol and 3.75 pmol respectively. These results show that co-formulation with the helper 
lipids cholesterol or DOPE resulted in enhanced siRNA delivery and EGFP silencing. siRNA 
lipoplexes of LinOS/Chol mixtures prepared by the direct mixing of the lipid mixture and 
siRNA, without any preceding pre-formulation steps of the lipid mixtures, resulted in 
enhanced siRNA delivery and EGFP knock-down, with very good cell viability (81-95%). 
Thus, LinOS/Chol (1:2) mixture is a promising candidate as an siRNA non-viral vector.  
Different approaches to further improve the performance of selected lipoplex formulations 
and to understand their mechanisms of action were carried out. The selection of the 
conjugates and their mixtures with helper lipids was based either on their high efficiency (e.g. 
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LinOS/Chol 1:2) or on a specific property (e.g. guanidine head-groups in DOSdiG and 
LinOSdiG). Mixing cholesterol and DOPE did not result in a significant enhancement of 
delivery or gene silencing relative to LinOS/Chol 1:2 lipoplexes, although the mixture 
resulted in significant increase in efficiency compared to LinOS lipoplexes at the same N/P 
ratio. Cholesterol mixtures with DOSdiG and LinOSdiG were much more efficient than the 
lipoplexes prepared with the cationic lipids only. However, no significant advantage of 
changing the type of head group, from amine to guanidine, was found. The inclusion of the 
pH sensitive cholesteryl hemisuccinate (CHS) in the lipoplex formulation resulted in an 
enhancement of gene silencing. Formulating the lipoplexes with the anionic polymer dextran 
sulfate (DS), resulted in a slight increase of gene silencing efficiency. Both CHS and DS 
formulation approaches are promising for further optimization of the lipoplexes. Carrying out 
transfection experiments in 50% FCS, showed that LinOS (with terminal primary amine 
groups) did not lose its efficiency, while LinOSdiG showed decreased efficiency compared to 
transfection in 10% FCS. Thus, the amine group is potentially more promising for future 
applications in vivo. Investigating the mechanism of cellular entry of the siRNA lipoplexes 
by carrying out transfection at decreasing temperatures, showed that the delivery was 
significantly decreased (10-fold at 6 °C), but whilst the subsequent gene silencing was also 
decreased, this was to a much lower extent (by 25%, from ~80% to ~60% silencing 
corresponding to ~20% and ~40% EGFP expression respectively). From these results it was 
concluded that a temperature sensitive mechanism aside from endocytosis is responsible for a 
large part of functional siRNA delivery.  
In summary, several lipopolyamines were designed to achieve effective siRNA delivery, 
efficient gene-silencing, and minimum toxicity to cells. Symmetrical DOS achieved efficient 
gene-silencing while symmetrical DEruS showed enhanced delivery. DOS is as good as the 
two leading (gold standard) non-viral transfection reagents TransIT-TKO and Lipofectamine 
2000 for gene silencing and for cell viability. Notwithstanding the huge siRNA delivery of 
TransIT-TKO and Lipofectamine 2000, the novel asymmetrical LinOS was developed which 
achieved complete gene silencing, still with excellent cell viability, and yet with significantly 
lower siRNA delivery. Coformulation of LinOS with cholesterol further enhanced its 
efficiency. Finally, as the half-life (t1/2) of EGFP is ~24 h, then 25% of EGFP will be present 
48 h post-transfection (after two half-lives of EGFP) which when compared to the gene 
silencing 48 h post-transfection with DOS and LinOS (20-24% expression of EGFP) leads to 
the conclusion that the biosynthesis of EGFP is 100% inhibited. 
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Efficient siRNA delivery and effective gene silencing by lipoplexes 
 
Metwally AA, Pourzand C, Blagbrough IS 
Department of Pharmacy and Pharmacology, University of Bath, Bath BA2 7AY, U.K. 
 
siRNA is double-stranded RNA typically 21-24 nucleotide base-pairs long. Gene silencing by 
siRNA has gained wide acceptance in genomics and is already in different phases of clinical 
trials as a potential therapeutic. Long chain fatty acid conjugates of spermine have previously 
been synthesized and evaluated in our research group for both gene and siRNA delivery [1, 
2]. We report the synthesis of two novel unsymmetrical N4,N9-difatty acid conjugates of the 
naturally occurring polyamine spermine with the aim of developing structure-activity 
relationships for their potential as non-viral, self-assembly vectors for siRNA delivery. After 
transfection with lipoplexes of Alexa Fluor® 647-labelled siRNA (a 24-mer from Qiagen), 
silencing EGFP expression, both the efficiency of delivery and the effectiveness of knock-
down (gene silencing) were evaluated in HeLa cells stably expressing EGFP. Analysis was 
by FACS 48 h post transfection. All transfection experiments were carried-out in DMEM 
containing 10% foetal calf serum. 
 
The efficiency of intracellular delivery was measured by the (normalized) fluorescence of 
Alexa Fluor® 647-labelled siRNA; N4,N9-dioleoylspermine (DOS) showed 150% of the 
delivery efficiency achieved with N4-linoleoyl-N9-oleoylspermine (LOS). However, knock-
down results show that LOS is more effective with a reduction of EGFP expression levels 
from control (100%) to 25 ± 3% at a concentration of 3 µg/well (N/P = 11, n = 3 and 
triplicate replicates). Under the same experimental conditions, DOS reduced EGFP 
expression to 27 ± 2% at a concentration of 6 µg/well (N/P = 22) and to 32 ± 2% at a 
concentration of 3 µg/well (N/P = 11). Cell viability was measured as the percentage of 
viable cells using the Alamar Blue® assay [3]. The results show that at 3 µg/well LOS cell 
viability is 83 ± 4%, at 6 µg/well LOS cell viability is 46 ± 8%, while at 6 µg/well DOS cell 
viability is only 32 ± 9%. Transfection of cells with LipofectamineTM 2000 resulted in 
reduction of EGFP expression to 37 ± 3%, with cell viability of 91 ± 6%. 
 
We conclude from these results that the unsymmetrical lipopolyamine LOS is an excellent 
transfecting agent for the delivery of siRNA producing effective gene silencing in the 
presence of 10% foetal calf serum. 
 
We thank the Egyptian Government for a fully-funded studentship to AAM. 
 
1 Ghonaim, H.M. et al. (2009) Very Long Chain N4,N9-Diacyl Spermines:  Non-Viral 
Lipopolyamine Vectors for Efficient Plasmid DNA and siRNA Delivery. Pharm. Res. 26, 19-
31 
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Efficient siRNA delivery and gene silencing by 
unsymmetrical fatty acid amides of spermine 
 
Metwally AA, Pourzand C, Blagbrough IS 
Department of Pharmacy and Pharmacology, University of Bath, Bath BA2 7AY, U.K. 
INTRODUCTION 
 
Gene silencing by siRNA i.e. synthetic 
dsRNA of 21-24 nucleotides, is already an 
important biological tool in the study of gene 
function and it also has many potential 
therapeutic applications for difficult-to-treat 
diseases [1]. 
Long-chain fatty acid amides of the 
naturally occurring polyamine spermine have 
previously been synthesized and evaluated in 
our research group for both pDNA and siRNA 
delivery [2-5]. Our SAR studies of long- (C18) 
and very-long (C20 and longer) fatty acid [6] 
conjugates of spermine are important in 
investigating the enhancement of siRNA 
delivery and of gene silencing. 
 
AIMS 
 
 To study the SAR of novel unsymmetrical 
long- and very-long chain fatty acid spermine 
conjugates that will be evaluated for their 
efficiencies of siRNA delivery and gene 
knock-down.  
 
MATERIALS AND METHODS 
 
N4-Arachidonoyl-N9-oleoylspermine 
(AOS), N4-lignoceroyl-N9-oleoylspermine 
(LIGOS), and N4-linoleoyl-N9-oleoylspermine 
(LINOS) were prepared using DCC coupling 
of the corresponding carboxylic acids, after di-
N-phthalimido protection of the primary 
amines. All transfection studies were carried 
out in the presence of foetal calf serum (FCS), 
10% in DMEM on HeLa cells stably 
expressing enhanced green fluorescent protein 
(EGFP). siRNA concentration in each well of 
24-well plates was 15 nM. Mean geometric 
fluorescence intensity of Alexa Fluor® 647 
labelled-siRNA and EGFP was measured by 
FACS analysis 48 h post transfection. The 
alamarBlue® assay [7] was used to evaluate 
cytotoxicity. 6000 cells/well were incubated 
for 44 h post transfection then alamarBlue® 
reagent was added to the culture media and 
cells were incubated for a further 3.5 h. 
 
 
 
 
RESULTS AND DISCUSSION 
 
Gated FACS analysis (of living cells) 
showed that LIGOS has the highest siRNA 
delivery as measured by the normalized 
geometric mean fluorescence of Alexa Fluor® 
647 (4-fold more compared to AOS and 
LINOS). However, more reduction in EGFP 
expression, in HeLa cells stably expressing 
EGFP, was achieved on siRNA delivery with 
AOS (to 34%, N/P = 21) and LINOS (to 29%, 
N/P = 11) compared to a reduction to 56% 
achieved with LIGOS (N/P = 18). Unsaturated 
fatty acid amide (linoleoyl; 18:2; 
arachidonoyl; 20:4) spermine conjugates 
showed higher knock-down efficiencies 
compared to (saturated) lignoceroyl (24:0) 
spermine conjugates.  
 
This knock-down effect might be due to 
the ability of unsaturated chains to enhance 
fusion with endosomal membranes and 
thereby to facilitate endosomal escape [2], a 
key factor in the efficiency of siRNA mediated 
knockdown by lipoplexes [2-6]. Although 
LIGOS gave better siRNA delivery, its 
relatively low knockdown (to 56%) means that 
whilst saturated fats might enhance delivery, 
unsaturated fats specifically enhance 
endosomal escape of the delivered siRNA. 
AlamarBlue® cytotoxicity evaluation 
showed that LINOS was less cytotoxic to 
HeLa cells (72% cell viability) compared to 
AOS (32%) and LIGOS (63%). The lower cell 
viability obtained with AOS may be attributed 
to the increased number (4) of C=C double 
bonds which has been reported to be a cause of 
cytotoxicity [8]. Under the same experimental 
settings, LipofectamineTM 2000 reduced EGFP 
expression to 34%, with cell viability of 82%. 
 
CONCLUSIONS 
 
 N4-Linoleoyl-N9-oleoylspermine (LINOS) 
is an efficient vector for the delivery of siRNA 
producing effective gene silencing even in the 
presence of FCS.  
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EFFICIENT siRNA DELIVERY AND EFFECTIVE GENE 
SILENCING BY LIPOSPERMINE LIPOPLEXES 
 
Abdelkader A. Metwally, Charareh Pourzand, and Ian S. Blagbrough 
Department of Pharmacy and Pharmacology, University of Bath, Bath BA2 7AY, U.K. 
E-mail:  prsisb@bath.ac.uk 
Purpose:  To develop structure-activity relationships of two novel 
unsymmetrical N4,N9-difatty acid conjugates of the naturally occurring 
polyamine spermine for their potential as non-viral, self-assembly vectors 
for siRNA delivery. 
Methods:  Synthesis of the unsymmetrical fatty acid spermine 
conjugates was achieved by stepwise DCC/DMAP coupling of fatty acids 
to N1,N12 protected spermine. Alexa Fluor® 647-labelled siRNA silencing 
EGFP expression (a 24-mer) was custom synthesized by Qiagen. All 
transfection experiments were carried-out in DMEM containing 10% 
FCS. The efficiency of delivery and the effectiveness of knock-down 
were evaluated in HeLa cells stably expressing EGFP by FACS analysis 
48 h post transfection. Cell viability was measured as the percentage of 
viable cells using the alamarBlue® assay. 
Results:  N4,N9-Dioleoylspermine (DOS) showed 150% more delivery 
efficiency compared to N4-linoleoyl-N9-oleoylspermine (LINOS). 
However, knock-down results show that LINOS is more effective with a 
reduction of EGFP expression levels from control (100%) to 25 ± 3% at 
3 µg/well (N/P = 11). DOS reduced EGFP expression to 27 ± 2% at a 
concentration of 6 µg/well (N/P = 22) and to 32 ± 2% at a concentration 
of 3 µg/well (N/P = 11). N4-Lignoceroyl-N9-oleoyl-spermine (LIGOS) 
showed 400% more delivery compared to LINOS while reducing EGFP 
expression to 56 ± 4%. At 3 µg/well LINOS cell viability is 65 ± 18%, 
while at 6 µg/well DOS cell viability is only 33 ± 7%. Cell transfection 
with LipofectamineTM 2000 reduced EGFP expression to 37 ± 3%, with 
cell viability 84 ± 10%. 
Conclusions:  Unsymmetrical lipopolyamine LINOS is an excellent 
transfecting agent for the delivery of siRNA producing effective gene 
silencing in the presence of 10% FCS. The efficiency of delivery is not 
necessarily a direct measure of gene silencing efficiency. 
Acknowledgments:  We thank the Egyptian Government for a fully-
funded studentship to AAM. 
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siRNA DELIVERY AND GENE SILENCING BY 
UNSYMMETRICAL FATTY ACID AMIDES OF SPERMINE 
 
Abdelkader A. Metwally, Charareh Pourzand, and Ian S. Blagbrough 
Department of Pharmacy and Pharmacology, University of Bath, Bath BA2 7AY, U.K. 
E-mail:  prsisb@bath.ac.uk 
 
Purpose:  The evaluation of siRNA delivery and gene silencing 
efficiencies using novel unsymmetrical long- and very-long chain fatty 
acid spermine conjugates.  
Methods:  We prepared N4-arachidonoyl-N9-oleoylspermine (AOS), N4-
lignoceroyl-N9-oleoylspermine (LIGOS), and N4-linoleoyl-N9-
oleoylspermine (LINOS). All transfection studies were carried out in the 
presence of 10% FCS in DMEM on HeLa cells stably expressing 
enhanced green fluorescent protein (EGFP). siRNA concentration was 15 
nM. Mean geometric fluorescence intensity of Alexa Fluor® 647 
labelled-siRNA and EGFP was measured by FACS analysis 48 h post 
transfection. Cytotoxicity was evaluated using the alamarBlue® assay. 
Results:  Living cells were gated for FACS analysis which showed that 
LIGOS gave the highest siRNA delivery, 4-fold more compared to AOS 
and LINOS (measured by the normalized Alexa Fluor® 647 geometric 
mean fluorescence). More reduction in EGFP expression was achieved 
on siRNA delivery with AOS (to 29%, N/P = 21) and LINOS (to 25%, 
N/P = 11) compared to a reduction to 56% achieved with LIGOS (N/P = 
18). Unsaturated fatty acid amide (linoleoyl; 18:2; arachidonoyl; 20:4) 
spermine conjugates showed higher silencing efficiencies compared to 
(saturated) lignoceroyl (24:0) spermine conjugates. AlamarBlue® 
cytotoxicity evaluation showed that LINOS was less cytotoxic to HeLa 
cells (65% cell viability) compared to AOS (31%) and LIGOS (49%). 
The lower cell viability obtained with AOS may be attributed to the 
increased number (4) of C=C double bonds which has been reported to be 
a cause of cytotoxicity. Under the same experimental settings, 
LipofectamineTM 2000 reduced EGFP expression to 37 ± 3%, with cell 
viability of 84 ± 10%. 
Conclusions:  N4-Linoleoyl-N9-oleoylspermine (LINOS) is an efficient 
vector for siRNA delivery and effective gene silencing. 
Acknowledgments:  We thank the Egyptian Government for a fully-
funded studentship to AAM. 
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EFFICIENT siRNA DELIVERY AND EFFECTIVE GENE 
SILENCING BY LIPOPLEXES 
Abdelkader A. Metwally, Charareh Pourzand, and Ian S. Blagbrough 
Department of Pharmacy and Pharmacology, University of Bath, Bath BA2 7AY, U.K. 
PURPOSE 
 
We report the synthesis and biological activity of two novel unsymmetrical N4,N9-
difatty acid conjugates of the naturally occurring polyamine spermine, with the aim of 
developing structure-activity relationships for their potential as non-viral, self-
assembly vectors for siRNA delivery. 
 
METHODS 
 
Transfection experiments 
Lipoplexes of Alexa Fluor® 647-labelled siRNA silencing EGFP expression were 
prepared at different N/P ratios. The efficiency of delivery and the effectiveness of 
knock-down (gene silencing) were evaluated in HeLa cells stably expressing EGFP. 
All transfection experiments were carried-out in DMEM containing 10% foetal calf 
serum (FCS) in 24-well plates. Analysis of fluorescence intensity was out FACS 48 h 
post transfection.  
Cytotoxicity assay by alamarBlue® 
Lipoplexes were added to HeLa cells in the same manner as the above transfection 
protocol with the exception of adjusting the amount of siRNA to the 96-well format. 
The % viability is calculated according to alamarBlue® manufacturer instructions. 
 
RESULTS 
 
The efficiency of intracellular delivery was measured by the (normalized) 
fluorescence of Alexa Fluor® 647-labelled siRNA; N4,N9-dioleoylspermine (DOS) 
showed 150% of the delivery efficiency achieved with N4-linoleoyl-N9-
oleoylspermine (LOS). However, knock-down results show that LOS is more 
effective with a reduction of EGFP expression levels from control (100%) to 25 ± 3% 
at a concentration of 3 µg/well (N/P = 11, n = 3 and triplicate replicates). Under the 
same experimental conditions, DOS reduced EGFP expression to 27 ± 2% at a 
concentration of 6 µg/well (N/P = 22) and to 32 ± 2% at a concentration of 3 µg/well 
(N/P = 11). Cell viability results show that at 3 µg/well LOS cell viability is 83 ± 4%, 
at 6 µg/well LOS cell viability is 46 ± 8%, while at 6 µg/well DOS cell viability is 
only 32 ± 9%. Transfection of cells with LipofectamineTM 2000 resulted in reduction 
of EGFP expression to 37 ± 3%, with cell viability of 91 ± 6%. 
 
CONCLUSIONS 
 
Unsymmetrical lipopolyamine LOS is an excellent transfecting agent for the delivery 
of siRNA producing effective gene silencing (even with FCS). 
We thank the Egyptian Government for a fully-funded studentship to AAM. 
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siRNA DELIVERY TO EFFECT EFFICIENT GENE SILENCING:  
OPPORTUNITIES WITH SELF-ASSEMBLY LIPOPLEXES OF 
UNSYMMETRICAL FATTY ACID AMIDES OF SPERMINE 
 
Abdelkader A. Metwally, Charareh Pourzand, and Ian S. Blagbrough 
Department of Pharmacy and Pharmacology, University of Bath, Bath BA2 7AY, UK 
E-mail:  prsisb@bath.ac.uk 
 
Purpose:  Our aim is to study the SAR of novel unsymmetrical long- and very-long 
chain fatty acid spermine conjugates evaluating their efficiencies in siRNA delivery 
and gene silencing. 
Methods:  N4-Arachidonoyl-N9-oleoylspermine (AOS), N4-lignoceroyl-N9-
oleoylspermine (LIGOS), and N4-linoleoyl-N9-oleoylspermine (LINOS) were 
prepared using DCC coupling of the corresponding carboxylic acids, after N4,N9-
diphthalimido protection of the primary amines. All transfection studies were carried 
out in the presence of 10% FCS in DMEM on HeLa cells stably expressing enhanced 
green fluorescent protein (EGFP). siRNA concentration in each well of 24-well plates 
was 15 nM. Mean geometric fluorescence intensity of Alexa Fluor® 647 labelled-
siRNA and EGFP was measured by FACS analysis 48 h post transfection. 
Cytotoxicity was evaluated using the alamarBlue® assay. 
Results:  Gated FACS analysis of living cells showed that LIGOS has the highest 
siRNA delivery as measured by the normalized geometric mean fluorescence of 
Alexa Fluor® 647 (4-fold more compared to AOS and LINOS). However, more 
reduction in EGFP expression was achieved on siRNA delivery with AOS (to 34%, 
N/P = 21) and LINOS (to 29%, N/P = 11) compared to a reduction to 56% achieved 
with LIGOS (N/P = 18). Unsaturated fatty acid amide (linoleoyl; 18:2; arachidonoyl; 
20:4) spermine conjugates showed higher silencing efficiencies compared to 
(saturated) lignoceroyl (24:0) spermine conjugates. LIGOS gave better siRNA 
delivery, however its relatively low knockdown (to 56%) means that whilst 
incorporating a saturated chain might enhance delivery, unsaturated chains 
specifically enhance the endosomal escape of the delivered siRNA due to the ability 
of unsaturated chains to enhance fusion with endosomal membranes. AlamarBlue® 
cytotoxicity evaluation showed that LINOS was less cytotoxic to HeLa cells (72% 
cell viability) compared to AOS (32%) and LIGOS (63%). The lower cell viability 
obtained with AOS may be attributed to the increased number (4) of C=C double 
bonds which has been reported to be a cause of cytotoxicity. Under the same 
experimental conditions, LipofectamineTM 2000 reduced EGFP expression to 34%, 
with cell viability of 82%. 
Conclusions:  N4-Linoleoyl-N9-oleoylspermine (LINOS) is an excellent vector for 
siRNA delivery and efficient gene silencing working through lipoplex self-assembly. 
Acknowledgments:  We thank the Egyptian Government for a fully-funded 
studentship to AAM. 
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Practical synthesis of unsymmetrical fatty acid conjugates of spermine for siRNA 
delivery 
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We have designed, synthesized, and purified C12 to C18 unsymmetrical fatty acid 
amides of the tetraamine spermine (lipospermines), conjugates containing two 
different fatty acid chains at the N4- and N9-positions of spermine.  Spermine contains 
two primary and two secondary amine functional groups which require orthogonal 
protection to synthesize unsymmetrical N4,N9-diacylated lipospermines.  One 
approach to their synthesis is to protect the primary amine functional groups as 
phthalimides, followed by BOC protection of one secondary amine.  The first fatty 
acid was introduced by HOBT/DCC coupling to the free secondary amine followed 
by BOC deprotection and then conjugation with the second long-chain fatty acid.  
Another practical approach uses DMAP/DCC to conjugate stoichometrically (40%) 
only one fatty acid to the diphthalimide of spermine.  After purifying from a small 
amount of the diacylated product, conjugating the second fatty acid avoids BOC 
introduction and TFA-mediated BOC deprotection.  After hydrazine deprotection of 
the phthalimides, the six unsymmetrical lipospermines were characterized.  One fatty 
acid chain was kept constant as oleoyl (C18) in conjugates of:  arachidonic (C20), 
erucic (C22), lignoceric (C24), linoleic (C18), nervonic (C24), and stearic (C18) 
acids.  HeLa cells stably expressing EGFP were transfected by lipoplexes of 
lipospermine with siRNA to silence EGFP production.  SAR of fatty acid chain 
length and saturation state were studied.  Unsaturated fatty acids were more efficient 
in knocking down EGFP, while saturated fatty acids enhanced siRNA delivery.  
These results show that unsymmetrical lipospermines are promising non-viral 
vectors. 
 
We thank the Egyptian Government (through Ain Shams University) for a fully-
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Efficient siRNA delivery and gene silencing by unsymmetrical fatty 
acid amides of spermine 
 
Abdelkader A. Metwally, Charareh Pourzand, and Ian S. Blagbrough 
Department of Pharmacy and Pharmacology, University of Bath, Bath BA2 7AY, U.K. 
 
Gene knock-down, gene silencing using siRNA (synthetic dsRNA of 21-25 base pairs), 
has many potential therapeutic applications for difficult-to-treat diseases [1].  We have 
designed, synthesized, and evaluated long-chain (C18) and very-long (C20 and C24) 
fatty acid amides of the naturally occurring polyamine spermine for siRNA delivery 
and gene knock-down [2].  Our latest spermine conjugates are unsymmetrical, 
possessing two different fatty acid chains conjugated at the N4- and N9-positions.  They 
are designed upon the observation that most mammalian diacylglycerols are composed 
of chains with different length or oxidation state.  Phospholipids usually have one 
unsaturated acyl chain in the sn-2-position, and so we kept mono-oleoyl as a constant 
feature in our novel unsymmetrical diacylspermine conjugates:   
N4-arachidonoyl-N9-oleoylspermine (AOS), N4-lignoceroyl-N9-oleoylspermine (LIGOS), 
N4-linoleoyl-N9-oleoylspermine (LINOS), and N4-nervonoyl-N9-oleoylspermine (NOS) 
evaluating their efficiencies with respect to siRNA delivery and gene knock-down. 
Synthesis of these unsymmetrical polyamine amides was achieved by DCC/DMAP 
catalysed coupling of the corresponding carboxylic acids, after protection of spermine 
primary amines with phthalimide.  Thus, using oleic acid (1.1 eq.) and N1,N12-
diphthalimido spermine (1.0 eq., 24 h, 20 oC) gave the N4-mono-oleoyl conjugate, 50% 
yield after flash chromatography.  Under the same conditions, the second long-chain 
fatty acid was then added.  Deprotection was by refluxing with hydrazine (10% v/v) in 
THF:DCM (1:1 v/v, 4 h) followed by flash column chromatography (40% over both 
steps).  Transfection studies were carried out in the presence of 10% foetal calf serum 
(FCS) in DMEM.  HeLa cells stably expressing enhanced green fluorescent protein 
(EGFP) were transfected with siRNA at a concentration of 15 nM.  Mean geometric 
fluorescence intensity of Alexa Fluor® 647 labelled-siRNA and of EGFP was measured 
by FACS analysis 48 h post transfection.  The alamarBlue® assay was used to evaluate 
cell viability where 6000 cells/well of 96-well plates were incubated for 44 h post 
transfection followed by adding alamarBlue® to the media and incubation for 3.5 h. 
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FACS analysis results indicated that LIGOS has the highest siRNA delivery – 4-fold more 
compared to AOS and LINOS.  However, more reduction in EGFP expression was 
achieved with AOS (to 34%, N/P = 21) and LINOS (to 29%, N/P = 11) compared to a 
reduction to 56% achieved with LIGOS (N/P = 18), and to 54% with NOS (N/P = 18).  
Unsaturated fatty acid spermine conjugates (linoleoyl; 18:2; arachidonoyl; 20:4) showed 
higher knock-down efficiencies compared to the lignoceroyl (24:0) or nervonoyl (24:1) 
conjugates.  This knock-down effect may be due to the unsaturated chains’ ability to 
enhance fusion with endosomal membranes and thereby to facilitate endosomal escape [3].  
Though LIGOS and NOS were almost equivalent in gene silencing, the siRNA delivered 
by LIGOS lipoplexes was twice that of NOS, in other words, NOS (24:1) achieved the 
same knock-down as LIGOS (24:0) with half the amount of siRNA.  AlamarBlue® cell 
viability evaluation showed that LINOS was less cytotoxic to HeLa cells (72% cell 
viability) at the N/P ratio that showed the best knock-down efficiency, compared to AOS 
(32%), LIGOS (63%), and NOS (22%).  The lower cell viability obtained with AOS and 
NOS (compared to LIGOS) may be attributed to the presence of C=C double bonds which 
relatively increases the cytotoxicity among other factors [4].  Using the same experimental 
conditions, LipofectamineTM 2000 reduced EGFP expression to 34% while cell viability 
was 82%.  N4-Linoleoyl-N9-oleoylspermine (LINOS) is an efficient vector for the delivery 
of siRNA producing effective gene silencing even in the presence of FCS showing 
protection in the self-assembled nanoparticle from RNase. 
We acknowledge financial support from the Egyptian Government (studentship to A.A.M.). 
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Polyamine conjugates are found widely distributed as natural products in plants, bacteria, 
invertebrates, and in mammals.  Although free polyamines are simple linear structures, often 
characterised by C-3 spacers derived from S-adenosylMet (SAM), or C-4, putrescine from 
Orn or Arg, or C-5, cadaverine from Lys, it is their pattern of positive charges as a result of 
their differing pKa values which, together with their three dimensional shape, brings about 
their intrinsic biological activity.  Such molecules display high affinity for a range of binding 
sites.  Whilst this may lead to some therapeutic possibilities, it is also likely to lead to non-
specificity, and even non-selectivity, so-called “dirty drugs” with no (or limited) therapeutic 
value.  The covalent attachment of side-chains through a variety of functional groups allows 
higher binding affinity and therefore more selectivity.  The simple amide, being neutral, takes 
away the possibility of a positive charge.  However, the guanidine, being the most basic 
functional group in medicinal chemistry, ensures the presence of a positive charge across the 
pH range.  Taken together with hydrogen bonding potential and van der Waals’ lipid-lipid 
non-bonding interactions arising from the conjugated moieties, means that a wide range of 
polyamine conjugates are now known that have roles or potential roles in therapy. 
Placing 4-6 positive charges around a 3D-template gives powerful antibiotic action, although 
with side-effects e.g. ototoxicity (permanent deafness).  Such polyamine conjugates, amino-
glycosides e.g. tobramycin, neomycin, find widespread use in hospitals.  As the polycationic 
polyamines have been known since their discovery to bind to polyanionic DNA, as in sperm, 
it is not surprising that they can interfere with various cancers.  Affinity and cytotoxicity can 
both be improved by the addition of an anthracene or acridine intercalator moiety.  Capping 
the N-termini with alkyl moieties has given rise to a large number of analogues, N1,N11-
diethylnorspermine (DENSPM) being one of the more famous.  One interesting effect of R,R-
dihydroxy-N1,N14-diethylhomospermine (from DEHSPM) is as an anti-diarrhoeal.  Increasing 
the spacing between the two central secondary amines and adding longer chain alkyl or 
aromatic end-groups turns the anti-cancer activity into anti-malarial activity. 
Spider and wasp venoms contain a plethora of polyamine amides.  These toxins are typically 
use-dependent voltage-sensitive cation channel blockers.  They are reversible paralysing 
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toxins which can cross the blood-brain barrier when it is compromised in stroke.  Although 
they do not need to be specific or even selective as invertebrate toxins, they show selectivity 
for potassium/sodium/calcium i.e. cation channel blockers.  We can therefore modify these 
polyamine amides, with molecular weights in drug-space (below 500 Da), to probe for 
selective cation channel block of interest in various CNS disorders and especially in stroke.  
It is unlikely, without an extremely efficient delivery vehicle, that these polyamine 
conjugates acting as reversible channel blockers will become commercial insecticides. 
Microbes have solved the problems of insoluble and toxic ferric ion by generating iron 
chelating systems, siderophores that complex (sequester) ferric ion for solubilisation and 
transport.  These siderophores are rich in polyamine and polyamide moieties e.g. parabactin, 
agrobactin, desferrioxamine B.  Phytosiderophores are low molecular weight ion-chelators 
endogenous to plants e.g. the triamine triacid nicotianamine.  These polyamine conjugates are 
important as probes to investigate iron transport and the roles of iron in infection, and as lead 
compounds for the potential treatment for haemochromatosis (-thalassemia).  DNA 
intercalator anthraquinones bound to metal chelating polyamines (ethylenediamines) that are 
complexed with cupric ions act as synthetic DNase.  Alternatively, using acridine for RNA 
intercalation, or adding a 19-mer of DNA complementary to the RNA sequence adjacent to 
the desired site for scission, and two units of ethylenediamine yields synthetic RNases. 
As part of our detailed studies of the SAR of polynucleotide delivery, we have a focus on 
using lipopolyamine conjugates for non-viral gene and small interfering RNA (siRNA) 
delivery, potential medicines for siRNA delivery to its site of action in the cytosol.  We are 
investigating the design, synthesis, formulation, and delivery of fluorescent siRNA by self-
assembly of nanoparticles measuring gene silencing efficiency.  We aim to silence the 
biosynthesis of selected proteins that are signals for cancers to grow or for selected causes of 
inflammation.  With regard to vector specificity, surprisingly, DNA transfer reagents cannot 
be used under similar conditions to achieve efficient and non-toxic delivery of siRNA. 
We acknowledge financial support from the Egyptian Government (studentships to A.A.M. 
and H.M.G.). 
 
 
 
 
 
195 
 
Models for Target Diseases with RNAi Therapy – Self-assembly siRNA Delivery 
Strategies 
 
Ian S. Blagbrough,* Abdelkader A. Metwally, and Hassan M. Ghonaim 
 
Department of Pharmacy and Pharmacology, University of Bath, Bath BA2 7AY, U.K. 
prsisb@bath.ac.uk 
 
ABSTRACT SUMMARY 
Animal models for RNA interference 
(RNAi) therapy are outlined together with 
evidence that this approach works from a 
Phase 1 clinical trial against age-related 
macular degeneration.  A novel strategy of 
lipoplex self-assembly is shown to be an 
efficient, non-toxic method for delivering 
siRNA to cells in the presence of serum. 
 
INTRODUCTION 
Many animal models e.g. rodents, and 
primates are now being investigated to pave 
the way for RNAi clinical trials [1].  In 1998, 
Fire and Mello published the mechanism for 
the degradation of mRNA transcribed from a 
specific gene in a sequence specific manner 
[2], a discovery for which they were rapidly 
awarded the Nobel Prize in Physiology or 
Medicine (2006).  Since then, and also rapidly, 
research relating to possible therapeutic 
applications of RNAi has reached the clinical 
trial stage.  Activating the RNAi pathway 
results in reduction of gene expression (knock-
down) by the intracellular delivery of either 
short hairpin RNA (shRNA) or small 
interfering RNA (siRNA), a process called 
sequence specific post-transcriptional gene 
silencing.  siRNAs can be used together with 
hematopoietic stem cell transplants stably to 
modulate gene expression in non-human 
primates and hence potentially to treat blood 
diseases e.g. HIV-1 [1].  Non-human primate 
models e.g. macaque, common marmoset, owl 
monkey are used for preclinical delivery 
vector safety and efficacy trials.  Li and Tang 
evaluated SARS coronavirus potent (in vitro) 
siRNA inhibitors for efficacy and safety in a 
rhesus macaque (M. mulatta) SARS, where 
three dosing regimens which showed siRNA-
mediated anti-SARS efficacy were evaluated 
as either prophylactic or therapeutic regimens 
[3].  Takeshita and Ochiya have reviewed the 
first in vivo delivery of siRNA (2002) 
achieved by the “hydrodynamic” technique in 
which naked siRNA is administered in large 
volumes of a physiological solution under high 
pressure into the tail vein of mice [4].  The 
efficacy of this delivery method was evaluated 
by co-injecting mice with plasmids that 
express the luciferase gene as a reporter along 
with an siRNA against luciferase mRNA [4].  
A phase 1 clinical trial for the treatment of 
choroidal neovascularization secondary to 
neovascular age-related macular degeneration 
has recently been reported, evaluating the 
tolerability and safety of single ascending 
intravitreal doses of (naked) siRNA in a proof-
of-principle of the biological activity of the 
specified siRNA [5].  Apart from tail vein and 
ocular delivery, a carrier (a vector e.g. 
positively charged atelocollagen [4]) offers 
advantages for efficient delivery of the 
polynucleotide therapeutic to target cells [6].  
The main functions of such a vector are to 
protect the RNA from serum nuclease 
degradation, to secure the efficient 
intracellular delivery of RNA, and to target a 
desired cell/tissue type if required.  Moving 
from in vitro experiments to in vivo clinical 
trials requires the use of non-human models to 
ensure the safety and the efficient intracellular 
delivery of siRNA/shRNA. 
We aim to design and evaluate our 
lipopolyamines [7-9], developing this strategy 
as a safe (non-toxic) and efficient non-viral 
approach clinically effective delivery of RNAi 
technologies.  The synthesized lipopolyamine 
vectors are prepared by conjugating two long 
fatty acid chains to the N4- and N9-amine 
functional groups of the symmetrical 
polyamine spermine.  The properties of the 
synthesized lipospermines can be varied by 
changing the length and oxidation state of the 
fatty acid.  We report the synthesis of five 
symmetrical lipospermines, characterized and 
tested for their safety and efficacy.  
 
EXPERIMENTAL METHODS 
Synthesis of lipospermines 
N4,N9-Dierucoylspermine 1, N4,N9-
dilauroylspermine 2, N4,N9-
dilinoleoylspermine 3, N4,N9-dioleoylspermine 
4, and N4,N9-distearoylspermine 5 were 
prepared using either DCC coupling of the 
corresponding carboxylic acids or coupling 
with the corresponding acyl chlorides, after di-
N-phthalimido protection of the primary 
amines with subsequent deprotection by 
hydrazinolysis.  They were all purified to 
homogeneity and showed satisfactory 
spectroscopic and spectrometric data, 
including:  1, HRMS m/z, ESI found (M+1)+ 
843.8355, C54H106N4O2 requires (M+1)+ 
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843.8316; 2, HRMS m/z, ESI found (M+1)+ 
567.5553, C34H70N4O2 requires (M+1)+ 
567.5572; 3, HRMS m/z, ESI found (M+1)+ 
727.6851, C46H86N4O2 requires (M+1)+ 
727.6824; 4, HRMS m/z, ESI found (M+1)+ 
731.7174, C46H90N4O2 requires (M+1)+ 
731.7137; 5, HRMS m/z, ESI found (M+1)+ 
735.7428, C46H94N4O2 requires (M+1)+ 
735.7450.  
 
Transfection experiments 
All transfection studies were carried out in 
the presence of 10% FCS in DMEM on HeLa 
cells stably expressing green fluorescent 
protein (GFP).  Cells were seeded at 65,000 
cells/well 24 h prior to transfection.  siRNA 
concentration in each well of 24-well plates 
was 15 nM.  Mean geometric fluorescence 
intensity of Alexa Fluor® 647 (AF) labeled-
siRNA and of GFP was measured by FACS 
analysis 48 h post transfection.  FACS 
measurements were carried out on the gated 
population of healthy cells.  The reduction in 
GFP expression was calculated as:   
100% x
cellscontrolofcefluorescenGFP
cellsdtransfecteofcefluorescenGFPGFP 
 
 
Cell viability assay 
The alamarBlue® assay [10] was used to 
evaluate cell viability after transfection.  HeLa 
cells were incubated in 96-well plates for 44 h 
post transfection then alamarBlue® reagent 
was added to the culture media and cells were 
incubated for a further 3.5 h.  Percentage 
viability was calculated by measuring 
absorbance at  = 570 nm and 600 nm using a 
VersaMax microplate reader and performing 
calculations according to the alamarBlue® 
supplier’s instructions. 
 
RESULTS AND DISCUSSION 
GFP expression 48h post transfection
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Fig. 1.  Knock-down of GFP expression in HeLa 
cells.  Values are mean ± SD (n = 6) for erucoyl 1 
(6 g/well), linoleoyl 3 (1.5 g/well), oleoyl 4 (6 
g/well), and stearoyl 5 (6 g/well), and 
commercially available transfection agents 
Lipofectamine 2000 (L, 2 L/well) and TransIT 
TKO (T, 4 L/well). 
Cell viability by alamarBlue assay
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Fig. 2.  Cell viability in HeLa cells mediated by 
fatty acid amides of spermine compared with the 
commercially available transfection agents 
Lipofectamine 2000 (L, 0.2 L/well) and TransIT 
TKO (T, 0.4 L/well).  Values are presented as 
mean ± SD (n = 6) using erucoyl 1 (0.6 g/well), 
lauroyl 2 (0.3 g/well), linoleoyl 3 (0.15 g/well), 
oleoyl 4 (0.6 g/well), and stearoyl 5 (0.6 g/well) 
in 96-well plates. 
 
siRNA delivery was evaluated by the 
amount of AF fluorescence 48 h post-
transfection with lipospermine/ siRNA 
lipoplexes.  1 showed the highest AF 
fluorescence (159 normalized units) at 6 µg of 
1, lipoplexes of 4 showed 17 normalized units 
at 6 µg of 4.  There was a direct 
proportionality between the amount of a 
specific fatty acid spermine conjugate and the 
intensity of AF fluorescence delivered.  Fatty 
acids with long chains and one double bond, 
22:1 and 18:1, resulted in a general trend of 
higher fluorescence for the same amount of 
lipid used.  At 6 µg, 4 resulted in AF 
fluorescence twice that of 5.  The least 
fluorescence (least delivery) was achieved 
with 2 (lauroyl 12:0) which was the most toxic 
conjugate. 
The most efficient knock-down of GFP 
expression in HeLa cells 48 h post-transfection 
(Fig. 1) (>80%) was achieved with N4,N9-
dioleoylspermine 4.  This conjugate together 
with N4,N9-dilinoleoylspermine 3 were the 
least toxic in the alamarBlue® assay (Fig. 2), 
and comparing favourably with the 
commercially available transfection agents 
Lipofectamine 2000 (L) and TransIT TKO 
(T). 
 
 
197 
 
CONCLUSIONS 
Lipoplexes of siRNA and N4,N9-difatty 
acid amides of spermine resulted in successful 
siRNA delivery and gene silencing of GFP in 
HeLa cells.  Variation of the chain length or 
saturation state of the fatty acids affected both 
the siRNA delivery and gene silencing 
efficiency where non-saturated fatty acids 
C18:1, C18:2, and C22:1 showed more 
efficient knock-down compared to that 
achieved with the saturated fatty acids C12:0 
and C18:0. 
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INTRODUCTION 
 
Gene silencing by siRNA is an important 
tool in the study of gene function with many 
potential therapeutic applications [1]. In this 
study, five spermine fatty acid conjugates were 
synthesized, characterized, and evaluated for 
their ability to deliver siRNA to knock down 
green fluorescent protein (GFP) expression in 
transfected HeLa cells that stably express 
GFP. 
 
AIMS 
 
 To study the SAR of the five 
synthetic spermine fatty acid conjugates and to 
evaluate these vectors for their efficiencies of 
siRNA delivery and gene knock-down. 
 
MATERIALS AND METHODS 
 
The N4,N9-di-fatty acid spermine 
conjugates were prepared using DCC coupling 
of the corresponding carboxylic acids (erucic, 
lauric, linoleic, oleic, and stearic), after di-N-
phthalimido protection of the primary amines. 
Particle size was measured by DLS and zeta-
potential was determined by measuring 
electrophoretic mobility of the lipoplexes. All 
transfection studies were carried out in the 
presence of foetal calf serum (FCS) 10% in 
DMEM on HeLa cells stably expressing GFP. 
siRNA concentration in each well of 24-well 
plates was 15 pmol/well. FACS analysis was 
carried out 48 h post transfection to measure 
mean geometric fluorescence intensity of 
Alexa Fluor® 647 labelled-siRNA and GFP. 
The alamarBlue® assay [2] was used to 
evaluate cytotoxicity. 
 
RESULTS AND DISCUSSION 
 
The particle size of the prepared lipoplexes 
was in the range 145-353 nm, and all the 
lipoplexes showed a positive zeta-potential. 
After FACS gating of healthy cells, siRNA 
delivery did not relate directly to gene 
silencing efficiency as N4,N9-dierucoyl 
spermine resulted in higher siRNA delivery (9-
fold) compared to N4,N9-dioleoyl spermine. 
GFP silencing in HeLa cells showed that the 
unsaturated fatty acid amides are more 
efficient than saturated fatty acid amides, with 
N4,N9-dioleoyl spermine resulting in the most 
efficient gene silencing (reduced GFP to 19%) 
followed by N4,N9-dilinoleoyl spermine 
(reduced GFP to 28%) in the presence of 10% 
FCS. The alamarBlue assay showed that 
spermine fatty acid amides have good viability 
(75%-85% compared to control), except N4,N9-
dilauroyl spermine with its lower cell viability 
of 50% at N/P = 15. These results show that 
unsaturated fatty acid amides of spermine of 
chain length C18 are efficient, non-toxic, non-
viral vectors for siRNA mediated gene 
silencing in HeLa cells. 
 
CONCLUSIONS 
 
 The symmetrical lipopolyamines N4,N9-
dioleoyl spermine and N4,N9-dilinoleoyl 
spermine are efficient non-viral siRNA 
delivery vectors producing effective gene 
silencing even in the presence of FCS. 
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INTRODUCTION 
siRNA sequence specific gene silencing 
has many potential therapeutic applications 
[1]. Guanidine groups with their high pKa = 
12.5 are practically fully protonated at 
physiological pH [2]. Four N1,N12-diamidino-
spermine N4,N9-fatty acid derivatives were 
designed, synthesized, purified, characterized, 
and evaluated as non-viral vectors for siRNA. 
 
AIMS 
To characterize and evaluate the four 
synthetic N1,N12-diamidino-spermine fatty acid 
conjugates as non-viral vectors for the delivery 
of siRNA and its sequence specific gene 
knock-down. 
 
MATERIALS AND METHODS 
The N4,N9-fatty acid spermine conjugates 
were prepared by DCC coupling of the 
corresponding fatty acids (erucic, lauric, 
linoleic, and oleic), after di-N-phthalimido 
protection of the primary amines. Deprotection 
of the primary amines, guanidinylation with 
1,3-di-BOC-2-
(trifluoromethylsulfonyl)guanidine triethyl 
amine followed by TFA deprotection yielded 
the di-TFA salts of the cationic lipids. Particle 
size was measured by DLS and zeta-potential 
by measuring electrophoretic mobility of the 
lipoplexes. All transfection studies were 
carried out in the presence of foetal calf serum 
(FCS) 10% in DMEM on HeLa cells stably 
expressing green fluorescent protein (GFP). 
siRNA concentration in 24-well plates was 15 
pmol/well. FACS analysis was carried out 48 h 
post transfection to measure mean geometric 
fluorescence intensity of Alexa Fluor® 647 
labelled-siRNA and GFP. The alamarBlue® 
assay [3] was used to evaluate cytotoxicity. 
 
RESULTS AND DISCUSSION 
The particle size of the prepared lipoplexes 
varied from 132-575 nm with zeta-potential in 
the range +28 to +50 mV. After FACS gating 
a healthy cell population, N1,N12-diamidino-
N4-linoleoyl-N9-oleoylspermine showed the 
best siRNA delivery compared to the other 
vectors and also showed the best GFP knock-
down (reduced GFP to 26% of control). 
N1,N12-Diamidino-N4,N9-dioleoylspermine was 
the next most efficient with GFP reduction to 
43% of the control value. Although N1,N12-
diamidino-N4,N9-dierucoylspermine showed 
comparable delivery to the dioleoyl conjugate 
over the different N/P ratios, the GFP 
fluorescence was reduced only to 85% at the 
highest N/P = 18. Guanidines interact 
efficiently with anionic cell membrane 
components [4]. The alamarBlue cell viability 
assay showed that HeLa cells 48 h post 
transfection had good viability (64%-83% 
compared to control), except the dilauroyl 
conjugate, which resulted in almost complete 
cell death at N/P = 26.  
 
CONCLUSIONS 
 These results show that N1,N12-diamidino-
spermine with N4,N9 unsaturated fatty acid 
conjugates of chain length C18 are potentially 
good non-viral vectors for siRNA mediated 
gene silencing. 
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INTRODUCTION 
 
Glycosaminoglycans (GAGs) are important 
negatively charged components of the 
extracellular matrix [1].  They could affect the 
composition and stability of lipoplexes, e.g. 
gene carrying DNA nanoparticles [2].  
Studying the formation of siRNA 
nanoparticles and their interactions with GAG 
components are important for the design and 
development of successful siRNA carriers.   
 
AIMS 
 
We have carried out a comparative study 
between four lipopolyamines in their 
efficiency both in siRNA condensation and in 
the stability of their lipoplexes against GAGs.  
Such a pre-formulation analytical study might 
be correlated with the transfection efficiency 
of these siRNA-lipopolyamine nanoparticles.   
 
MATERIALS AND METHODS 
 
Chemicals were purchased from Sigma-
Aldrich, UK.  N4,N9-Dierucoylspermine, 
N4,N9-dioleoylspermine, N1,N12-diamidino-
N4,N9-dierucoylspermine, and N1,N12-
diamidino-N4,N9-dioleoylspermine were 
synthesized, purified, and characterized.  
siRNA (21 b.p., Negative Control, Qiagen) 
(2.97 µg, 10 µl) was diluted in HEPES buffer 
(1.5 ml, pH = 7.3).  Immediately prior to 
analysis, ethidium bromide (EthBr) solution 
(3.3 µl, 0.5 mg/ml) was added to the stirring 
solution and allowed to equilibrate for 1 min 
[3].  Separately, aliquots (according to the N/P 
ratio required) were added to the stirring 
solution and the fluorescence measured after 1 
min equilibration using fluorimeter (λexcit = 
260 nm, λemiss = 595 nm).  Aliquots of each 
GAG were then added according to the 
negative charge that the GAG 
carries/ammonium (at N/P = 5) and finally the 
fluorescence recovery was measured. 
 
RESULTS AND DISCUSSION 
 
N4,N9-Dioleoylspermine shows good 
condensing efficiency for siRNA as the 
normalised fluorescence is quenched by 90% 
at N/P = 2.  N4,N9-Dierucoyl-spermine and 
N1,N12-diamidino-N4,N9-dioleoyl-spermine 
formed weaker complexes with siRNA as they 
quenched the fluorescence by about 60% at 
N/P = 2.  N1,N12-Diamidino-N4,N9-dierucoyl-
spermine caused the lowest reduction in 
fluorescence of only 20% at N/P = 2.  
Whilst on reaction with dermatan sulfate, 
N4,N9-dioleoylspermine siRNA lipoplex 
fluorescence only recovered to 40% of the 
normalised value (i.e. by 30%), fluorescence 
recovered to about 60% with the other three 
lipopolyamines.  Our recent transfection data 
show that N4,N9-dioleoylspermine gave the 
best knock down of GFP in HeLa cells which 
stably express GFP, with reduction to 19 %.  
N4,N9-Dierucoylsperm-ine and N1,N12-
diamidino-N4,N9-dioleoylspermine both 
caused reduction of GFP to 43% whilst N1,N12-
diamid-ino-N4,N9-dierucoylspermine only 
gave a reduction to 85%.   
 
CONCLUSIONS 
 
These assays yield important information 
about the interactions between siRNA and 
lipopolyamines, and their stability against 
GAGs.  These data offer an early pre-
formulation indicator of potential transfection 
efficiency.   
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PURPOSE 
 
 To evaluate four synthetic N1,N12-diamidino-spermine N4,N9-di-fatty acid conjugates as 
non-viral vectors for the delivery of siRNA and its sequence specific gene knock-down.  
 
METHODS 
 
N4,N9-Di-fatty acid spermine conjugates were prepared by DCC coupling of the 
corresponding fatty acids (erucic, lauric, linoleic, and oleic), after di-N-phthalimido 
protection of the primary amines.  Deprotection of the primary amines, guanidinylation, 
followed by TFA deprotection yielded the di-TFA salts of the cationic lipids.  Particle size 
was measured by DLS, zeta-potential by electrophoretic mobility of the lipoplexes, and all 
transfection studies were carried out in the presence of fetal calf serum (FCS) 10% in DMEM 
on HeLa cells stably expressing green fluorescent protein (GFP).  siRNA concentration in 24-
well plates was 15 pmol/well.  FACS analysis was carried out 48 h post transfection to 
measure mean geometric fluorescence intensity of Alexa Fluor® 647 labeled-siRNA and 
GFP.  The alamarBlue® assay was used to evaluate cytotoxicity.  
 
RESULTS 
 
Lipoplex particle sizes varied from 132-575 nm with zeta-potentials from +28 to +50 mV.  
After FACS gating a healthy cell population, N1,N12-diamidino-N4-linoleoyl-N9-
oleoylspermine showed the best siRNA delivery compared to the other vectors and also 
showed the best GFP knock-down (reduced to 26% of control).  N1,N12-Diamidino-N4,N9-
dioleoylspermine reduced GFP to 43%.  Although N1,N12-diamidino-N4,N9-dierucoylspermine 
showed comparable delivery to the dioleoyl conjugate over the different N/P ratios, the GFP 
fluorescence was reduced only to 85% at the highest N/P = 18.  Guanidine groups, with their 
high pKas = 12.5, interact efficiently with anionic cell membrane components.  The 
alamarBlue cell viability assay showed that HeLa cells 48 h post transfection had good 
viability (64%-83% compared to control), except the dilauroyl conjugate, which resulted in 
almost complete cell death at N/P = 26.  
 
CONCLUSIONS 
 
These results show that N1,N12-diamidino-spermine N4,N9-di-fatty acid conjugates with 
C18 chain length are good non-viral vectors for siRNA mediated gene silencing. 
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PURPOSE 
 
 To study the SAR of five synthetic spermine fatty acid conjugates and to evaluate these 
non-viral vectors for siRNA delivery and gene knock-down. 
 
METHODS 
 
Five N4,N9-di-fatty acid spermine conjugates were prepared using DCC coupling of the 
corresponding erucic, lauric, linoleic, oleic, and stearic carboxylic acids, after di-N-
phthalimido protection of the primary amines.  Particle size was measured by DLS, zeta-
potential by electrophoretic mobility of the lipoplexes, and all transfection studies were 
carried out in the presence of fetal calf serum (FCS) 10% in DMEM on HeLa cells stably 
expressing GFP.  siRNA concentration in each well of 24-well plates was 15 pmol/well.  
FACS analysis was carried out 48 h post transfection to measure mean geometric 
fluorescence intensity of Alexa Fluor® 647 labeled-siRNA and GFP.  The alamarBlue® 
assay was used to evaluate cytotoxicity. 
 
RESULTS 
 
Lipoplex particle sizes were in the range 145-353 nm, with positive zeta-potentials.  After 
FACS gating of healthy cells, siRNA delivery did not relate directly to gene silencing 
efficiency as N4,N9-dierucoyl spermine resulted in higher siRNA delivery (9-fold) compared 
to N4,N9-dioleoyl spermine.  GFP silencing in HeLa cells showed that unsaturated fatty acid 
amides are more efficient than saturated fatty acid amides, with N4,N9-dioleoyl spermine 
resulting in the most efficient gene silencing (reduced GFP to 19%) followed by N4,N9-
dilinoleoyl spermine (reduced GFP to 28%) in the presence of 10% FCS.  The alamarBlue 
assay showed that spermine fatty acid amides have good viability (75%-85% compared to 
control), except N4,N9-dilauroyl spermine with its lower cell viability of 50% at N/P = 15. 
 
CONCLUSIONS 
 
These results show that our synthetic unsaturated C18 chain length fatty acid amides of 
spermine are efficient, non-toxic, non-viral vectors for siRNA mediated gene silencing in 
HeLa cells.  The symmetrical lipopolyamines N4,N9-dioleoyl spermine and N4,N9-dilinoleoyl 
spermine are efficient siRNA delivery vectors producing effective gene silencing even in the 
presence of FCS. 
We thank the Egyptian Government for a fully-funded studentship to AAM.  We thank Dr 
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